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1.1 Drug discovery and development 
The process of developing new medication is complex, expensive, time-consuming and full 
of risks. On average the development of a single new drug takes about 12 years and costs 
in the order of US $1 billion [1-3]. Despite the increasing investments in pharmaceutical 
research and development (R&D), there has been a steep rise in the attrition rate of 
drug candidates [4, 5]. This is currently one of the main challenges facing pharmaceutical 
industry as a whole. A global overview of the process from target discovery to market 
approval is shown in Figure 1.1. 
Figure 1.1: Drug discovery and development pipeline. The first essential step in the drug discovery 
pipeline is the target discovery, which involves the identification and early validation of disease-
modifying targets. Subsequently a compound with the desired biological activity is identified in 
the lead discovery phase and its properties (potency, solubility, lipophilicity, metabolic stability, 
bioavailability, specific protein binding, and toxicity) are optimized in the lead optimization step. 
Explanatory development of leads is first pursued in animal models in the pre-clinical development 
phase, where the compounds safety profile is tested. Clinical development starts with phase I 
trials, in which the safety profile is checked in humans. These trials typically take 1-2 years and 
are performed in 20-80 healthy individuals. Subsequently, the efficacy and safety is tested in a 
small patient population of 100-300 patients which again takes 1-2 years. Next, a phase 3 trial is 
performed to test efficacy and safety in a large group of 1000-3000 patients. Finally, the drug is 
sent to regulatory authorities for review and approval and brought to the market upon successful 
completion. 
In the target discovery phase, a disease modifying target has to be identified that can 
undergo a specific interaction with a drug to treat or diagnose the indication of interest. 
The vast majority of drug targets are proteins [6], which are either inhibited or activated 
via specific binding of a small molecule ligand. In the lead discovery phase compounds 
which modulate the biological activity of the selected target are identified by screening 
large compound collections in vitro. Subsequently in lead optimization, the identified 
bioactive compounds are chemically modified to improve potency and other desired 
drug-like properties, to for example allow safe oral administration. Next, compounds are 
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tested in preclinical development for the desired effect and to determine the toxicity 
profile in animal models. On average only 1 in 50 compounds passes this stage and is 
finally tested in human trials in the clinical development stage. Again only 1 out of 5 
compounds in clinical development gets registered eventually and will be introduced 
to the market. As a result, the costs of drug development steeply rise after each step 
in the drug discovery process.  It is therefore of crucial importance to keep the failure 
rate in the later stages of development as low as possible. Traditionally, this is done by 
assessing several protein targets and a large number of compounds to select the best 
target protein and lead compound. A relatively cheap solution is to use computational 
approaches which can be used to prioritize target proteins and drug candidate that have 
the desired properties to ultimately become a successful drug.
1.2 Pharmacophores
It is for example possible to characterize protein binding pockets by considering the 
relevant physicochemical properties and shape of the ligand binding pocket. Such 
descriptions are useful to assess the druggability of the target protein, but also to select 
compound sets with likely activity on the target and to chemically optimize a compound 
to improve activity or improve the properties of a compound while maintaining activity. 
An often used concept in this context is the pharmacophore. This is a three dimensional 
arrangement of chemical features necessary for biological activity [7-10] (Figure 1.2). 
These can be derived from either known active compounds or from the three dimensional 
target protein structure. Pharmacophores are especially useful for protein families for 
which only a limited number of high resolution protein structures are available.   
Figure 1.2: Schematic picture of a dopaminergic pharmacophore aligned to eticlopride [11] 
(left). Crystal structure pose of eticlopride as bound to the dopamine D3 receptor [12] with the 
corresponding 3D dopaminergic pharmacophore (right).
1.3 G protein-coupled receptors
G protein-coupled receptors (GPCRs), like other membrane proteins, are notoriously 
difficult to crystallize. Obtaining high-quantity and high-purity GPCR proteins is very 
challenging, because membrane proteins are typically produced in a heterogeneous 
environment by cells with varying glycosylation. Other challenges in the crystallization of 
membrane proteins relate to the flexible nature of constitutive active receptors and the 
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stabilization of the receptor structure as it is exposed to solvent.
In this thesis we describe the development and application of a pharmacophore modeling 
technique for the G protein-coupled receptor (GPCR) family. GPCRs comprise a large 
family [13, 14] of membrane proteins which are responsible for the signal transduction of 
endogenous signals into an intracellular response in many different physiological pathways 
[15]. As a result, GPCRs are effective drug targets for various diseases and of major interest 
to pharmaceutical companies. Of all drugs currently on the market approximately 25-
50% interacts with a GPCR and new drugs targeting this protein family are continuously 
developed [15-20]. Most interesting from a drug development perspective is the class A 
family, also called rhodopsin-like, GPCRs. Characteristic for this family is that they contain 
relatively short N-termini. It is believed that the ligand binding pocket is located between 
the transmembrane region, which is shared between all GPCR’s (Figure 1.3). This region 
resembles a barrel comprising seven structurally conserved α-helices that span the 
cell membrane in an anti-clockwise manner. Upon binding of an agonist, an activating 
molecule, to a GPCR, a conformational rearrangement of the intracellular segments of 
the transmembrane helices triggers a signaling cascade in the cytoplasm. In this process 
G-proteins and  β-arrestins are considered as the two primary signal transducers.
  
Figure 1.3: Schematic picture of a GPCR (left). Structure of the dopamine d3 receptor co-crystalized 
with eticlopride (right). The seven transmembrane helices are colored ranging from blue (TM I) to 
red (TM VII). 
1.4 Outline of this thesis
The main focus of this thesis is the development and application of a software tool, 
named Snooker, which can be used to derive pharmacophores from protein structure 
models. A schematic outline of the work described in this thesis is depicted in Figure 1.4. 
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Figure 1.4: Outline of this thesis. Chapter two provides an overview of available algorithms to 
generate structure based pharmacophores. Chapter eight assesses the quality of pharmacophore 
search algorithms in terms of accuracy in virtual screening and binding mode hypothesis generation 
as applied to four different proteins. 
Chapter 2 gives an overview of currently available methods to derive pharmacophores from 
protein structures and discusses possible applications of pharmacophores in drug design. 
Chapter 3 describes the molecular class specific information system (MCSIS) GPCRdb. This 
database with annotated information about GPCR protein sequences of different species 
provides a good overview of the available data. In addition, it enables data mining to for 
example retrieve inter species differences, ligand binding effecting mutations or sequence 
patterns which can characterize certain subfamilies within the molecular class. In chapter 
4 we report ss-TEA, a method to predict ligand binding residue positions for GPCRs based 
on a multiple sequence alignment. Chapter 5 describes how these ligand binding residue 
predictions are used to generate structure based pharmacophores with Snooker and 
how these can be applied to binding mode hypothesis generation and compound library 
design. Chapter 6 reviews the successful ligand binding mode predictions produced by 
Snooker in combination with the flexible docking algorithm Fleksy, which were submitted 
to a global assessment on GPCR structure prediction. Chapter 7 reports on a compound 
library design experiment in which Snooker was used in combination with a frequent 
substructure mining approach and also reports on the successful identification of new 
compounds for three different class A GPCR targets. Finally, in chapter 8, a benchmark 
study of different pharmacophore search algorithms is presented in which compound 
library enrichment and compound pose prediction is evaluated for four different protein 
targets.
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Abstract
A pharmacophore describes the arrangement of molecular features a ligand must contain 
to efficaciously bind a receptor. Pharmacophore models are developed to improve 
molecular understanding of ligand-protein interactions, and can be used as a tool to 
identify novel compounds that fulfil the pharmacophore requirements and have a high 
probability of being biologically active. Protein structure-based pharmacophores (SBPs) 
derive these molecular features by conversion of protein properties to reciprocal ligand 
space. Unlike ligand-based pharmacophore models, which require templates of ligands 
in their bioactive conformation, SBPs do not depend on ligand information. The current 
review describes the different steps in the construction of SBPs: i) protein structure 
preparation, ii) binding site detection, iii) pharmacophore feature definition, and iv) 
pharmacophore feature selection. We show that the SBP modeling workflow poses 
different challenges than ligand-based pharmacophore modeling, including the definition 
of protein pharmacophore features essential for ligand binding. A comprehensive 
overview of different SBP modeling and screening methods and applications is provided 
to illustrate that SBPs can be efficiently used for virtual screening, ligand binding mode 
prediction, and binding site similarity detection. Our review demonstrates that SBPs are 
valuable tools for hit and lead optimization, compound library design and target hopping, 
especially in cases where ligand information is scarce.
18    Chapter 2
2.1. Introduction
The pharmacophore concept was first introduced in 1909 by Ehrlich who defined a 
pharmacophore as ‘a molecular framework that carries (phoros) the essential features 
responsible for a drug’s (pharmacon) biological activity’ [1]. Later, the pharmacophore 
concept was more precisely described by Kier [2] who stated that a drug must possess 
‘(a) those atomic features suitable for the requisite drug-receptor interaction phenomena 
and (b) the appropriate spatial disposition of these features necessary to bring about 
the required simultaneous or required sequential interaction events with the receptor’ 
[3]. Gund further updated Kier’s definition and described a pharmacophore in 1977 as 
“a set of structural features in a molecule that is recognized at a receptor site and is 
responsible for that molecule’s biological activity” [4]. Pharmacophores have proven to 
be extremely effective in silico filters in the search for bioactive molecules on several 
targets. Their use reduces the number of compounds and costs which have to be 
considered in large biophysical screenings [5-8]. In contrast to e.g. topological/2D 
ligand similarity searches which take a whole-structure, ‘global,’ view on the activity 
of molecules, pharmacophores focus on ‘local’ similarity and study the molecular 
determinants and their specific arrangement required for biological activity [9]. As a 
result they provide an explanation for the predicted activity of molecules. Ligand-based 
pharmacophores (LBPs), i.e., pharmacophore models derived from one or multiple active 
ligand(s), have been extensively used in the discovery and design of biologically active 
molecules [6]. Protein structure-based pharmacophores (SBP), derived from the three-
dimensional (3D) structure(s) of one or more protein target(s), are receiving more and 
more attention in the past few years [6, 10]. One of the reasons for the rising interest 
in SBPs is the significant increase in high resolution protein structures. Currently more 
than 75.000 three-dimensional structures of biological macromolecules (mostly proteins) 
are deposited in the Protein Databank (9th August 2011)[11], leading to unprecedented 
understanding of these molecular drug targets. SBPs can be used as a tool to give insights 
into ligand-protein interactions and to enable large scale structural chemogenomics 
studies to identify new ligands for specific proteins (ligand profiling), or find new targets 
for specific ligands (target fishing)[12-16]. As such, there are three benefits of SBPs over 
LBPs: i) SBPs allow the identification of novel scaffolds, as they are less biased towards 
existing ligand chemotypes. ii) SBPs can be used to elucidate protein-ligand binding mode 
hypotheses within the protein structural framework [17-20], making SBPs suitable tools 
for structure-based ligand optimization. iii) SBPs lead to better understanding of ligand 
binding sites. These insights can for example be used to find ligands for orphan receptors 
[21] or to study ligand binding site similarities between different proteins to address 
cross-pharmacology [22] and suggest new targets for existing drugs [23].
Generally four different steps in the construction of SBPs can be distinguished: i) protein 
structure preparation, ii) binding site detection, iii) pharmacophore feature definition, 
and iv) pharmacophore feature selection (Figure 2.1). Protein structure preparation and 
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binding site detection are obviously specific aspects of SBP modeling. The protonation 
states of functional groups and conformation of the pharmacophore modeling template 
are clearly equally important determinants of LBPs and SBPs. For SBPs however, the 
possible variation in protonation states and conformations (at protein backbone, 
sidechain, or polar hydrogen atoms level) is in principle larger, simply because ligand 
binding sites (in most cases) contain more atoms than ligands do. Whereas the features 
included in SBPs are generally the same as in LBPs, the initial number of features in 
SBPs is generally higher. As a result, pharmacophore feature selection (an important 
step in both LBP and SBP modeling workflows) requires a different approach and poses 
different challenges in LBP and SBP modeling protocols. Structural alignment of different 
ligands can be used to identify essential features in LBPs, and experimental data such as 
structure-activity relationships (SAR) can be used to further emphasize specific features 
in LBPs. Selection of essential features in SBPs is however not straightforward, even 
when guided directly by experimental data such as site-directed mutagenesis studies or 
indirectly by including amino acid sequence based knowledge or ligand information. The 
larger number of conformational and spatial possibilities in SBPs make the selection of 
pharmacophore features more complex than in LBPs.
The current review gives a comprehensive overview of different methodologies to 
construct SBPs and describes the specific benefits and challenges (paragraph 2.2.2). 
Furthermore, representative applications of SBPs are provided to illustrate that SBPs 
can be efficiently used for virtual screening, ligand binding mode prediction, and binding 
site similarity detection (paragraph 2.2.3), Our review demonstrates that SBPs are 
valuable tools for hit and lead optimization, compound library design and target hopping, 
especially in cases where ligand information is scarce.
2.2. Protein Structure Based Pharmacophore Modeling Methodology
In principle, the availability of a three dimensional protein structure or model is the only 
absolute pre-requisite for SBP methods. If the target protein structure is not known a 
protein structure model may be generated by homology modeling with the use of the 
sequence and the three dimensional structure of a close homolog [24]. The subsequent 
steps in the SBP modeling workflow, protein preparation (paragraph 2.2.1), binding 
site detection (paragraph 2.2.2), pharmacophore feature definition (paragraph 2.2.3), 
and pharmacophore feature selection (paragraph 2.2.4) are outlined in Figure 2.1 and 
discussed in this section. An overview and classification of the different SBP methods for 
binding site detection, feature definition and selection is presented in Table 2.1.
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Figure 2.1: Methods for deriving structure based pharmacophores (SBPs). I.) The first step in 
deriving a SBP is the preparation of the protein structure. An example (PDB:2BNU) is shown with in 
green favorable interactions and unfavorable interactions in red.  Three unfavorable interactions are 
observed in the original input file; an asparagine bumps into a lysine, a hydrogen of a neighboring 
asparagine clashes with the backbone and two partial negatively charged oxygens of an asparagine 
and backbone alanine are in close proximity. Flipping these asparagines removes all unfavorable 
interactions and gain one additional favorable interaction [65]. II.) Next, a cavity is defined using a 
grid-based, solvation, alpha sphere or Delaunay tessellation based approach. III.) Pharmacophore 
features are subsequently derived by calculation of spatially favorable positions for functional 
groups by using known interaction geometries, probe docking, or by docking one or more ligands 
and extracting this information from ligand poses. IV.) To increase pharmacophore specificity 
an energy or statistics based method is finally applied to reduce the number of pharmacophore 
features in the final pharmacophore hypothesis. V.) Three possible applications for pharmacophores 
are virtual screening, ligand binding mode prediction and binding site similarity prediction.
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Table 2.1: Different structure based pharmacophore methodologies and their specifications. 
Method/Software Protein 
preparation
Binding site 
detection
Feature 
definition
Feature 
selection
Resolutiona AutomationbR Reference
Catalyst/Discovery 
Studio
Yes Grid Geometry Energy Medium Medium [50]
Chemogenomics 
(Kklabunde)
No Fixedc Fixedc - Low High [28]
FLAP Yes Grid Geometry Energy Medium Medium [66, 67]
GBPM Yes Grid Geometry Energyd Medium Medium [68]
HS-Pharm Yes Grid Geometry Empirical Medium Medium [69]
LigandScout Yes - Ligand Energy High High [70]
MOE Yes Alpha spheres Ligand Energy/
Manual
High High [52]
MUSIC Yes Solvation Probe Energy Low Medium [47]
Pocket v2 Yes Grid Geometry Energy Medium High [71]
Schrodinger Yes Grid Probe,Ligand Energy High Medium, High [72]
Snooker No Delaunay 
tesselation
Geometry Empirical Low High [73]
Sybyl Yes Grid,Solvation Grid, Solvation Knowledge, 
Energy/
Manual
Medium Low [49]
aHigh resolution methods require one high resolution structure from which all information is deduced. Medium resolution methods are able to 
combine different high resolution structures. Low resolution models do not require a high resolution structure, instead typically using interaction 
geometries, rotamer ensembles or simulations to cover a range of probable conformations.
bHighly automated methods can produce pharmacophores by the push of a button and have a fully integrated workflow. Medium automation 
requires a call to separate procedures. Low automation methods require the user to specify at which location or residue a feature should be 
positioned without giving much guidance except possibly the coloring of surfaces according to calculated properties.
cMethod uses fixed position for pharmacophore features and positions them solely based on sequence information.
dMethod requires ligand
2.2.1 Protein structure preparation
2.2.1.1 Protonation states
The first step in the derivation of a SBP is the preparation of the protein structure 
(Figure 2.1), including the consideration of non-protein groups (e.g. water molecules 
or cofactors), the determination of protonation states and positions of hydrogen atoms 
of protein residues, and the consideration of (alternative) protein conformations. 
Structures obtained by traditional X-ray crystallography and deposited in the PDB 
usually lack the positions of the hydrogens. These atoms are added according to basic 
pH dependent chemistry rules. Protonation states of aspartate, glutamate and histidine 
are typically solved by pKa predictions of the local structural environment while flipping 
of asparagines, glutamine and histidine side chains as well as tautomer optimization for 
histidine are performed to optimize the hydrogen bonding network [25]. An assessment 
of the accuracy of various methods for predicting hydrogen positions in protein structures 
has been reported by Forrest and Honig [26]. A protein preparation step is recommended 
since many structures deposited in the PDB were shown to contain errors [27]. An energy 
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minimization is optional to obtain the protein structure (or protein-ligand complex in case 
of a holo-structure) at the closest local minimum. Not all SBP methods require a correctly 
prepared protein structure (Table 2.1). Both the chemogenomics approach as described 
by Klabunde et al. [28] and Snooker [29] do not require high resolution ‘cleaned’ protein 
structures. The chemogenomics method uses fixed pharmacophore positions and needs 
only a correlation matrix between available pharmacophore features plus the sequence 
to create a pharmacophore. Snooker uses a structural template together with the 
sequence to build an ensemble structure which contains all likely rotamers of all residues. 
Since Snooker uses fixed rules for residue interaction geometries which are tautomer and 
protonation state independent, a protein preparation step is not required.
2.2.1.2 Protein conformations
Although LBP methods can in theory consider protein flexibility by aligning ensembles 
of molecular conformations, they typically assign primacy to the ‘biologically active’ 
ligand conformation and use only this to align multiple active molecules and deduce 
a pharmacophore [30-31]. However, a recent systematic study suggests that ligands 
rarely bind in their lowest calculated energy conformation [32], obviously making the 
problem of selecting biologically active conformations for constructing LBPs more 
complicated. Alternatively, many applications allow an externally derived conformation 
of an active molecule to be used as a template in the alignment of active molecules 
from which the pharmacophore is derived. In SBP modelling, it has been widely 
accepted that the conformational flexibility of proteins has to be taken into account. 
Flexible docking algorithms typically consider a number of proteins conformations and 
keep a limited number of residues flexible during the docking run [33-35] Carlson and 
Meagher developed an approach to incorporate protein flexibility in SBPs by generating 
pharmacophores from molecular dynamics (MD) simulations of protein-ligand complexes 
[36] based on clustering of the aligned pharmacophores of different snapshots. It is 
similarly possible to align the results of dockings, rendering this method suitable for the 
modeling of flexible proteins. Loving et al. [37] and Salam et al. [38] for example used 
Phase [39] to flexibly dock ligands/fragments and generate pharmacophore sites based 
on the docking solutions. They subsequently decomposed the Glide XP docking scores 
to energy terms for all individual probe fragments (hydrogen bond acceptors/donors, 
positive and negative ionizable groups and hydrophobic and aromatic interactions) 
and mapped these onto different the pharmacophore sites to rank the features. Using 
this approach Loving et al. reproduced the binding modes of 12 targets and recovered 
known actives from a database screen, while Salam et al. generated 30 successful 
reduced pharmacophore definitions and used them in enrichment studies. Geometry 
based methods also allow the generation of ‘consensus’ pharmacophores by overlaying 
protein structures and thus interaction maps. Molecular interaction fields (MIFs)[40], 
LUDI [41,42] and Snooker interaction maps generated from different models of the same 
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protein can be superposed to extract the most robust regions of interactions. Snooker 
by default uses the rotamer statistics as obtained from a rotamer library [43] to build an 
ensemble model for each protein. 
2.2.2 Binding site detection
The second step in the SBP modeling workflow (Figure 2.1) is to define the location of the 
ligand binding site by the application of binding site detection algorithms. Retrospective 
studies show that these algorithms perform very well in the case of ligand bound crystal 
structures, correctly detecting up to 95% of the ligand binding pockets,  but are less 
accurate for apo-structures [44]. Structure based binding site detection can be divided 
into energy based methods (incl. solvation methods) and geometry based (incl. grid 
based, alpha sphere, Delaunay tesselation) as summarized in Figure 2.1 and Table 2.1. 
Energy-based algorithms, like PocketFinder [45], SuperStar [46], MUSIC [47], the solvation 
method of SiteID (Tripos) and SiteMap (Schrödinger) try to describe the local surface 
properties of a cavity by the simulation of solvent molecule interactions with  the protein 
surface. SiteMap [48] uses a grid to sample binding site properties but is nevertheless 
fully based on interaction energy calculation. MUSIC [47] floods the pocket with probe 
fragments instead of solvent molecules and simulates the interactions of those fragments 
in short MD-simulations. Geometry based methods can be divided into two categories: 
discrete grid-based sampling and analytic methods like Delaunay tessellation and alpha 
sphere based methods. Grid-based methods available in SiteID (Tripos [49]), GRID [40] 
and in the binding site analysis module of InsightII (Accelrys [50]) typically select grid 
points close to but not overlapping with protein atoms, and define the pocket after 
a flood filling algorithm of grid points located in a cavity, where cavity grid points are 
defined as grid points with a substantial number of contacts with the protein. Snooker 
identifies the protein pocket by a Delaunay tessellation [51] of Cα-atoms and a calculated 
mean side chain atom, followed by the indexing of tetrahedra with at least one ‘long’ 
edge (Figure2.1). Delaunay tessellation implies the generation of an aggregate of space-
filling irregular tetrahedral. These tetrahedra are deduced from a set of coordinates such 
that for each tetrahedron, the four vertices are on the circumspheres while no other 
vertices are inside the circumsphere. It is used to identify all tetrahedra which span 
large distances and cover potential ligand binding pockets. Finally, all indexed tetrahedra 
having a triangle in common are merged and the largest merged volume is defined 
as the pocket, while all non-indexed tetrahedra form the protein volume. SiteFinder 
(MOE [52]), PASS [53], SURFNET [54], LIGSITE [55], APROPOS [56], and CAST [57, 58] 
use alpha complexes to detect pockets. Alpha shapes are an extension of the convex 
hulls proposed by Edelsbrunner and Mucke [59]. Alpha spheres associated with 4 atoms 
can be generated from the simplices of a Delaunay tessellation (Figure 2.1). Solvent 
exposed alpha spheres and those corresponding to inaccessible areas (small spheres) are 
removed and the pocket is detected by aggregation of remaining nearby alpha spheres. 
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Two reviews summarizing and explaining ligand-binding site detection have been written 
by Prymula et al. [60] and Henrich et al. [61].
2.2.3 Pharmacophore feature definition 
In the third step in the SBP flow scheme (Figure 2.1), pharmacophore features are 
derived from the co-crystallized ligand or from the ligand binding site (determined in 
the previous step) itself (Table 2.1). Protein structure based pharmacophore methods 
typically use geometric entities, such as spheres, vectors and planes with given attributes 
to characterize favorable interactions. The commonly used interaction types include 
H-bond acceptors, H-bond donors, positive and negative ionizable groups, lipophilic 
regions and aromatic rings. Their positions are set according to either positions of co-
crystalized ligands or basic interaction geometry rules. Derivation of pharmacophores 
from ligands is ostensibly straightforward with features positioned at functional groups 
of the ligand. Ligand based pharmacophore modeling tools are generally similar although 
they may produce slightly different pharmacophores due to differences in feature 
definitions and algorithmic search strategies [62, 63]. An excellent review providing a 
detailed explanation of the available molecular alignment techniques has been written 
by Lemmen and Lengauer [64]. As each software package has differences in feature 
definition criteria, it is appropriate to use the same algorithm for both pharmacophore 
elucidation and pharmacophore searching, in order to ensure compatibility. If the 
structure of a protein-ligand complex is available, a pharmacophore can be constructed 
by positioning features at the functional groups of ligands (Table 2.1). Structure based 
pharmacophore derivation from apo structures is in contrast more challenging. The 
number of potential interacting residues in a ligand binding site is typically larger than 
the number of observed interactions in protein ligand complexes. Furthermore is it not 
straightforward to determine the optimal interaction geometry and there is no guarantee 
that ligands will interact at the predicted favorable sites of interaction. Some targets even 
have diverse ligand-binding modes and require a set of different pharmacophores to 
cover the interaction observed for all ligands [74-80]. Pharmacophore feature placement 
is therefore less accurate in structure based pharmacophore methods and tolerances 
of pharmacophore features are typically less strict. FLAP [66, 67], GBPM [68], Pocket 
V2 [71], Discovery Studio (Accelrys [50]), Sybyl (Tripos [49]) and Snooker [29] can create 
SBPs without the use of any ligand information and apply knowledge from residue based 
interaction geometries to predict likely interactions and their locations. MUSIC [47] and 
Schrodinger [37, 38] also do not require information about known actives and use a 
multiple copy simultaneous search (MCSS) method [81] to identify energetically favorable 
positions and properties of probes to generate pharmacophore features. In the MCSS 
method a protein’s active site is filled with thousands of copies of organic functional groups 
which are allowed to energy-minimize onto the protein surface. Groups that minimize at 
the same location and bind most tightly are subsequently converted into pharmacophore 
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features. MOE [52] and LigandScout [70] at least require one known active ligand and a 
protein structure. Both can be used to generate a binding mode hypothesis and extract 
pharmacophore features from the modelled interactions. An improved pharmacophore 
can potentially be defined if multiple ligands are docked into the receptor active site 
and if only the conserved interactions are translated into pharmacophore features. Two 
recent comparative reviews on pharmacophore elucidation methods have recently been 
published by Luu et al. and Wallach. [82, 83].
2.2.4 Selection of essential pharmacophore features
To obtain valid binding mode hypotheses and subsequent compound library enrichment 
it is important to select only those features that correlate to biological activity (step 4 
in the SBP modeling work flow (Figure 2.1)). Three different approaches can be defined 
to select essential pharmacophore features (Figure 2.1, Table 2.1): i) using interaction 
energy calculations (paragraph 2.4.1), ii) using protein-ligand interaction information 
(paragraph 2.4.2), and iii) based on analysis of amino acid sequence variation (paragraph 
2.4.3). Finally, SBPs can be refined by training pharmacophore models with known 
active compounds (paragraph 2.4.4) and by complementing SBPs with shape restraints 
(paragraph 2.4.5).  
2.2.4.1 Energy-based selection
Several SBP methods select pharmacophore features based on their (potential) interaction 
energy with ligands (Table 2.1). In cases where (the binding mode of) only one ligand 
is known, protein-ligand interaction energies can be estimated to prioritize interactions 
and discard those with small contributions to the overall binding energy. Methods using 
probe docking or simulation typically select features at positions where probes have 
high interaction energies. Here the possibility also exists to examine multiple protein 
structures obtained via experimental methods or homology modeling. Such structures 
can be overlaid after which ‘hot spots’ can be identified which represent conserved 
or highly favourable  interactions. Most challenging is the selection of features after a 
geometry-based feature definition. Often, these methods place many pharmacophore 
features in the binding pocket and provide little information on which features to select. 
Sybyl [49] allows the user to manually pick the residues which correlate to binding 
activity and provides guidance via the calculation of surface properties. FLAP [66, 67] 
uses GRID [40] to generate molecular interaction fields (MIFs) which are condensed 
into discrete points representing the most favorable interactions. Pocket v.2 [71] uses 
a similar approach and generates a scored grid with the Pocket program to rank the 
protein-ligand interactions observed in the structure and utilizes this to automatically 
reduce the multitude of features to a reasonable number. Pocket v.2 also has the ability to 
suggest new binding spots besides the pharmacophore features already represented by 
a protein-ligand complex. Accelrys provides Ludi interaction maps [41] for H-bond donor, 
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H-bond acceptor and hydrophobic interactions. These are extracted from distributions of 
non-bonded contacts generated by a search through the Cambridge Structural Database 
[42] (which contains statistics about small molecule crystal structures) or generated by 
the application of interaction geometry rules which typically describe desired distances 
and angles between interacting pairs. Features are most likely in denser areas of those 
distributions. An alternative approach to GRID, LUDI and scored grids of the Pocket 
program is the extended electron distribution (XED)[84]. In contrast to the three methods 
previously described, XED generates field points based on a quantum orbital model. 
This enables the generation of multipoles for electronegative and atoms with Π orbitals 
resulting in a potentially more precise description of the desired sites of interaction.
2.2.4.2 Selection based on protein-ligand interaction information
If multiple ligands are available and binding mode hypotheses are generated, features 
which correlate to conserved protein-ligand interactions may be identified (Table 1). 
McGregor for example generated a pharmacophore for small molecule protein kinase 
inhibitors after extraction of conserved interactions in 220 kinase crystal structures 
[85]. Fingerprint methods like SIFt [86], SQUID [87] and FLAP [66] encode protein-ligand 
interactions in binary bitstrings and have been shown to be very useful for such analysis. 
The fingerprints typically contain information on the residue numbers and interaction type 
(HBA, HBD, positive ionisable, negative ionisable, hydrophobic, aromatic) observed in a 
protein-ligand complex. HS-Pharm [69] prioritizes cavity atoms that should be targeted 
for ligand binding, by training machine learning algorithms with atom based fingerprints 
of known ligand-binding pockets and was shown to have better enrichment curves for 2 
out of 3 targets compared to docking algorithms [69]. An overview of pharmacophore 
methods classified according to the pharmacophore comparison method (alignment/
fingerprint based) can be found in a recent review by Luu et al. [82]. 
2.2.4.3 Selection based on variation of protein amino acids in the ligand binding site
Amino acid sequence variations can be used to evaluate the role of individual amino 
acid residues in the binding site and select those that are important for ligand binding. 
These data can be derived from single nucleotide polymorphisms (SNPs), site-directed 
mutagenesis studies, or sequence alignments of protein families. Snooker prioritizes 
cavity residues by analysis of a multiple sequence alignment (MSA) of a large set of 
homologous protein sequences. Klabunde [28] uses a set of 10 homology models and 3 
X-ray structures to generate 35 single-feature pharmacophore elements associated with 
a sequence motif, the assumption being that certain sequence motifs at fixed positions 
are by definition important for ligand binding. Methods that use knowledge based 
prioritization of interactions (Table 2.1) are usually less dependent on the accuracy of the 
structures and models and are therefore better suited for protein families for which little 
structural data is available, like the G-protein coupled receptor (GPCR) family.
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2.2.4.4 Training of SBPs with known actives
Known active compounds can be used to select specific (combinations of) pharmacophore 
features and to include shape restraints in the SBP model. Purely structure based 
pharmacophore models can be tested and optimized by searching a set of known active 
compounds and selecting only combinations of pharmacophore features which correlate 
to actives. Accelrys offers for example the Ligand Profiler Protocol to create a heatmap 
of ligands vs. pharmacophores. In this way, retrospective virtual screening studies can 
be used to identify pharmacophore features which discriminate known ligands from 
inactive  (or decoy) molecules [69]. Snooker has been used to select compound sets by 
using ligand-based shape constraints based on poses of active compound in different 
sub-pharmacophores. The scoring function used by FLAP can be trained by supplying a 
set of known actives and known inactives and simultaneously minimizing the fraction of 
false positives and false negatives. 
2.2.4.5 Shape restraints
Shape and volume are valuable concepts in drug design as outlined in a review by Nicholls 
et al. [88] Both concepts provide guidance for scaffold ‘decoration’ with chemical groups 
for virtual screening and lead optimization and can also be used in library design, ligand 
fitting, pose prediction, or active site description. The selectivity of pharmacophores 
can also be increased by the addition of shape restraints. Greenidge et al. [89] showed 
that the number of false positives can be decreased by a factor of 2-5 by the application 
of excluded volumes while the number of true positives remains nearly unchanged. 
Klabunde et al. [28] indicate that the enrichment they obtain is largely due to the 
addition of shape restraints to their initial pharmacophores. The program FLAP has the 
ability to describe the shape of the binding site by using shape probes in the GRID force 
field on which the fingerprints are based [66, 90]. Restraints can be added at positions 
occupied by the receptor, by space not occupied by a set of known actives or by setting 
a minimum shape similarity (volume overlap) to a reference compound. Using a shape 
restraint often ensures that especially large molecules with many interacting groups can 
only match the pharmacophore features in a conformation which is complementary with 
the protein binding site and do not match purely by increased probability. Rella et al. [91]
showed the contribution of different shape restraints for angiotensin converting enzyme 
2 inhibitors. First they generated a pharmacophore comprising 5 features (two hydrogen 
bond acceptors (HBA), two hydrophobic groups and one zinc binding group) and screened 
a compound library of 3.8M compounds of which they retrieved 1M compounds. By the 
addition of a shape restraint set at 130% of the co-crystalized ligand volume, a further 
reduction to 91000 compounds was achieved. Filtering of this set with 25 excluded volume 
spheres placed at positions occupied by the receptor gave 56000 compounds while only 
38000 compounds were selected after the reduction in HBA tolerances to 1.3Å. A final 
shape filter of 110% and 100%, of the reference structure volume reduced the selection to 
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35000 and 16665 compounds, respectively. Seventeen compounds were selected based 
on high fit values as well as diverse structures and subjected to experimental validation 
in a bioassay. All these compounds showed an inhibitory effect on ACE2 activity. Some 
virtual screening methodologies are even entirely based on shape, like the ROCS method 
from OpenEye and Shape4 developed by Ebalunode et al. [92]. Both have been reported 
to perform well in terms of virtual screening [93, 94]. However to derive specific shape 
restraints the conformation and binding mode of at least one known active molecule is 
required and these methods have therefore limited compatibility with structure based 
pharmacophores. 
2.3. Applications of SBPs
SBPs are developed to improve molecular understanding of ligand-protein interactions 
(paragraph 2.3.1). As already mentioned in paragraph 2.1, SBPs can be used for virtual 
screening (paragraph 2.3.2), ligand binding mode prediction (paragraph 2.3.3), and 
binding site similarity detection (paragraph 2.3.4).  The lower part of Figure 2.1 gives a 
pictorial description of three different uses of SBPs and an overview of relevant articles 
concerning the application of structure-based pharmacophores is presented in Table 2.2. 
The application papers discussed in this review are diverse with respect to generation 
method, target family, available data and used software and will be discussed in more 
detail in this section. The SBP models described in the current paragraph furthermore 
exemplify: 1) some of the potential advantages of SBPs over LBPs; 2) the discovery of 
novel scaffolds different from known chemotypes; 3) the elucidation of protein-ligand 
binding modes, 4) better understanding of ligand binding sites. 
2.3.1 SBPs versus LBPs
While comparative ligand- and structure-based pharmacophore modelling studies are 
relatively scarce [95], more and more protocols are reported in which LBP and SBPs are 
combined [96-99]. This is in line with recent comparative virtual screening studies which 
show that ligand- and protein structure-based methods are complementary approaches 
in identifying different ligand chemotypes [99-101]. 
Thangapandian et al. [95] report a comparative study of ligand- and structure-based 
pharmacophores for the design of novel histone deacetylase 8 inhibitors. The LBP 
comprised 4 features retrieved 117 compounds of which 87 were active (corresponding 
to a ~8-fold enrichment over random picking), while. the SBP contained 6 features 
,and retrieved 74 compounds of which 63 were active (corresponding to a comparable 
enrichment value of ~10). Kumar et al. [96] describe a method which combines LBPs and 
SBPs in order to identify additional interaction sites with c-Jun N-terminal kinase-3 that 
cannot be derived by ligand-based approaches alone. Using a training set of 21 c-Jun 
N-terminal kinase-3 inhibitors a LBP of 4 features was derived and used to construct 
a quantitative pharmacophore model to predict the affinities of 85 inhibitors with a 
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correlation coefficient r2 of 0.846. Conserved hydrogen bond interactions with the hinge 
region were subsequently identified by docking of the 85 inhibitors into the kinase 
binding site and a SBP was derived which contained three additional features (2 donors 
and 1 acceptor) compared to the previously constructed LBP.  Griffith et al. [97] and Singh 
et al. [102] have described protocols that combine the speed of LBPs with the ability of 
SBPs to predict ligand binding modes and to discover novel molecules.
Comparative retrospective virtual screening studies report similar [99] or somewhat 
higher [100, 101] overall enrichment for ligand-based methods compared to structure-
based virtual screening approaches [101]. The performance of different ligand-based 
[103, 104] and docking-based methods [105] as well as the relative performance of 
ligand- vs. structure-based methods [99-101], can however be highly target dependent, 
justifying the use of both ligand-based and structure-based drug design techniques 
as complementary ligand discovery tools.  Evers et al. [100] for example performed a 
retrospective virtual screeninig study on four biogenic amine-binding G-protein couped 
receptors (GPCRs) in which three ligand-based methods (LBPs [106, 107], 2D [108], 
and 3D similarity searches [109]) were compared with docking [110-112] in homology 
models. They showed that ligand-based methods outperform structure based methods, 
although structure-based methods still have satisfying enrichment factors (up to 60% 
of actives in the top-ranked 1% of the screened database). Krüger et al. [99] compared 
docking [113-116], 3D similarity searches [117] and 2D similarity searches [118] and 
reported almost equal enrichments. Hit lists obtained from different algorithms were 
however complementary and the combination of different approaches is likely to result 
in more (and more diverse) actives.
Table 2.2: Examples of structure based pharmacophore studies demonstrating the potential and 
wide variety of applications of SBPs for different protein targets
Target Family Input Method Predictiona Result Reference
AlaR Racemase X-ray Overlay VS 19 compounds selected for 
testing
[121]
C3AR1 GPCR - Chemoprintsb VS 4 new ligands found [28]
various Me-Lys binders X-ray Proteinc BS similarity Similar sites identified [139]
CDK2 Transferase X-ray Overlay Model validation recognition known ligands [140]
CHK1 Transferase X-ray Overlay VS Enrichment > 9 fold [122]
DHFR-TS Synthase X-ray Complex BM correct prediction 6 ligands [141]
DNMT1 Transferase Model Probe BM + VS Explanatory pharmacophore 
model derived
[142]
HIV-1 RT Transcriptase X-ray, NMR Geometry BM HIV-1RT superligand 
generated
[138]
HtrA Protease Model Geometry VS 6 new ligands found [120]
Kinase Transferase X-ray Geometry BS similarity Relevant clustering of kinase 
families
[90]
Kinase
Thrombin
Transferase Protease X-ray Geometry BS similarity Bio-isosters proposed for 
multiple targets
[143]
Kv1.5 Potassium channel Model Geometry VS 19 new ligands found [124]
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Target Family Input Method Predictiona Result Reference
NK1R GPCR Model Overlay VS 1 new ligands found [123]
NS3 protease/helicase/
NTPase
X-ray Overlay BM + VS 15 compounds selected for 
testing, ligand interacting 
residues identified
[135]
Renin Angiotensinogenase X-ray Interaction BM + VS 2 new ligands found [136]
RSK2 Transferase Model Overlay BM + VS 2 new ligands found [144]
Thrombin Protease X-ray Geometry VS + scaffold 
hopping
Enrichment > 15 fold, suc-
cessful scaffold replacement
[137]
TrXr, 
HIV-1N
Reductase,  Integrase X-ray Geometry VS 1 new ligand found [119]
various - X-ray Complex VS Average 40.1 fold enrich-
ment
[38]
various - X-ray Geometry VS Average 17 fold enrichment [67]
a VS: virtual screening, BM: binding mode hypothesis generation, BS similarity: binding site similarity prediction 
b Chemogenomics approach has fixed positions for features and positions features dependent on the protein sequence. 
d Features are positioned on the protein (do not describe desired ligand features) 
2.3.2 Virtual Screening (VS) for new ligands
Structure based pharmacophores (SBPs) are very well suited to combine the efficient 
screening methodologies of pharmacophores with structure information obtained from 
X-ray crystallization and NMR spectroscopy efforts. In this section 7 studies are described 
[28, 38, 67, 119-123] which use different methods (geometry (paragraph 3.2.1), 
probe (paragraph 3.2.2), complex (paragraph 3.2.3), overlay (paragraph 3.2.4), and 
chemogenomics (paragraph 3.2.5) based) to derive and select pharmacophore features 
and applied these to virtual screening (Figure 2.1).
2.3.2.1 VS using geometry based SBP
 Tintori et al. used GRID to generate SBPs and showed that they could identify active 
molecules for thioredoxin reductase enzyme in a virtual screen and discover novel classes 
of active compounds able to inhibit complex formation between HIV-1 1N and viral host 
[119]. Pirard et al. used PASS (Putative Active Site with Spheres)[53] to identify the 
binding site and GRID to generate molecular interaction fields [124]. Manual selection of 
minima from the GRID energy maps and virtual screening with Unity [49] resulted in 19 
novel potassium channel blockers. Cross et al. used FLAP to generate SBPs for 13 different 
targets extracted from the DUD (Directory of Useful Decoys) and showed enrichment 
values of approximately 17 fold over random at a false positive rate of 1% [67]. Significantly, 
they retrieved a variety of chemotypes demonstrating that lead-hopping and scaffold 
hopping into different chemical classes with SBPs is feasible [67, 125]. Löwer et al. used 
PocketPicker [126, 127] to extract binding pockets and generated interaction points 
complementary to the protein residues using Ludi rules [42, 128]. A pharmacophore was 
identified in regions of high interaction point density by the LIQUID program [129]. With 
this SBP six compounds (from 22 selected in silico hits) were identified that were able to 
block E-cadherin cleavage by HtrA [120].
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2.3.2.2 VS using probe based SBP
Mustata et al. used molecular dynamics (MD) simulations to take protein flexibility into 
account in the construction of SBPs [121]. Ligbuilder [130] was used to generate property 
maps of the individual frames of the simulation of alanine racemase. Subsequently a 
dynamic pharmacophore was extracted using a MCSS approach [81] and the resulting 
SBP was used to identify compounds from ACD for experimental validation.
2.3.2.3 VS using complex based SBP
Salam et al. derived SBPs from 30 different protein-ligand complexes and used the 
energetic terms computed by the Glide XP scoring function to rank the importance of 
pharmacophore features. In a subsequent virtual screen they obtained enrichment 
values ranging from 3 to 100 (average 40) at 1% of the decoy database screened [38]. 
2.3.2.4 VS using overlay based SBP
Chen et al. derived a common feature pharmacophore by clustering multiple structure 
based pharmacophore features from different Chk1-ligand complexes in comparable 
binding modes [122]. This pharmacophore was used in combination with excluded 
volumes and shape constraints and showed an enrichment factor of >9 in a virtual 
screen. Evers et al. used the MOBILE method [131] to generate a NK1 receptor model 
that was able to accommodate known NK1 antagonists from structurally diverse classes. 
Using mutational data from literature and the features common to all known NK1 
antagonists considered, they deduced a pharmacophore model which was used to select 
7 compounds for biochemical testing, 1 of which showed affinity in the submicromolar 
range [123].
2.3.2.5 VS using chemoprint based SBP
Klabunde et al. used homology models and corresponding binding mode hypotheses 
to derive pharmacophore features associated with specific amino acid sequence motifs 
[28]. These so-called chemoprints were used to generate SBPs for the Urotensin-II 
receptor and Complement component 3a receptor 1 (C3AR1). Additional shape restraints 
were extracted from binding mode hypotheses of known active compounds and a virtual 
screen resulted in the successful retrospective identification of 81 Urotensin-II receptor 
ligands and in a prospective identification of 4 C3AR1 ligands. 
2.3.3 Ligand binding mode prediction
In contrast to ligand-based pharmacophores, structure-based pharmacophores add to the 
understanding of the interaction of a (set of) ligand(s) with the protein. This is beneficial 
for affinity and selectivity prediction, defining Structure Activity Relationships (SAR), 
and hit optimization. SBPs can also be used for a complete exploration of the binding 
pocket and enable the targeting of residues that have not previously been utilized in 
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interactions with ligands. A prerequisite for all these studies is the correct prediction of 
the ligand binding. So far only few studies have shown that SBPs are capable to reproduce 
ligand binding modes of experimentally determined protein-ligand complexes.  Loving et 
al. [37] showed that they could reproduce the binding modes observed in 12 different 
protein ligand complexes, while Sanders et al. used SBPs to correctly predict the binding 
modes of a set of beta-2-adrenergic agonists and antagonists/inverse agonists. SBPs can 
also been used in pharmacophore constrained docking and several studies have shown 
that pharmacophore constraints can significantly improve binding mode predictions and 
virtual screening enrichment [39, 132-134]. In this section several different methods to 
derive and use SBPs in binding mode prediction will be discussed.
2.3.3.1 Ligand BM prediction using geometry based SBP
Kaczor et al. have derived a SBP from a LUDI interaction map of the NS3 binding site 
[135]. This SBP was successfully used to identify new ligand interacting residues for this 
protein. Thangapandian et al. used Discovery Studio to generate LUDI maps of the crystal 
structure of renin with co-crystalized aliskiren and used the cluster pharmacophore tool 
to generate pharmacophore features [136]. Superimposition and analysis of two other 
structures with co-crystalized ligands overlaid on the aliskiren structure resulted in the 
selection of representative pharmacophoric features of catalytic importance. Ahlström et 
al. constructed a thrombin SBP model based on GRID molecular interaction fields (MIFs) 
for ligand scaffold replacements of active molecules [137]. A similarity search of curated 
scaffolds resulted in thrombin-derived scaffolds among the top solutions and docking of 
the entire molecules with replaced scaffolds showed feasible binding patterns. Griffith et 
al. used the Unity-3D module of Sybyl to generate a ‘superligand’ from different crystal 
and NMR structures to facilitate the design of structurally diverse inhibitors that interact 
with residues of HIV1-RT (mutants) in a novel manner [138]. 
2.3.3.2 Binding mode prediction using complex based SBP
Schormann et al. used LigandScout to extract pharmacophores for 8 different co-
crystalized DHFR inhibitors from the same chemical series [141]. All individual complex 
derived pharmacophores contain 5 hydrophobic features, 2 donors and 1 negative 
ionizable feature.  This pharmacophore was used together with docking to generate a 
ligand alignment and allow quantitative structure activity relation (QSAR) modeling with 
HASL [145] to predict affinity values for different inhibitors. Yoo et al. used the energy-
optimized pharmacophore (e-pharmacophore)[37, 38] approach that is based on Glide 
XP energy terms to extract the most favorable sites of interaction from 14 docked 
inhibitors in human DNA methyltransferase 1 (hDNMT1) and derived an explanatory 
pharmacophore for hDNMT1 inhibitors [142].
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2.3.3.3 Binding mode prediction using overlay based SBP
Zou et al. generated a SBP for CDK2 inhibition and reduced the number of features by 
selection of the top ranked 7 features as found in the 124 protein–ligand complexes 
[140]. They show that this most-frequent-feature pharmacophore encompasses 
previously reported ligand-based pharmacophore models. This pharmacophore was 
successfully used to discriminate CDK2 inhibitors from inactives and predict activities in 
retrospective virtual screening studies.  Nguyen et al. constructed a homology model of 
the RSK2 N-terminal kinase domain and optimized the models for different classes of 
active molecules, mimicking the ligand induced structural changes of the ATP-binding 
site of RSK2 [144]. A common pharmacophore was subsequently constructed from 5 
consistently recurring protein-ligand interactions. 
2.3.4 Ligand binding site comparison 
Many different methods to compare ligand binding sites based on pharmacophore 
or pharmacophore related properties have been developed in the past decade (for 
extensive reviews see Henrich et al. [61] and Kellenberger et al. [146]). Most methods, like 
FuzCav [147], CavBase [148] and PocketMatch [149] compare binding sites by assigning 
pharmacophore features directly to the protein. Campagna-Slater identified ligand 
binding sites that are chemically similar to known methyl-lysine binding domains using 
such SBP models [139]. The KRIPO method, developed by Ritschel et al., uses protein ligand 
interaction features derived from the ligand binding site to create 3D-pharmacophore 
fingerprints. This method has been successfully used to identify similar binding pockets 
and suggest structural modifications to ligands based on presumed bioisosteres [143]. 
Sciabola et al. used FLAP to compare protein binding sites and were able to cluster kinase 
protein families in a relevant manner, predict ligand activity across related targets and 
perform protein-protein virtual screening [90]. These methods are very well suited to 
identify proteins which can be selectively targeted  and compounds which might have 
activity on proteins with pharmacophorically similar binding sites. 
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2.4. Conclusion
The current review describes the different steps in the construction of SBPs: i) protein 
structure preparation, ii) binding site detection, iii) pharmacophore feature definition, 
and iv) pharmacophore feature selection. SBP generation typically starts with a protein 
preparation step to correct and optimize the starting structure. Subsequently the ligand 
binding pocket can be defined by a pocket detection algorithm and several strategies 
can be used to convert the protein properties to ligand. A choice of method can be 
made depending on the resolution of the available protein structure or model and 
the availability of known active ligands and corresponding binding mode hypotheses. 
Geometric methods to derive SBPs are typically least restrictive and are together with 
the probe based method the only approaches which can be applied in the absence 
of known ligands. A real challenge in SBP design is the reduction of the typically high 
number of features in a structure based pharmacophore to only those features which 
are related to biological activity. Energy based methods to construct SBPs in these 
cases typically depend on the accuracy of the input structure and the binding mode 
hypothesis generated, while statistics based measures, such as those relying on protein-
ligand complex or protein variance information, are generally more robust with a greater 
capability to deal with low resolution or low quality structures. The relatively simple 
concept of a pharmacophore makes it an attractive tool for various research applications. 
Several studies have described the successful use of SBPs for binding mode hypotheses 
generation, virtual screening and binding site similarity calculations, demonstrating that 
SBPs are valuable tools for hit and lead optimization, compound library design and target 
hopping, especially in cases where ligand information is scarce.
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Abstract
The GPCRDB is a Molecular Class-Specific Information System (MCSIS) that collects, 
combines, validates, and disseminates large amounts of heterogeneous data on 
G protein-coupled receptors (GPCRs). The GPCRDB contains experimental data on 
sequences, ligand binding constants, mutations, and oligomers, as well as many different 
types of computationally derived data such as multiple sequence alignments and 
homology models. The GPCRDB provides access to the data via a number of different 
access methods. It offers visualization and analysis tools, and a number of query systems. 
The data is updated automatically on a monthly basis. The GPCRDB can be found online 
at http://www.gpcr.org/7tm/.
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3.1 Introduction
G protein-coupled receptors constitute a large family of cell surface receptors. They 
regulate a wide range of cellular processes, including the senses of taste, smell, and 
vision, and control a myriad of intracellular signalling systems in response to external 
stimuli. GPCRs are a major target for the pharmaceutical industry as is reflected by the 
fact that more than a quarter of all FDA approved drugs act on a GPCR [1]. GPCRs are 
arguably one of the most-researched classes of proteins, but despite intensive academic 
and industrial research efforts over the past three decades, little is known about the 
structural basis of GPCR function. From about 350 genes that code for the non-olfactorial 
receptors in the human species [2], only about 30 are truly validated therapeutic targets 
[3], indicating this family’s immense potential for future drug development. The fact that 
GPCRs can form homo-oligomeric and hetero-oligomeric complexes [4] has created a lot 
of new challenges and opportunities in the rational drug design process. In addition, a 
number of high-resolution crystal structures recently became available, providing new 
insights in receptor structure and function and giving the GPCR field a big stimulus.
Researchers who focus on one particular protein or a class of proteins are confronted 
with the fact that both the number and the size of databases are expanding at an ever-
increasing pace. Although many databases like PDB [5], UniProtKB [6], KEGG [7], EMBL [8], 
GenBank [9], etcetera are invaluable for their research, for the average wet-lab scientist 
these databases are less suitable for gathering, integrating, and updating different types 
of data in an easy and efficient manner. Studies that involve carrying over information 
from one protein to the other seem simple at a first glance, however, the amount of 
data that needs to be collected from heterogeneous sources, converted to syntactic and 
semantic homogeneity, validated, curated, stored, and indexed, is enormous.
The GPCRDB is a data source that holds a large amount of heterogeneous data in a well-
organized and easily accessible form. This data is validated, internally consistent, and 
updated regularly. In addition to being a one-stop GPCR resource, the data in the GPCRDB 
facilitates inferring new information using a wide spectrum of bioinformatics techniques. 
The GPCRDB is a paradigm for MCSIS technology [10, 11].
3.2 New features
The previous release of the GPCRDB [12] was almost entirely a static website, neither 
offering much dynamic content, nor possibilities for complex interactions or the use of 
computational tools. We addressed this problem by rewriting the entire system. The 
use of new tools and modern-day e-Science technologies has resulted in improved 
flexibility and greater user-friendliness. We have updated the methods for harvesting 
GPCR sequences, expanded the number of data types available, and added new tools and 
services to the GPCRDB. Nearly all of the functionality that is offered through the web 
interface is also available in the form of web services. This allows for the easy integration 
of the GPCRDB in custom built tools and scripts or in workflow management tools such 
47GPCRDB
 
Ch
ap
te
r 3
as Taverna [13] and Pipeline Pilot (http://www.accelrys.com/products/pipeline-pilot/). 
All pages now offer extensive context-sensitive help functionality, explaining what kinds 
of data are displayed and how to use the available interactive functionalities such as 
searching and computational tools. 
3.3 Data content
The contents of the GPCRDB can be categorized in three classes: primary, secondary, and 
tertiary data. Sequence data, ligand binding constants, mutant information, structural 
data, and oligomer interactions make up the experimentally determined primary 
data. Data types such as multiple sequence alignments, homology models, correlation 
patterns, and entropy-variability data are inferred from these primary data, and fall in the 
category of secondary, or computationally derived data. Curator provided interpretations 
and other user help facilities make up the tertiary data category. Table 3.1 shows a few 
vital statistics about the volume of the data content of the GPCRDB.
Table 3.1: Statistics for the September 2010 release of the GPCRDB.
Sequences 27045
Families (and multiple sequence alignments) 1270
Mutations 7703
Ligand binding data 12086
Protein structures 195
Homology models 22616
Residues 11290993
Species 1521
Oligomers 115
3.4 Primary data
3.4.1 Sequences
GPCR sequences are extracted from NCBI’s NR database, which is a non-redundant 
protein sequence database with entries from a set of sequence repositories that 
include GenBank CDS translations, UniProtKB, and PDB. GPCR sequences are selected 
by classifying them against a database of Hidden Markov Models (HMMs). For each of 
the protein families in the GPCRDB a HMM is available. These HMMs are created from 
multiple sequence alignments (MSA) of the previous GPCRDB release. HMM files are 
created with the HMMER software package (http://hmmer.wustl.edu/).
As a first step in harvesting GPCR sequences we perform a BLAST search with all the 
HMM consensus sequences against the NR database. By using a very relaxed cut-off value 
we collect a large number of resulting hits, including many false positives. This step is 
necessary to limit the amount of sequences that will be used for the actual classification 
while ensuring a minimal false-negative rate. This step reduced the search space (for 
the September 2010 GPCRDB release) from about 11 million sequences to about 80 
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thousand. These hits are scored against the collection of HMMs to place them in the 
correct family or discard them as not being a GPCR sequence. Additional filter steps are 
applied such as filtering out sequence fragments and sequences that contain ambiguous 
amino acid characters, resulting in a final set of about thirty thousand sequences. The 
corresponding database entries of the selected sequences are retrieved with MRS [14] 
and additional data such as gene names and species information is extracted and stored. 
The GPCRDB holds for each sequence one principal access page. Figure 3.1 shows an 
example of such a page.
The protein detail page (Figure 3.1) contains a panel that visualizes sequence annotations 
such as helix boundaries, cysteine bridges and glycosylation sites. These annotations 
are loaded in real time using the DAS distributed annotation system [15, 16] and are 
visualized by Dasty2 [17], resulting in always up-to-date annotations. We use the UniProt 
DAS server to retrieve sequence annotations.
Figure 3.1: Screenshot of the principal protein sequence page of the human beta-2 adrenoceptor. 
The top table contains details about the protein record and hyperlinks to the protein family browsing 
page and other data sources that contain information about this protein. The middle table holds 
the sequence in which each amino acid is linked to its own residue page. The bottom table holds 
annotations that are obtained in real time using the DAS (15) system.  
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3.4.2 Ligand binding data
Ligand binding constants are available for a large number of GPCRs and are obtained 
from various sources. For each GPCR we provide links, if possible, to the ChEMBL [18] 
and GLIDA [19] databases. In addition, ligand-binding information that is obtained from 
collections from P. Seeman [20] and Organon N.V. [21] is available. Since ligand binding 
data is very hard to obtain from the literature we encourage academic and industrial 
researchers to submit their ligand binding data to the GPCRDB in order to make this data 
accessible to the scientific community.
3.4.3 Mutations
The GPCRDB contains a large number of well-annotated mutations obtained from different 
sources. We have two sets of mutations that were manually extracted from literature. 
Mutant data from the tinyGRAP database [22] contains references to scientific literature 
describing point mutations as well as insertions, deletions, and chimeric receptors. A 
collection of in-house manually extracted mutant data contains a few thousand point 
mutations and the effects of those mutations on the function of the receptor. We have 
extracted sentences from the papers that qualitatively describe the effects of these 
mutation and we have extracted quantitative data such as effects on ligand binding, 
expression, activation, or constitutive activity. 
In addition to the two manually curated datasets we also have a large body of mutations 
that were extracted from the literature by the software package MuteXt [23]. A sentence 
describing the effects of the mutations is available for all mutations extracted by MuteXt. 
3.4.5 Structures
Structures are obtained from the PDB. Links to structures that were re-refined in the 
PDB_REDO project [24] are included. We provide manually ‘cleaned’ monomers of the 
major GPCR PDB files that have been prepared for easy casual use by the life sciences 
community.
3.4.6 Oligomers
GPCR oligomerization has been an area of interest and controversy for many years. 
Recently there has been increasing evidence that both homo-dimers and hetero-
dimers play a crucial role in GPCR signalling [25-27]. The GPCR-OKB [28] is a database 
that stores manually extracted computational and experimental information about 
GPCR oligomerization. Lists of protomers, experimental details and, where available, 
inferred oligomer interaction sites are available for all oligomers. This data has been 
fully integrated in the GPCRDB, making the information about both GPCR protomers and 
oligomers readily available. 
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3.5 Secondary Data
3.5.1 Multiple sequence alignments
Multiple sequence alignments (MSAs) are available for all families. MSAs are generated 
with WHAT IF [29] for all GPCR sub-families using hand-optimized sub-family specific 
profiles. Position-specific annotations such as secondary structure information and 
generalized residue numbers are stored in the profiles and are incorporated in the 
alignments. The general residue numbers are relative to the arbitrarily selected numbers 
for very conserved  residues and motifs such as the well-known E/DRY and NPXXY motifs. 
Using a profile to align a GPCR sub-family allows for the mapping of the general residue 
numbers on the sequences that are being aligned. The result is that the residues in the TM 
domains, helix VIII and sections of the loops are labelled with a general residue number. 
For creating alignments of parent GPCR families we make use of these general residue 
numbers. For all the GPCRs that are being aligned we select all the general residue 
positions that the sub-families have in common and create the alignment by listing, for 
each sequence, the residues at the selected positions. GPCR parent family alignments are 
thus not built using standard alignment algorithms but are created by selecting residues 
that are likely to share the same position in the three-dimensional structure.
3.5.2 Homology models
Despite the recent publication of a number of GPCR structures the amount of structural 
information on GPCRs is still very limited. We have built structure models of all Class A 
receptors to at least partially fill this gap. Information extracted from the profile-based 
multiple sequence alignments is used to generate high-quality sequence-structure 
alignments between GPCR sequences and a number of experimentally determined 
structures. Based on these alignments homology models of all GPCRs have been 
automatically created and will be automatically updated as more sequences become 
available. Template structures are selected based on sequence identity and a number of 
structure quality criteria. The homology models are created with WHAT IF and YASARA 
[30]. Models will be automatically replaced when new structures become available 
that are better templates, with better being defined as either being solved with higher 
resolution data, or as having a higher percentage sequence identity.
3.5.3 Correlated mutation analyses
Correlated mutation analysis (CMA) is a technique that can find pairs of residues that 
remain conserved or mutate in tandem during evolution. Residues that show correlated 
behaviour in multiple sequence alignments are likely to be functionally related, and 
networks of those correlating residues indicate functional groups [31]. The rationale 
behind this analysis is that when a mutation occurs at a functionally important site, the 
protein either becomes functionally impaired or may acquire its original or a different 
function due to compensatory mutations at one or more other positions. Correlation 
scores are available in a number of different formats for all GPCR (sub)families. 
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3.5.4 Entropy and variability data
The amount of entropy and variability that is observed for a certain position in multiple 
sequence alignment tells something about the types of pressures exerted on that position 
during evolution [32-34]. Entropy-variability data is available for each multiple sequence 
alignment in the GPCRDB. We offer this data in tabular from, entropy-variability plots 
[35], and more advanced subfamily specific two-entropy plots [36] based on the original 
method described by Ye et al. [37] (Figure 3.2).
Figure 3.2: Screenshot of the interactive entropy and variability page. Residues are interlinked in 
all page elements, clicking results in highlighted selections. A: The multiple sequence alignment 
of the selected subfamily. B: the approximate location of this position in the 3D model of the 
transmembrane domain of class A GPCRs is shown in red and is annotated with general residue 
number information. The orange ball in the structure model indicates the approximate location of 
the assumed binding site for low molecular weight compounds of class A GPCRs. C: In this panel the 
user can choose among four display modes that describe the entropy and variability of all positions 
in the alignment; shown is the entropy cluster variant.
3.6 Tertiary data
3.6.1 Residue annotations
Residues in the GPCRDB are labelled with the original Oliveira et al. [38] numbering 
scheme as well as with residue numbers from the more recent Ballesteros-Weinstein 
scheme. Use of these general residue numbers allows for easy transfer of information 
between proteins. General residue numbers are available for all residues within 
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conserved structure elements. These include all transmembrane helices, helix VIII, and 
a few sections in the loops. For each residue with a general residue number a short 
description of its properties and interactions is available. These descriptions are based 
on a manual analysis of the currently available crystal structures. 
3.6.2 Cytoscape networks
The GPCRDB provides cytoscape [39] network files for all GPCR families. These network 
files contain the proteins of a family with distances calculated from the family alignments. 
For all proteins the protein family information, species names and the amino acid types 
for all the residues annotated with a general residue number are available as attributes. 
This allows for complex analyses, such as colouring proteins by amino acids at a certain 
residue position to compare i.e. species or sub-type specific differences.
3.6.3 Mutation predictions
For all positions for which a general residue number is available we have investigated 
the most likely effects of mutations at these positions. Short fragments of text have been 
created that explain for each of these positions the likely effects of the mutation on 
structural and functional levels. References to key papers in which experimental evidence 
for these effects is available are included in the fragments. Examples of such effects are 
the loss of ligand binding affinity when mutating a residue in the ligand binding pocket, 
the loss of G protein binding when mutating residues at the G protein binding interface, 
and increased constitutive activity when residues are mutated a the interface between 
helix III and VI. 
3.6.4 Workflows
We have created a number of Taverna workflows that use the web services of the GPCRDB 
as a starting point for users who want to programmatically access the GPCRDB. Workflows 
are available that use the GPCRDB BLAST service, create custom-built alignments and 
retrieve several different data types. The workflows and documentation are available 
via the myExperiment web portal [40] and are tagged with ‘GPCRDB’. We encourage 
researchers to share their own workflows via the myExperiment portal.
3.7 Data access
The GPCRDB provides fast and easy access to all its data and information. The GPCRDB 
does not merely lists available data, but all data types are fully integrated. For example, 
mutations are accessible via the protein detail pages but can also be found at the residue 
level. The same holds true for oligomer interaction interfaces, where details about these 
interactions are available via the oligomer pages, but also via the protein detail pages 
of interacting members, as well as via the pages of residues that are reported in the 
interaction. This tight data integration makes it a very efficient resource to use. The 
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GPCRDB’s user interface allows the user to easily navigate from one data type to another 
and often suggests multiple routes to explore the data, thereby hopefully generating 
ideas and questions while the user navigates the system.
The four fundamental facilities to be provided by information systems are browsing, 
retrieval, query, and inferencing. These four types of access have been an integral part 
of the GPCRDB set-up from the beginning. The total redesign of the GPCRDB that has 
taken place the past few years has allowed us to add novel access facilities in all these 
four categories.
3.7.1. Browsing
The main way to access the data is via a hierarchical list of GPCR families, which is based 
on the pharmacological classification of GPCRs [41] (Figure 3.3). Users can traverse the 
GPCR family tree and view or download the data for a selected family. Available data types 
include multiple sequence alignments, entropy-variability analyses, and lists of family 
members. Alignments can be viewed in multiple ways. In addition to the classic HTML 
view, the GPCRDB offers an interactive multiple sequence alignment viewer (JalView [42], 
that can show additional information about the MSAs, supports a number of viewing and 
sorting options, and that can be used to generate phylogenetic trees. Residues for which 
mutation data is available are hyperlinked in the alignments to pages that contain more 
details about those mutations.
Figure 3.3: Screenshot of the GPCR family page. The GPCR family tree is shown on the left with the 
amine sub-family expanded. On the right-hand side the data for the selected family (adrenoceptors) 
is shown.
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The pages that display data on individual proteins (Figure 3.1) contain a large amount of 
data and links to other data sources. Table 3.2 lists the remote databases that have been 
indexed in the GPCRDB. Some of these remote data are actually most easily queried via 
the GPCRDB. 
Table 3.2: Non-GPCRDB data facilities that can be found through the GPCRDB.
Database Type of data Address
GPCR-OKB (GPCR Oligomerization Knowledge 
Base)
Dimer information http://data.gpcr-okb.org/gpcr-okb/
GPCRRD (GPCR Restraint Database) Modelling restraints http://zhanglab.ccmb.med.umich.edu/
GPCRRD/
GLIDA (GPCR Ligand Database) Ligand data http://pharminfo.pharm.kyoto-u.ac.jp/
services/glida/
gpDB (G Protein Database) G Protein data http://biophysics.biol.uoa.gr/gpDB/
Uniprot Protein information http://www.uniprot.org/
Nava Sequence variants http://nava.liacs.nl/
ChEMBL Ligand data http://www.ebi.ac.uk/chembl/
Ensembl Genomic information and annotations http://www.ensembl.org
On the protein detail page the sequence is displayed and each residue is hyperlinked 
to its individual page where additional information is listed about that specific residue; 
residue numbers in multiple numbering schemes, available mutation data for that specific 
residue and mutations at equivalent positions, and reported oligomeric interactions. 
Snake plots are available for all proteins in the GPCRDB (Figure 3.4). Residues for which 
mutations are available are hyperlinked from the snake plots to pages that contain details 
about those mutations. 
Figure 3.4: Snake plot of the human β2 adrenoceptor.
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Other data types such as mutations, ligand binding constants and information about 
oligomerization states are displayed when available and links are provided to pages that 
contain more detailed information about those data (Figure 3.5). 
The pages with mutation details contain links to the scientific literature and if available 
in that literature, the qualitative and quantitative data on the effects of the mutations is 
displayed. The oligomer detail page contains links to the GPCR-OKB and to the individual 
protomers in the GPCRDB. If certain residues are involved in the oligomer interaction, 
hyperlinks to individual residue pages are available. 
Figure 3.5: Screenshot of the detail page of residue W175 in OPSD_HUMAN. Residue numbers 
in different formats are shown, the approximate location of the residue is visually indicated and 
available mutations and oligomer data for this residue are listed. 
3.7.2 Retrieval
Data can be retrieved via the web pages and via the web services. The web services offer 
very extensive retrieval possibilities, together allowing for the retrieval of all data types 
present in the GPCRDB. Subsets have been created for frequently requested data sets 
such as all human sequences and the human non-olfactory sequences. Protein family 
alignments can be downloaded in a number of different formats. Sequences, structures, 
ligand binding data and mutations can be downloaded from the protein detail pages. 
After querying the GPCRDB via the web pages, query result sets can be downloaded in 
FASTA format. A complete copy of the GPCRDB is freely available for in-house usage by 
academic and industrial researchers alike. 
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3.7.3 Query
Users can query the GPCRDB via a number of different search pages. Identifiers, genes, 
species, descriptions, and protein family names can be used to search for GPCRs (Figure 
3.6). There are a number of filters available to limit the search results. Users can indicate 
whether only GPCRs should be shown for which mutations, structures, oligomers, or 
ligand binding data are available. 
Mutations can be found via the mutant search page, where one can search by residue 
number (multiple numbering schemes are available) and/or residue types. The GPCRDB 
offers a BLAST service that allows users to BLAST their sequence against the sequences 
in the GPCRDB. 
All search options and the BLAST services are available via the web interface and as web 
services. A full SQL search facility will be made available in the near future to allow for 
complex queries and analyses.
Figure 3.6: The protein search page. 
3.7.4 Inferences
The amount of available GPCR related data is too large for a human to grasp and 
disseminate. The GPCRDB contains a series of inference engines that determine 
interesting correlations between the data, while a series of software tools help the user 
with data reduction and abstraction.
3.7.4.1 Building alignments
The GPCRDB offers the possibility to create custom-made alignments. The alignments 
are created by using the procedure that is used for the parent GPCR families as discussed 
earlier. Users can select the proteins and residue positions that should be aligned, 
allowing for the creation of e.g. an alignment of all binding pocket residues for a selection 
of proteins (Figure 3.7). The custom-built alignments are available for download and 
users can directly interact with the alignments using JalView. 
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3.7.4.2 Predicting the effects of mutations
We have started to create a service where users can predict the effects of a point 
mutation. As for now, predictions are mainly based on human knowledge that is stored 
in a computer readable format. This information is combined with a number of simple 
analyses on a homology model of the receptor being mutated, such as looking for steric 
clashes and helix disruptions. Results are presented as text-fragments that explain the 
effects of the mutation on the structure. Care has been taken to ensure that the results 
are presented in a life scientist friendly manner. The text contains references to literature 
and is enriched with figures and animations of the mutation and its surrounding 
environment. In the near future more intelligence will be added to the software, such 
as incorporating the quantitative data from the mutations extracted from literature and 
ligand binding information.
3.7.4.3 Analysis of entropy derived patterns
We offer a page where users can interactively analyze the protein family alignments (Figure 
3.2). Plots displaying entropy and variability scores are displayed with a 3-dimensional 
model and a multiple sequence alignments. Residues are linked in the three page 
elements, so that clicking on a residue position in the multiple sequence alignment will 
highlight the residue position in the structure as well as in the entropy and variability plots. 
This offers researchers a very intuitive way of looking at conservation scores, even at the 
subfamily or receptor level, and relating those scores to the 3D structure. In combination 
with above mentioned accessible data site directed mutagenesis candidate selection, 
homology modeling and ligand binding hypotheses generation can be performed. 
Figure 3.7: A list of proteins and an 
optional list of residue positions can be 
used to generate custom alignments. 
In this figure we have selected a 
number of proteins for which crystal 
structures are available. The GPCR 
binding pocket residue positions as 
proposed by Gloriam et al. [43] are 
used. The result will be an alignment 
of all pocket residues of the selected 
proteins.
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3.7.4.4 Annotating scientific literature
We have developed a new interface for the GPCR data in the form of a GPCR-specific PDF 
reader [44]. This reader can annotate scientific literature on GPCRs on the fly, providing 
users with context sensitive data from the GPCRDB (Figure 3.8). This software is available 
upon request and will be made freely available at the day of publication of this article.
3.8 Implementation 
The data in the GPCRDB is stored in a PostgreSQL (http://www.postgresql.org/) relational 
database. The web service interface is developed with the Apache CXF (http://cxf.
apache.org/) web services framework. We offer both SOAP and REST endpoints. The web 
interface is built using the Apache Wicket (http://wicket.apache.org/) web application 
framework. The database is accessed via a Hibernate (http://www.hibernate.org) object-
relational mapping layer. The server is running within Sun’s Glassfish (http://glassfish.org) 
application server. 
Figure 3.8: An impression of the PDF reader (Utopia Documents [45], Utopia Documents-GPCRDB 
(in preparation)) interface to the GPCRDB data. A: A scientific paper [46] is shown that is annotated 
by the GPCRDB. Annotations are available for all the highlighted words. B: An example of such an 
annotation (the mutation F339L) is displayed. C: A short, manually extracted description of the 
effects of this mutation is included. 
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3.9 Future directions
In the near future we would like to extend the interactive facilities of the GPCRDB by 
offering users more tools to analyze the available data. The entropy-variability analysis 
pages are a good example of the types of services we will be offering. In addition to our 
main focus of data collection and integration we would like to extend our focus towards 
the more challenging field of knowledge integration. The mutation effect predictor is 
a pilot project to explore the things we can do by combining human expertise with 
computational power. We are in the process of transforming the GPCRDB from mainly a 
one-stop resource for GPCRDB data to a place where scientists can use tools to interact 
with the data and make predictions. 
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Abstract 
G-protein coupled receptors (GPCRs) are involved in many different physiological 
processes and their function can be modulated by small molecules which bind in the 
transmembrane (TM) domain. Because of their structural and sequence conservation, 
the TM domains are often used in bioinformatics approaches to first create a multiple 
sequence alignment (MSA) and subsequently identify ligand binding positions. So far 
methods have been developed to predict the common ligand binding residue positions 
for class A GPCRs. 
Here we present 1) ss-TEA, a method to identify specific ligand binding residue positions 
for any receptor, predicated on high quality sequence information. 2) The largest MSA 
of class A non olfactory GPCRs in the public domain consisting of 13324 sequences 
covering most of the species homologues of the human set of GPCRs. A set of ligand 
binding residue positions extracted from literature of 10 different receptors shows that 
our method has the best ligand binding residue prediction for 9 of these 10 receptors 
compared to another state-of-the-art method.
The combination of the large multi species alignment and the newly introduced residue 
selection method ss-TEA can be used to rapidly identify subfamily specific ligand binding 
residues. This approach can aid the design of site directed mutagenesis experiments, 
explain receptor function and improve modelling. The method is also available online via 
GPCRDB at http://www.gpcr.org/7tm/ .
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4.1 Introduction 
G-protein coupled receptors (GPCRs), also known as 7 transmembrane receptors, 
represent a large superfamily of proteins in the human genome and are responsible 
for the transduction of an endogenous signal into an intracellular message, which 
triggers a response in many different physiological pathways. The structural architecture 
and chemo-mechanical concept of G-protein coupled receptors can be seen as an 
evolutionarily success as witnessed by the large amount of family members and diversity 
of applications in biological processes [1]. 
Not surprisingly, an increasing number of these GPCRs is the subject of investigation as 
targets in drug discovery. Historical drug discovery approaches have identified GPCRs as 
a successful drug target, since 25-50% of the drugs currently on the market interact with 
a GPCR [1, 2].
In humans, the family of 7 transmembrane receptors is represented by approximately 
900 members which can be divided in several classes based upon standard similarity 
searches [3-5].
Recently there has been a reclassification of receptors according to the GRAFS system 
which has the following groups: glutamate, rhodopsin, adhesion, frizzled/taste2, and 
secretin[6]. From the structural and functional viewpoint the rhodopsin-like family, also 
known as the class A receptors, is the largest and best studied family [6].
Receptors from different families are very diverse [1, 5, 7], but can all be characterized 
by the presence of seven structurally conserved alpha helices, which span the cell 
membrane. Most GPCRs couple to a G-protein complex upon ligand binding, resulting in 
the dissociation of the alpha subunit from the beta and gamma subunit. The final signal 
depends on the alpha subunit of the G-protein (Gαi, Gαs , Gαq/11 , Gα12/13 ) which is 
activated and is presumed to be receptor and ligand dependent [8-12].  The non olfactory 
Class A receptors recognize a large variety of ligands including photons [13], biogenic 
amines [14], nucleotides [15], peptides [16], proteins [17] and lipid-like substances [18-
21]. Most ligands are believed to bind fully or partly within the transmembrane bundle 
and to trigger signaling through a conserved canonical switch [9]. The assumption that 
similar molecules bind to similar receptors [22] and that small molecules bind within the 
upper part of the transmembrane helices, similar to 11-cis retinal in bovine rhodopsin, 
carazolol in the human beta adrenergic receptor 2, timolol in the turkey beta adrenergic 
receptor 1 and ZM-241385 in the human adenosine A2 receptor, gives rise to the 
application of pattern recognition analysis on multiple sequence alignments of those 
helices or parts thereof to identify ligand binding residues. It has also been shown that for 
some receptors which bind large proteins, like the luteinizing hormone receptor (LHR), 
low molecular weight (LMW) compounds can be designed which bind in between the 
TM-bundle and modify signaling [23, 24], suggesting that the same pattern detection 
techniques could be used for those receptors as well. 
Structure based drug design strategies often rely on high resolution information derived 
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from protein crystal structures. Elucidating GPCR structures at atomic resolution remains 
difficult and has only been successful for a small set of receptors so far (bovine rhodopsin 
[25], squid rhodopsin [26], human beta-2-adrenergic receptor [27], turkey beta-1-
adrenergic receptor [28] and the human A2A adenosine receptor [29]). These structures 
have been extremely helpful for understanding the function and ligand binding properties 
of class A receptors and are a major step forward towards rational drug design in this 
class of receptors. However, understanding the differences in for example agonist and 
antagonist binding or extrapolating structural information on a small subset of GPCRs to 
evolutionary distant receptors remains problematic and perhaps may only be solved as 
more structures become available [30]. As long as this information is limited there will 
be a need for comparative methods to explain the structural and functional differences 
between GPCRs.
With the recent genome sequencing efforts, more and more data becomes available to 
perform comparative modelling. Currently, data on 51 species is available in ensemble 
[31] (release 56) enabling the large scale comparison of sequences within and across 
species. Methods to mine sequence data and identify structurally and functionally 
important residues have been developed. For example, in 1996 Lichtarge introduced the 
evolutionary trace method to calculate the conservation of a residue in each trace of 
a phylogenetic tree[32]. In 2004 Oliveira et al. introduced the entropy variability plot 
and showed that the location of the aligned residue positions in these plots correlate 
to structural characteristics[33]. Based on a similar concept as the entropy variability 
plot Ye et al. introduced the two entropy analysis (TEA) in 2006 to identify structural and 
functional positions in the transmembrane region of class A GPCRs[34].
Here we present subfamily specific two entropy analysis (ss-TEA), the first method to 
identify the ligand binding residues on subfamily level. In contrast to the previously 
published methods ss-TEA is able to discriminate between subfamilies and able to 
identify the approximately five residues that are involved in ligand binding for each 
individual subfamily of the class A GPCRs. ss-TEA is predicated on high quality sequence 
information deduced from a multiple sequence alignment (MSA) which was generated 
by extracting species homologues of the class A non olfactory GPCR sequences with a 
method reported here. This new MSA is characterized by a more complete set of species 
orthologs which improves the subfamily definition and results of ss-TEA. Receptor 
specific sets of ligand binding residues, generated by ss-TEA, improve the understanding 
of receptor ligand interactions and the design of mutagenesis experiments, and guide the 
process of homology modelling.
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4.2 Results and discussion 
4.2.1 Sequence retrieval & Alignment
Using a template set of 286 human GPCR sequences, a BLAST search was performed 
to retrieve non olfactory class A GPCR sequences. This resulted in 20111 sequences 
originating from 1941 species. An alignment of the transmembrane helices was obtained 
by gap free alignment of all retrieved sequences using HMM models of the TM domains. 
Subsequent removal of sequences with low HMM scores resulted in a MSA of 13324 
class A GPCR sequences. 33 of the 1941 species contained over 100 class A non olfactory 
GPCR sequences and were deposited in a database and used for further analysis. The 
resulting multiple sequence alignment (MSA) comprises 6876 sequences of which 4816 
sequences originate from Ensembl and 2060 from Swissprot and TrEMBL. For all aligned 
helices in the database, it can be shown that the overlap with the predicted helices in 
Swissprot is over 90% for 90% of the TM sequences and that almost no helices can be 
found which have less than 75% overlap (data not shown). Due to the gap free alignment 
procedure of TM domains only those regions are subject to further analysis, loop regions 
will be omitted and anomalies in helix architecture, i.e. proline induced kinks will not be 
addressed.
From the distance matrix of all 6876 sequences a hierarchical tree was constructed. A 
visualization of all human entries of this tree is depicted in Figure 4.1A. The number of 
sequences from all other species, which can be grouped together with a human entry by 
collapsing a node, is indicated behind the receptor name. Phylogenetic analysis between 
human and mouse indicated that most human GPCRs have one ortholog in mouse [35]. 
Since most of the 33 species in our alignment are mammals with an evolutionary distance 
to human comparable to mouse, it is to be expected that one ortholog from every 
species can be grouped together with every human receptor. Exceptions to expected 
1-1 ortholog pairs will be receptors that have been subject to gene expansion or have 
become pseudogenes. Examples include the MAS-related G-protein coupled receptors 
in which gene expansion has occurred, and the GNRHR and 5HT5A receptors which have 
pseudogenes in human [36]. Figure 4.1B shows the distributions of species sequences 
grouped together in a node with the thyroid stimulating hormone receptor (TSHR). 
Figure 4.1C displays that in most cases one sequence per species is grouped together in 
a node containing only one human sequence, suggesting that these are orthologs of this 
human receptor.
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Figure 4.1: Phylogenetic tree of all GPCR sequences. A: Visualization of the human entries from the 
hierarchical tree constructed from the MSA of the TM domains from all sequences in the database. 
The number indicated after the receptor name equals the number of sequences which are grouped 
together in the visualized node.  Leafs are colored according to the IUPHAR [36] family definition. 
B: Detailed view of the hierarchical tree of the branch including the human thyroid stimulating 
hormone receptor 1 with the leafs colored according to phylogenetic relatedness. C: Distribution of 
the number of sequences per species grouped together in a node containing one human receptor 
sequence. The number of missing receptor sequences was calculated with the assumption that 
each human receptor has one ortholog in each species.
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4.2.2. Subfamily definition
To identify ligand binding residues we use a score composed of two entropy values. The 
underlying hypothesis for this score is that the ligand binding residues are conserved 
within a subfamily but not across all GPCRs. The residues which are conserved amongst 
all GPCRs are likely to be structurally important and can be easily identified by a low 
entropy value for all GPCRs. The size and variability of the subfamily should ensure that 
apart from structurally important residues only ligand binding residues are conserved 
within the subfamily. Phylogenetic distance is a measure for the sequence conservation 
in a subfamily. Figure 4.2 shows that most of the human receptors in our test set 
have small phylogenetic distances in subfamilies with sizes towards ~20 sequences. A 
subfamily of ~20-60 receptors contains homologous receptors (Figure 4.1) with slightly 
larger phylogenetic distances.  
Figure 4.2: Phylogenetic distance towards the human receptor as a function of the xth  most similar 
receptor for the 10 receptors in the test set.
It is impossible to conclude whether or not ligand binding residues are conserved in a 
subfamily based on solely phylogenetic distances. Important aspects to consider in 
subfamily selection are that the receptors in a subfamily must bind to relatively similar 
ligands ensuring evolutionary pressure on the conservation of the residue positions 
involved in ligand binding, and that evolutionary distances are large enough to observe 
different amino acid usage amongst residue positions which are not involved in 
maintaining the structural architecture of the GPCR, signal transduction or ligand binding. 
We have therefore chosen to calculate the entropy values of all subfamilies with at least 
50 and at most 300 sequences.
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4.2.3. Reference set
Site directed mutagenesis experiments offer a tool to investigate the function of specific 
residues in receptors. These experiments have helped to identify residues related to 
the signal transduction pathway as well as residues involved in ligand binding in GPCRs. 
Extracting this information from such experiments can however be very complicated, 
especially if ligands are compared which use different signaling pathways or when agonist 
are compared to antagonists. Antagonists only have to block active sites and this can be 
done via interactions with arbitrary residues. Agonists have to trigger certain responses 
and it is possible that ligands bind to different residues to trigger different responses. 
Another important aspect in the interpretation of mutation data is to separate direct from 
indirect effects. Mutations on the membrane facing side of a helix will for example very 
likely not affect ligand binding in a direct manner, but are more likely to have an influence 
due to distortion of the secondary structure. We have used site directed mutagenesis 
data described in literature, to the best of our knowledge, to compile a reference set 
of ligand binding residues for 10 selected receptors. This reference set consists of 47 
residues located at 22 different positions (Figure 4.3).
Figure 4.3: Heatmap of reference residues sorted on position and receptor. 
Ligand binding residues are colored black
4.2.4. Ligand binding residue prediction
Prediction of ligand binding residues as performed by for example evolutionary trace, 
TEA and Multi-RELIEF is limited to the family level and results in a common description 
of the structurally important residues and ligand binding pocket. Analyses of the charged 
aspartate 3.32 in the amine receptors and lysine 7.33 in the opsins, known to be crucial 
for ligand binding from crystallography, show remarkable conservation characteristics. 
In both cases the residue is fully conserved inside the family and only rarely observed 
outside. This suggests that ligand binding residues can be identified by comparing the 
conservation level of a residue position within a subfamily to the conservation at this 
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same position for all sequences outside this subfamily. In Figure 4.4A the two entropy 
values reflecting both observations are plotted for the ADRB2 receptor subfamily, which 
also includes the human receptors ADRB1 and ADRB3. The residues shown to disrupt 
ligand binding are colored green and are found in the upper left corner as expected. The 
distance of each residue to this upper left corner is used to rank the residues and used 
to evaluate the performance of ss-TEA. In Figure 4.4B the crystal structure of the ADRB2 
receptor, co-crystalized with carazolol (pdbid: 2RH1) is visualized with the residues 
disrupting ligand binding colored green. The receiver operating characteristic (ROC) 
curves in Figures 4.4C and 4.4D, plotted with linear and logarithmic x-axis, show the 
improved ranking of residues according to ligand binding likelihood compared to random 
ranking. The area under the semi-logarithmic curve (Figure 4.4D) was used for further 
analysis because it puts more emphasis on correctly predicted ligand binding residues 
in the early phase of the recovery curve. It is typically in this region where performance 
needs to be outstanding, since many modeling approaches rely heavily on the correct 
assignment of only a limited number of ligand binding residues. 
Figure 4.4: Residue selection for the ADRB2 receptor. A: Plot of the entropy within the ADRB2 
receptor subfamily versus outside the subfamily. Lines are drawn at equal score and residues 
disrupting ligand binding upon mutation are colored green. B: Crystal structure of ADRB2 co-
crystalized with carazolol (pdbid: 2RH1), residues disrupting ligand binding upon mutation are 
colored green. C: Receiver Operator Characteristic (ROC) curve showing the ability of ss-TEA to 
select ligand binding residues compared to random selection. D: ROC curve with logarithmic x-axis.
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Table 4.1 shows that the mean area under the semi-logarithmic curve of the theoretically 
optimal ranking and ss-TEA are both 1.9. ss-TEA has the highest score in 7 out of 10 
cases compared to the theoretically optimal ranking with the 4 highest scores out of 
10 cases. A more realistic example is given by the comparison with the multi-RELIEF + 
3d contacts method, which was reported to be the best performing method amongst 
several state-of-the-art methods [37]. The average pROC AUC of multi-RELIEF is 1.32 if 
the 22 reference residues are top ranked (see Methods section). ss-TEA gains 0.4 in the 
pROC AUC compared to multi-Relief in this situation and 0.5 if all residues are taken 
into account. It is also noteworthy that ss-TEA outperforms multi-Relief for all individual 
reference receptors except V1AR.
Table 4.1: Area under the semi logarithmic receiver operator curve (pROC AUC) of different rankings 
of residues for different targets. Top scoring methods are indicated in bold.
Target Reference seta Multi-Relief ss-TEA Theoretically
optimal 
(top-ranked)
Multi-Relief
(top-ranked)
ss-TEA 
(top-ranked)
ADRB2 3.32, 3.33, 5.42, 
5.43, 5.46, 6.55, 
7.35, 7.39
1.2 1.4 1.9 1.6 1.6
PI2R 2.65, 3.28, 7.39, 
7.40
1.0 1.7 1.5 1.4 1.8
CNR2 3.28, 3.31, 4.64, 
5.39
0.7 1.5 1.6 1.1 1.8
C5AR 3.28, 3.32, 5.39, 
5.42, 5.43, 7.35
1.1 1.5 2.1 1.5 1.7
GNRHR 2.61, 2.64, 2.65, 
3.32, 5.39, 6.58
1.4 1.8 1.7 1.7 1.9
V1AR 2.57, 2.61, 3.29, 
3.32, 4.60, 5.43, 
6.55
1.7 1.3 1.8 1.9 1.5
FFAR1 5.39, 6.55, 7.35 0.9 2.1 2.2 1.3 2.2
CCR5 1.39, 2.60, 3.32, 
7.39
1.1 1.5 1.7 1.6 1.9
P2Y11 3.29, 7.39, 6.55 1.5 1.8 1.9 1.8 2.0
P2Y13 6.55, 7.35 1.0 2.1 2.2 1.4 2.2
Average total 22 1.2 1.7 1.9 1.5 1.9
aBallesteros and Weinstein numbering
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Three distinct receptors (ADRB2, CCR5 and GNRHR) which use different residue positions 
to bind ligands (Figure 4.3) have been selected as an example to illustrate the advantage 
of the subfamily specific approach of ss-TEA. 
Figure 4.5 shows in green the residues involved in ligand binding to the ADRB2 receptor 
only. Likewise, the ligand binding residues for CCR5 and GNRHR are colored blue and red 
respectively. Residue 7.39 is important for ligand binding in both the ADRB2 and CCR5 
receptors and is colored yellow, while position 3.32, colored maroon is a ligand binding 
residue for all three receptors.  Figure 4.5 shows that green residues are mainly located 
in the upper left corner of the ADRB2 plot, while the red and blue residues are positioned 
more to the right. Similar distributions are observed for the blue and red residues in the 
CCR5 and GNRHR plot respectively, clearly illustrating that the selection of residues by 
ss-TEA are subfamily specific. 
Figure 4.5: ss-TEA plots of ADRB2, CCR5 and 
GNRHR respectively. Ligand binding residues 
of the ADRB2 receptor are colored green, CCR5 
receptor: blue, GNRHR receptor: red, ADRB2 
and CCR5 receptor: yellow and of all three 
receptors: maroon.
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Analyses of the highest ranked residues for all individual human receptors identify 
subfamily ligand binding characteristics. Determination of the top 10 scoring residues 
for all human receptors visualized in Figure 4.6 and colored according to the IUPHAR 
family definition [36], shows that there is no generic ligand binding mode for class A 
GPCRs since none of the positions is scored amongst the top 10 for more than 50% of 
the in total ~300 human receptors. Furthermore it can be seen that that helix I is rarely 
important for ligand binding, as also observed in the available crystal structures. Even 
so, some orphan, adenosine and chemokine receptors are characterized by conservation 
patterns for residues in this helix and might bind ligands with residues from this helix. In 
addition, the amine receptors can be characterized by the importance of helix three in 
ligand binding. 
Figure 4.6: Distribution of residue positions scoring amongst the top 10 based on ss-TEA for all 
human receptors. Bars are colored according to the iuphar family description. 
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However the comparison of individual receptors within a receptor family also reveals 
interesting differences in ligand binding behavior. This is illustrated by e.g. position 3.32, 
which is well conserved in about 50% of all subfamilies, including the aminergic receptors 
and a subset of the adenosine receptors. For the aminergic receptors it has been 
proposed that this aspartate is crucial for ligand binding due to its interaction with the 
positively charged nitrogen of the basic amines, a hypothesis which is confirmed by the 
crystal structures of ADRB2 and ADRB1. For other receptors this same position is thought 
to be important for ligand binding involving different amino acids. For example, AA2AR 
receptor has a conserved valine at position 3.32. Mutation of this valine to alanine or 
aspartate disrupts ligand binding and illustrates the importance of this conserved valine 
for this receptor [38]. Position 3.32 ranks at position 45 in the AA1R subfamily, while it 
ranks at position 11 the AA2AR subfamily suggesting a less important function for the 
valine in the AA1R receptor, which is indeed confirmed by site directed mutagenesis [38].
Interestingly, receptors with endogenous ligands which completely or largely bind to the 
N-terminus and/or extracellular loops also demonstrate subfamily specific conservation 
of residues at the extracellular side of the transmembrane helices. It is remarkable, for 
example, that 8 of the top 10 ranked residues for the luteinizing hormone receptor are 
in fact pocket residues. Also noteworthy is that Asp2.64, known to interact with the 
endogenous ligand [39], is ranked 3rd.   
4.3 Conclusions 
We have introduced an alignment methodology to create a large multiple sequence 
alignment of the transmembrane domains of class A non olfactory GPCRs from multiple 
species. We also introduced a new method to identify ligand binding residues from a MSA, 
named ss-TEA, and demonstrated the advantage of this new method in combination with 
the new MSA for the selection of ligand binding residues. The results show the advantage 
of receptor specific residue selection compared to receptor class specific selection, as well 
as an improved residue selection for 9 of the 10 reference sets in comparison to the state-
of-the-art method Multi-Relief. The large MSA including sequences of multiple species 
allows us to compare receptors with high sequence similarities and more identical ligand 
binding profiles which results in a better understanding of the characteristics of those 
receptors. If more sequence data becomes available for more species, larger alignments 
can be made, which could possibly even explain differences between close homologs. 
Our alignment in combination with the residue selection method described here can 
be used to quickly identify ligand binding residues. This can subsequently be used to 
design site directed mutagenesis experiments, explain receptor function and improve 
modelling. The ss-TEA predictions for class A GPCRs can be accessed via GPCRDB at www.
gpcr.org/7tm/.
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4.4 Methods
Our approach makes use of different input sources which are connected via algorithms as 
outlined in Figure 4.7. All steps will be outlined and discussed in sequential order below.
Figure 4.7: Schematic flowchart of the methodology to create the alignment, score the residues 
and evaluate the performance of the residue selection method. Publicly available data sources are 
indicated with a bold border style, in-house data with dashed a border style and methods with a 
normal border style. The numbers indicate the number of sequences which is used at each step.
4.4.1. Sequence retrieval
The first step in our approach is to extract GPCR sequences for different species from 
available data sources. To obtain sequences we performed a BLAST [40] search with 286 
manually curated query sequences from human class A non-olfactory GPCRs against 
Swissprot, Ensembl and TrEMBL. All query sequences were blasted against Swissprot 57.13 
[41, 42], Translated EMBL (TrEMBL) 40.13 [42, 43] and Ensembl Protein 56 [31], using the 
BLOSUM62 scoring matrix, an expected cutoff of 10 and word size 3. Furthermore, a gap 
opening penalty of 11 and a gap extension penalty of 1 were used. Finally, we selected all 
sequences with an e-value < 0.01, subject length identity > 25%, alignment identity > 40% 
and a minimal query length of 20 amino acids.
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4.4.2. Alignment
The available GPCR crystal structures have shown that all helices can be structurally 
aligned without introducing gaps in the sequence alignment. For this reason a manually 
curated gap-free alignment of the TM domains of the human class A non-olfactory GPCR 
sequences was created and used to construct a Hidden Markov Model (HMM) for each 
separate helix, using HMMbuild (HMMER [44] 2.3.2 (Oct 2003)) with default settings. 
Subsequently each hmm model of each helix was aligned against all extracted sequences 
from the previous step, without allowing the introduction of gaps, using HMMalign. 
Alignments which had an incorrect helix ordering were subsequently extracted and subject 
to realignment on a smaller part of the sequence. A typical example is the realignment 
of one helix on the sequence in between two correctly aligned neighbor helices (Figure 
4.8). As a final filter, all sequences with a low similarity score to the hmm model for over 
4 out of 7 helices were discarded. A threshold of 4 was chosen, since a few annotated 
human sequences, e.g., the prostanoids, were shown to have weak patterns for up to 4 
helices. The threshold for the similarity score of each individual helix was set after the 
compilation of artificial sequences with an identical amino acid distribution for each helix 
as in the manually curated alignment of human GPCRs. These artificial sequences were 
subsequently aligned to the previously built hmm model of the helix, and the threshold 
for the helix was set to the score at which 95% of the artificial sequences fails to pass. Low 
sequence quality may cause duplicate entries of the same receptor and species. To avoid 
these duplicates, all but 1 sequence, of all sets of sequences of an individual species 
which had less than 10 amino acids difference, were removed. 
Figure 4.8: Schematic representation of the alignment procedure. First a HMM model is calculated 
for each TM domain from a manually curated alignment of the 7TM domains of 286 human GPCRs. 
Each HMM model is subsequently aligned to each GPCR sequence after which the ordering of the 
aligned helices is checked. In case of an incorrect ordering realignment is performed on smaller 
parts of the sequence. Finally the significance of each aligned helix is checked. 
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4.4.3. Database
Incomplete sequencing of the genomes of many species causes bias towards certain 
receptor subfamilies. To prohibit such bias, all sequences of species with less than 100 
amino acid sequences of GPCRs were removed from the MSA. All GPCR sequences 
of species of which at least 100 different sequences were obtained, were stored in a 
database and used in all analysis discussed below. To enable querying on a higher level 
than the individual sequences, a hierarchical tree of the phylogenetic distance matrix 
calculated from the alignment of all 7 TMs of all receptors was created, using the neighbor 
joining algorithm as implemented in clustalW [45] 2.0.11 with a 100 fold bootstrap. The 
sequences which group together at a node in this tree, a so called subfamily, can be 
queried for their properties.  
4.4.4. Residue selection
To perform knowledge based residue selections which reflect the likelihood of residues 
being involved in ligand binding, we added two Shannon entropy scores for each alignment 
position of each receptor to the database. One entropy value reflects the conservation 
of a position inside the subfamily (Ein) while the other entropy reflects the conservation 
of this same position in all sequences which do not belong to this subfamily (Eout). The 
Shannon entropy itself is given by: 
       (1)
With 
       (2)
Numberia is the number of sequences with residue type a at alignment position i. 
Others have already suggested that ligand binding residues can be obtained from both 
calculated entropy values [33, 34]. Therefore we introduce one score which combines 
both calculated entropies.
       (3)
A final score for each residue position was calculated after evaluation of the score at 
multiple branches of the hierarchical tree using:
                                      (4)
where j reflects the number of sequences selected in the branch. To validate the 
performance we finally ranked all residues according to the score with the minimum 
scoring residue at rank 1.
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4.4.5. Reference Set
Site directed mutagenesis data is available for many GPCRs with different levels of detail 
depending on the research question. In this paper ten well studied and evolutionary 
diverse Class A GPCRs are used for which extensive site directed mutagenesis data exists 
as well as a binding model based on these data. For each of the receptors a reference set 
of residues crucial for ligand binding was compiled using the mutation data described 
in GPCRdb [5] and literature models of the binding mode. The choice of receptors from 
different branches of the sequence tree was made to emphasize the advantage of a 
method able to identify different ligand binding residues for different receptors and to 
show that the method does not have a bias towards certain subfamilies. The receptors in 
the reference set are; beta-2 adrenergic receptor (ADRB2) [27, 46]; Prostacyclin receptor 
(PI2R) [47]; C5a anaphylatoxin chemotactic receptor (C5AR) [48]; Cannabinoid receptor 
2 (CNR2) [49, 50]; Gonadotropin-releasing hormone receptor (GNRHR) [51]; Vasopressin 
V1a receptor (V1AR) [24]; Free fatty acid receptor1 (FFAR1) [52]; C-C Chemokine receptor 
type 5 (CCR5) [53]; P2Y purinoceptor 11 [54] and 13 [55] (P2Y11, P2Y13). Residues that 
were not part of the pocket [56] were neglected as well as mutations which are debatable 
because of different effects using different ligands or because results were not consistent 
in different measurements. The final selection only includes residues with substantial 
effect on ligand binding. The A2A adenosine receptor was deliberately not used as a 
reference set in this study, since site directed mutagenesis data and the crystal structure 
suggest that there is no general, family conserved receptor binding pocket for the A2A 
adenosine receptor [29, 38].
4.4.6. Performance measure (Area Under the Log Curve)
The performance of our residue ranking method is assessed using the Area under the 
semi-logarithmic receiver operating characteristic (ROC) curve [57]. This method favors 
true ligand binding residues early in the recovery curve and is calculated using:
                                                 (5)
Where n is the number of true ligand binding residues and βi is the false positive frequency 
corresponding to the point at which the ith true residue is found. βi is typically calculated 
as the fraction of false positives which is ranked higher than the ith true positive. The 
score of the pROC AUC corresponding to a random selection is 0.434 and is unbounded 
on the high side. A perfect ordering of ligand binding residues amongst 100 non ligand 
binding residues will for example score 2.0.   
pROC ∑ 





=
n
i in
AUC
β
1log1 10  
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4.4.7. Benchmark
To illustrate the advantage of subfamily specific ranking over generic ranking we compiled 
a theoretically optimal generic ranking of ligand binding residues. This ranking is created 
by ordering the residues of ten different receptors according to the number of receptors 
which use these positions for ligand binding. The ranking of positions used by the same 
number of receptors is arbitrary, potentially altering the results, although it is expected 
to have only a minor effect. Because the theoretically compiled optimal ranking includes 
information about the location of the pocket we also included this information in the 
ss-TEA and Multi-Relief method and scored the 22 residues included in the theoretically 
compiled optimal ranking prior to all other residues. The rankings which include this 
information will be indicated in this paper as top ranked. As a benchmark we compared 
our top ranking to both the theoretically compiled optimal ranking and Multi-Relief + 
3d contacts top ranking [37]. Briefly, Multi-Relief takes a multiple sequence alignment 
and predefined subfamily ontology as input, then iteratively selects 2 subfamilies and 
optimizes a weight vector able to optimally separate the sequences from both [37].  The 
optimization of a single weight vector in the iterative process results in one vector able to 
discrimate between all provided classes. The weight of a residue in the Multi-Relief + 3d 
contacts method can be altered towards its local environment as obtained from recent 
crystal structures.
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Abstract
G-protein coupled receptors (GPCRs) are important drug targets for various diseases 
and of major interest to pharmaceutical companies. The function of individual members 
of this protein family can be modulated by the binding of small molecules at the 
extracellular side of the structurally conserved transmembrane (TM) domain. Here, we 
present Snooker, a structure-based approach to generate pharmacophore hypotheses 
for compounds binding to this extracellular side of the TM domain. Snooker does not 
require knowledge of ligands, is therefore suitable for apo-proteins and can be applied 
to all receptors of the GPCR protein family. The method comprises the construction of a 
homology model of the TM domains and prioritization of residues on the probability of 
being ligand binding. Subsequently, protein properties are converted to ligand space and 
pharmacophore features are generated at positions where protein ligand interactions 
are likely. Using this semi-automated knowledge-driven bioinformatics approach we 
have created pharmacophore hypotheses for 15 different GPCRs from several different 
subfamilies. For the beta-2-adrenergic receptor we show that ligand poses predicted 
by Snooker pharmacophore hypotheses reproduce literature supported binding modes 
for ~75% of compounds fulfilling pharmacophore constraints. All 15 pharmacophore 
hypotheses represent interactions with essential residues for ligand binding as observed 
in mutagenesis experiments and compound selections based on these hypotheses 
are shown to be target specific. For 8 out of 15 targets enrichment factors above 10 
fold are observed in the top 0.5% ranked compounds in a virtual screen. Additionally, 
prospectively predicted ligand binding poses in the human dopamine D3 receptor based 
on Snooker pharmacophores were ranked amongst the best models in the community 
wide GPCR dock 2010 assessment.
5.1. Introduction
G-protein coupled receptors (GPCRs) represent a large superfamily of membrane proteins 
responsible for the signal transduction from the extracellular to intracellular side of the 
cell membrane in many different physiological pathways. Therefore, they are effective 
drug targets for various diseases and of major interest to pharmaceutical companies [1, 
2]. 
The GPCR family is characterized by seven conserved alpha-helices, which span the cell 
membrane. To date the crystal structure of only six different GPCRs have been elucidated 
because proteins from this family are, like many other membrane proteins, difficult to 
crystallize. The lack of high resolution structural data complicates the process of rational 
drug design especially for large and structurally diverse families such as the GPCRs. In 
modern drug discovery, computer-aided techniques are often used to speed up the design 
process. These techniques are typically divided into ligand-based and structure-based 
approaches. Ligand-based drug design techniques rely on the availability of known active 
compounds and have proven to be very successful in the design of new compounds [3-8]. 
Commonly used ligand-based techniques that are frequently combined with structure-
based approaches include the use of a spatial arrangement of key chemical features, a so 
called pharmacophore, to discriminate active from inactive compounds. A disadvantage 
of ligand derived pharmacophore hypotheses is the assumption that active compounds 
bind in a similar binding mode, and consequently, the designed compounds usually have 
less novelty [9].
Structure-based drug design, on the other hand, does require a three-dimensional 
structure of the protein, acquired by means of several techniques, including electron 
microscopy, atomic force microscopy, X-ray crystallography and NMR spectroscopy, or 
by computational methods e.g. homology modeling. Depending on the accuracy of a 
three-dimensional model, structure-based searching strategies, such as docking, have 
proven to be very successful in the design of new active compounds [10-13] also for 
GPCRs [14-16]. However, working with less accurate structures, as typically obtained by 
homology modeling, remains a major challenge. New developments, such as induced fit 
docking, have increased the accuracy of results [17], but are computationally expensive 
and remain dependent to some extent on prior knowledge.
A protein-based approach that depends less on protein structure resolution is the 
association of sequence motifs with ligand (interaction) features. In the thematic analysis 
method [18], structure activity relationships (SAR) of class A and B GPCRs were used 
to generate a pairing of sequence patterns/themes and ligand structural motifs. Next, 
focused libraries can be designed by inclusion of compounds with structural motifs 
which occur in ligands for receptors which share similar sequence patterns. This method 
contains limited three dimensional structural information and is limited to the structural 
motifs observed in known ligands.
Another low resolution approach in structure-based drug design is the use of 
89Snooker
 
Ch
ap
te
r 5
pharmacophore models derived from protein binding sites. These structure based 
pharmacophore models can be derived from homology models and have been successfully 
applied for characterizing ligand binding pockets and virtual screening for ligands fort 
various protein targets, including GPCRs [14, 19-22]. Kratochwil et al. [23] developed a 
method to characterize a GPCR pocket with 35 pharmacophore features representing the 
35 residues aligning the ligand binding pocket. 
Klabunde et al. presented an approach to construct structure-based pharmacophore 
hypotheses for class A GPCRs based on chemoprints of the pharmacophore hypotheses 
derived from 10 different homology models and 3 X-ray structures of GPCRs [24]. 
Integrating ligand- and structure-based approaches allows for optimal use of all available 
data and has resulted in a number of successful virtual screens in which new compounds 
have been identified [25, 26]. 
Recently, the structures of several new GPCRs together with an increasing amount of 
annotated ligand data have been available in databases such as PDB, CheMBL [27], 
DrugBank [28], BindingDB [29-31], PDBBind [32, 33], MOAD [34, 35], WOMBAT [36] and 
Glida-DB [37]. All these data repositories allow data mining to construct for example 
structure activity relationships (SAR), including Glida-DB and GPCR SARfari (based 
on CheMBL), which are dedicated to GPCRs. However, they generally do not provide 
structural understanding of receptor-ligand interactions and offer only limited tools 
for the discovery of new chemical entities. There is an urging need for tools to connect 
structure and ligand data especially in the field of GPCRs where only limited crystal 
structures are available. 
We present here Snooker, a low resolution approach whereby structure-based 
pharmacophore hypotheses are constructed with no prior knowledge of ligand 
structure or interactions.  The pharmacophore hypotheses are obtained from homology 
models constructed on-the-fly, based on an in-house sequence alignment of the seven 
transmembrane domains [38] and a crystal structure template. Residues important for 
ligand binding are identified by analysis of Shannon entropies of structurally conserved 
positions in a multiple sequence alignment and chemical features representing protein-
ligand interactions are positioned in the binding pocket. This abstraction of protein-
ligand interaction properties into pharmacophores allows for the discovery of new active 
compounds and connects structural knowledge to ligand data. 
The validity of our pharmacophores is tested in three different experiments. First of 
all, poses of known active compounds are reproduced in a retrospective ligand binding 
mode prediction experiment in the beta-2 adrenergic receptor (ADRB2). Secondly, the 
eticlopride binding mode in the dopamine D3 receptor (DRD3) is successfully predicted 
in the community wide GPCR DOCK 2010 assessment prior to the release of the DRD3 co-
crystal structure. Finally, structure-based pharmacophore models of 15 different GPCRs 
(matching key ligand binding residues) are successfully used to identify target specific 
ligand sets and discriminate active from inactive compounds in a virtual cross-screen.
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5.2. Outline of the approach 
The Snooker approach consists of several stages outlined and discussed in sequential 
order below. Figure 5.1 shows the construction of a pharmacophore model and an 
example of a subsequent pharmacophore search. For clarity and reference, Figure 5.1 
shows the results obtained at each different stage of pharmacophore construction for the 
human beta2 adrenoceptor based on the rhodopsin crystal structure co-crystalized with 
retinal  (Protein Data Bank (PDB)  entry 1GZM [39]) and the subsequent pharmacophore 
search of R-R-formoterol using the obtained pharmacophore.
Figure 5.1: Visual outline of the Snooker approach, illustrated using the pharmacophore hypothesis 
generation for the human beta 2 adrenergic receptor based on a bovine rhodopsin crystal structure 
(pdb code: 1GZM) and the subsequent positioning of R-R-formoterol in the pharmacophore. 
Starting with the crystal structure of bovine rhodopsin, (1) the structurally conserved alpha-helices 
(cyan) and five residues at each side of each helix (orange) are extracted. A homology model (2) is 
constructed based on the alignment of the model receptor sequence with this template. An alpha 
helix specific rotamer library is used to add a rotamer ensemble (3). The pocket is detected (4) by 
a Delaunay tessellation of the Cα-atom and average side chain atom positions. Residues are scored 
upon ligand binding probability (5) by multiple sequence alignment analysis, and ‘interaction’ 
points (6) are placed inside the pocket volume using in literature described interaction geometries 
with densities corresponding to the residue score and rotamer probability. Next, pharmacophore 
features are generated (7) with a fuzzy pharmacophore algorithm applied on the interaction points. 
Finally, (8) ligands fulfilling all pharmacophore constraints are aligned to the pharmacophore. In 
this example, R-R-formoterol matches a pharmacophore comprised of 6 features.
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5.2.1. Template selection
The initial stage of the Snooker protocol starts with the selection of one or multiple template 
structures. When this research was conducted only the structures of the rhodopsin, 
adenosine A2A and the beta 1 and 2 adrenergic receptor were available. However future 
crystal structures and custom made homology models or combinations thereof can be 
used as template structures as well. Because loop modeling for GPCRs remains very 
challenging, the templates are stripped down until only the 7 transmembrane helices 
remain. Inclusion of loops or even single residues is still possible but requires manual 
adjustments of the provided templates and is only recommended for highly similar loop 
regions or where prior knowledge on the target is available. The orange and cyan colored 
residues of the template shown in panel 1 of Figure 5.1 are used as the starting point for 
the construction of the homology model.
5.2.2. Homology model construction
The 7 transmembrane (TM) domain sequences of the desired GPCR are extracted from an 
in-house gap-free multiple sequence alignment of those 7TM domains [38] and is used 
together with the template sequence and structure to construct the homology model. 
The backbone and conserved residues are kept rigid during this stage. Placement of non-
conserved residues is based upon a position-specific rotamer library [41]. Finally the 
hydrogen bond network is optimized and bumps are removed. 
5.2.3. Rotamer sampling. 
For all residues we include the most likely rotamers from an alpha-helix specific rotamer 
library [42] to account for possible model inaccuracy of the initial homology model. 
During the generation of these new rotameric states, clashes are allowed, with the 
intent to maximize sampling. The procedure stores the probability of each rotamer in 
the ensemble for later use in the protein- and pocket volume definition as well as in the 
placement of the interaction features. The use of an ensemble of rotamers avoids the 
computational magnitude that would result from considering all possible models which 
can be obtained by combining all possible rotamer states for each single residue. The 
rotamer ensemble is subsequently used to generate both the protein- and pocket volume 
definition.
5.2.4. Protein- and pocket volume definition. 
To restrict the placement of pharmacophoric features to the ligand binding pocket, both 
pocket and protein volumes are constructed. Traditional pocket detection techniques 
like grid-based sampling methods require high resolution structures, cannot deal with 
ensemble structures and are extremely sensitive to small deviations, and are therefore 
less suitable for our approach. Thus, we have chosen to describe each rotamer ensemble 
with the position of the Cα-atom and an estimated point representing the sidechain. 
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This estimated point is effectively an averaging over all rotamers which will describe the 
sidechain almost exactly if just one rotamer exists, and will approximate the Cα-atom for 
a diverse rotamer ensemble.
5.2.5. Residue scoring
It has been suggested that residues which are conserved within a subfamily yet not 
across the complete GPCR family are important for ligand binding [43-45]. To identify 
ligand binding residues we calculated the sequence conservation (expressed as entropy 
values) inside- and outside each subfamily for each residue position[38]. A residue score 
is defined by a combination of both entropy values and reflects the importance of the 
residue position for ligand binding.
5.2.6. Placement of interaction features
Interaction feature points complementary to the residue properties (acceptor, donor, 
positive ionizable, negative ionizable and hydrophobic) are positioned in the pocket 
volume for each rotamer with densities related to the residue score and rotamer 
likelihood. The density of interaction points is for each rotamer evenly spread over the 
surface as described by the corresponding interaction geometry [46-50]. All interaction 
points inside the protein volume or outside the pocket volume are removed resulting in 
features which are accessible and which can be used to mimic compounds which bind 
within the 7 TM domain.  
5.2.7. Pharmacophore hypothesis generation
Pharmacophore features are generated at regions of high interaction feature density for 
a given property. It is suggested that residues which are close to each other in space 
can enhance the importance of those residues in ligand binding [51-54]. By using the 
interaction feature point density instead of the residue numbers, residues close in space 
but not necessarily in sequence can enhance each other. A measure for the importance of 
a feature is subsequently introduced by scoring the ratio between the number of points 
and the volume of a feature. These are indirectly influenced by rotamer conservation as 
well as residue score. A consensus hypothesis is introduced by identification of regions 
of high interaction feature point densities in the overlay of the interaction feature point 
densities of individual models. A subset of features from each pharmacophore hypothesis 
is selected to reduce the total number of features and improve virtual screening 
performance. This subset comprises the top 2 scoring features of each interaction type 
(acceptor, donor, positive ionizable, negative ionizable and hydrophobic). 
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5.2.8. Pharmacophore comparison
Pharmacophore hypotheses differ due to the use of different templates on which the 
models are based and from which the subsequent hypotheses are derived. A measure 
of robustness is therefore not introduced by comparison of pharmacophore feature 
locations in different pharmacophore hypotheses, but by analysis of the residues 
which contribute to all single pharmacophore features. The contribution of a residue 
to a feature is calculated and depicted in a pie-chart (Figure 5.2). The pie-charts of 
all different pharmacophore features of the different templates can be compared to 
quantify the robustness and template dependence of the Snooker method to generate 
pharmacophore hypotheses. 
Figure 5.2: Combination of hydrophobic ‘interaction points’ of four different residues leads to a 
hydrophobic pharmacophore feature. The contribution of the different residues is visualized in a 
pie-chart, 4 out of the 12 interaction points can be assigned to residues 3.33 (cyan) and 3.36 (blue) 
and 2 out of 12 to residues 6.51 (green) and 6.52 (red). Coloring of the pie-charts is according to 
transmembrane membrane domain from which the residues originate.
5.2.9. Pharmacophore screening
3D conformations of a compound satisfying the pharmacophore constraints are matched 
to the pharmacophore hypothesis with a minimal root mean square deviation (RMSD) 
according to the fitting procedure as explained in the Materials and Methods section. 
5.2.10. Method validation
Three different experiments were performed to assess the quality of the Snooker 
pharmacophore hypotheses. First, human beta 2 adrenergic receptor ligands are matched 
to the Snooker pharmacophore hypothesis and compared to literature supported 
binding mode hypotheses. Second, an evaluation of whether receptor pharmacophore 
hypotheses are able to identify the correct ligands with a higher accuracy than ‘random’ 
Snooker pharmacophore hypotheses was undertaken. Third, the enrichment of active 
ligands is tested for multiple class A GPCRs.
5.2.10.1. Retrospective binding mode prediction
To assess whether our approach positions the appropriate features at the correct 
positions, we have analyzed which residues contribute to pharmacophore features 
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and evaluated how well the pharmacophore hypotheses perform in a pose prediction 
experiment. For this purpose we have built pharmacophore hypotheses of the human 
beta 2 adrenergic receptor and performed a search on a set of known full, partial and 
inverse agonists as well as antagonists. The RMSD between the poses as reported in 
literature [55] and the poses as generated after a short energy minimization of the initial 
pharmacophore matching pose is calculated and reported. 
5.2.10.2. Prospective binding mode prediction
Crystal structures of the human DRD3 and human CXCR4 receptor structure co-crystallized 
with a small molecule have been solved recently [56, 57]. To assess the current status 
of GPCR modeling, research groups were invited to submit models of those receptors 
with the bound ligands [58]. We submitted binding mode hypotheses based on Snooker 
pharmacophores derived from custom made homology models, and optimized with 
Fleksy [17]. These models were scored on the accuracy of the receptor structure model 
as well as the predicted binding mode.  
5.2.10.3. Target-specific ligand identification
To demonstrate the target specificity of each pharmacophore hypothesis, virtual cross-
screens of 15 different GPCR pharmacophore hypotheses and compound sets are 
performed.  The target receptors and families used are listed in Table 5.1.
Table 5.1: Targets used in the virtual cross-screen with their corresponding receptor families 
according to the GPCRDB family classification [59].
Target Family
5HT7R Serotonin family
AA2AR Adenosine family
ADA2B Alpha adrenoceptors family
ADRB2 Beta adrenoceptors family
AGTR1 Angiotensin family
CLTR1 Cysteinyl leukotriene family
DRD2 Dopamine family
EDNRA Endothelin family
GASR Cholecystokinin CCK family
GHSR Thyrotropin-releasing hormone and secretagogue family
HRH3 Histame family
MCHR1 Melanin-concentrating hormone receptors family
NPY5R Neuropeptide Y family
OPRM Opioid family
TA2R Prostanoid family
 
The enrichment is calculated for each combination of a compound set and pharmacophore 
hypothesis. Target specificity can be assumed if the hypothesis and corresponding 
compound set have better enrichment compared to the average enrichment of all 
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screens using this same compound set. To show that the final results are not biased by 
the properties of the active compounds we performed the same experiment for a set of 
inactive compounds with similar physicochemical properties as the actives.
Library enrichment. Shape constraints are known to improve enrichment in virtual 
screening [24, 60]. To evaluate the possible performance of the Snooker pharmacophore 
hypotheses in library enrichment we added a shape constraint to filter the poses as 
generated in the target specificity experiment and calculated the enrichment of the set 
of remaining compounds. 
 
5.3. Materials and methods
5.3.1.Template Selection
Three-dimensional coordinates of the template receptors (pdb ids: 1GZM [39], 1L9H 
[61], 2RH1 [62], 2VT4 [63], 3CAP [64], 3D4S [65], 3DQB [66], 3EML [67]) were obtained 
from the PDB and structurally aligned using the Needleman and Wunsch algorithm [68] 
as embedded in YASARA [69] (http:www.yasara.org). Residues which are 5 amino acids 
apart from the transmembrane helices were removed as were the ligands, waters and 
other hetero-atoms. Ballesteros and Weinstein numbers [40] of transmembrane helices 
are: TM1: 1.33-156; TM2: 2.40-2.65; TM3: 3.25-3.51; TM4: 4.43-4.64; TM5: 5.38-5.63; 
TM6 and 6.37-6.59; TM7: 7.34-7.56.
5.3.2. Homology model
Homology models were built and optimized using WHAT IF [70] and upon completion 
residues not part of a transmembrane helix were removed. 
5.3.3. Rotamer Sampling
The conformational space of all residue side chains is sampled  sequentially using the 
dihedral angles as reported by Lovell et al. [42]. To reduce the number of rotamers we 
only add a rotamer if it occurs more frequently than 5% in alpha-helices. In order to make 
our procedure more GPCR-specific we have introduced an additional 50% probability 
for the rotamer that possesses an average sidechain vector most similar to the average 
sidechain vector of the available GPCR crystal structures, and we have given a weight of 
25% to this particular rotamer in the initial homology model.  
5.3.4. Protein- and Pocket Volume Definition
For all residues in our model the Cα-atom position is calculated as well as the average 
vector between the Cα and the mean coordinate of the sidechain, whilst taking the 
rotamer distribution into account. This average vector was multiplied by 1.5 and added to 
the mean Cα position. These calculated coordinates for all residues and 7 dummy points 
representing the end of the N-terminus and the starts and ends of the extracellular loops 
are subsequently used in a Delaunay tessellation [71]. The dummy points are positioned 
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at the end of the vectors starting at the average Cα-atom position of the 4 residues of 
each helix closest to the extracellular environment, and directed 6Å towards the pocket 
centre (pocket centre: mean coordinate of the Cα-atoms of residues 3.32, 5.32 and 7.39) 
and 2Å towards the extracellular side. After removal of all tetrahedra with any edge 
longer than 8.5Å, the cavities are exposed. All surfaces of which a point 5.0Å along the 
normal vector is within the original tessellation are marked as potential cavity surfaces. 
Next, cavity surfaces, which share an edge and have an angle < 0.5π radians between the 
normal vectors, are merged. Subsequently, the pocket surface is defined as the largest 
surface of at least 500Å2 and within 15Å of the pocket centre. Finally, all tetrahedra which 
have at least one pocket surface and contain no heavy atoms are removed, a procedure 
which is repeated until all pocket surfaces are part of tetrahedra which contain at least 
one heavy atom. 
5.3.5. Residue Scoring
Receptor families are defined based on sequence homology of the 7 transmembrane 
helices and entropy scores (reflecting sequence conservation) inside and outside the 
family are calculated for each position in the multiple sequence alignment [38, 72] 
according to: 
        Ei =        (1)
        Fia = Numberia / m     (2)
Where Numberia is the number of sequences with residue type a at alignment position i 
and m the number of total sequences. Fia is the frequency of residue type a at position i 
and Ei the entropy of alignment position i. Subsequently one score is calculated for each 
residue by combining both scores according to equation 3, with Ein the entropy inside a 
cluster and Eout the entropy of all sequences not part of the cluster.
        (3)  
 
5.3.6. Placing interaction features
Hydrophobic and polar interaction geometries are extracted from Rarey et al. [50]. 
Charged interactions are described by a cone, the narrow end of which is positioned at 
the charged center as described by Kumar and Nussinov [73]. The interaction surface is 
described by the part of the sphere where a vector of 3.5Å, starting at the narrow end 
of the cone, is within 38° of the vector between the Cα-atom and the corresponding 
charged centre (Figure 5.3). 
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Figure 5.3: Example of a negatively charged interaction geometry.
The final density of interaction points is obtained after sampling a grid on the interaction 
surfaces. For each rotamer of each residue, sampling starts with the point which is closest 
to all other interaction points of the same type. Additional points are added iteratively 
according to:
        (4)
With Pnew the updated set of interaction points, x a potential point to be added to the 
selection, Psel the points already selected, Pleft all not yet selected points and D(x,P) the 
average distance between x and all points in P. Addition of points stops if the number of 
interaction points has reached:
         S = Nbasic  X  1.0/fi    X   Rij    (5)
Where fi is the entropy based residue score of residue i, Rij the rotamer likelihood of 
rotamer j of residue i and Nbasic is the initial density for each residue. After the completion 
of the sampling phase, all points which are not in the pocket volume or in the protein 
volume are removed.
5.3.7. Pharmacophore hypothesis generation
Pharmacophore features are generated by applying a fuzzy pharmacophore algorithm 
to all interaction points using an Rc value of 2.5Å [74]. Features are centered at the 
mean coordinate of all points contributing to the feature and the radius of each feature 
is set to 2.0Å. The weighted average vector of the centre of all donor and acceptor 
features towards the residues which contribute to the respective feature is used as a 
direction vector for the polar feature. The tolerance of this directionality is defined as 
the minimum of the standard deviation of the vector and ¼π radians. The consensus 
hypothesis is constructed from the overlay of the interaction feature point densities 
based on the models using the templates 1GZM, 1L9H, 2RH1, 2VT4, 3CAP, 3D4S, 3DQB 
and 3EML. Pharmacophore features are ranked according to the number of interaction 
points per volume. The pharmacophore which is finally used in screening comprises the 
top 2 ranked features of each interaction type.
 )),(),(max(arg leftselPxnew PxDPxDP left −= ∈
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5.3.8. Customization of automatically generated pharmacophore hypotheses based on 
mutagenesis data. 
5.3.8.1. EDNRA
Mutagenesis data of the EDNRA receptor suggests a crucial role for Gln3.32 [75]. This 
residue is not correlated to a pharmacophore feature in the consensus hypothesis 
due to limited accessibility of this region in models based on some of the templates. 
However, this region is accessible in the models which have used 3EML and 3CAP as 
template. Gln3.32 is related to pharmacophore features for the hypotheses based on 
these templates. Therefore pharmacophore hypotheses based on these two templates 
are screened for the EDNRA receptor.
5.3.8.2. NPY5R
For the NPY5R the residues Cys3.33 and Cys4.57 were omitted from the Delaunay 
tesselation. This adjustment is a consequence of the hypothesis that both form a 
disulfide bridge due to a slight rearrangement of TM3 and TM4 caused by the helix-
disturbing residues Pro3.29, Gly4.23 and Pro4.61. Position 5.46 is known to be important 
for agonism in the aminergic receptors [76] and is also extremely conserved in the NPY5R 
receptor cluster. Hence, the polar pharmacophore features corresponding to this residue 
is promoted from rank 3 to rank 2.
5.3.8.3. TA2R
Residue position 7.36 and 7.40 have a remarkably high residue score (data not shown) 
and are therefore likely to be involved in ligand binding for the tromboxane A2 receptor 
(TA2R). A modification to the alignment is made for this receptor such that residue 7.36 
matches residue 7.35 of the template structure and 7.40 matches 7.39. This effectively 
results in a kinked helix, as also observed in TM2 of the CXCR4 receptor structure, and 
positions 7.36 and 7.40 in the pocket. All ligands in the training set contain a carboxyl 
which seems crucial for the activity. The largest distance to a polar feature is for most 
ligands within 8-12Å of this carboxyl. We choose to use the pharmacophore based on a 
beta 2 adrenoceptor template (pdbid: 2RH1) instead of the consensus pharmacophore 
because the hypothesis derived from the homology model based on the 2RH1 template 
has a distance of ~12Å between the negative ionizable feature corresponding to Arg7.40 
and the acceptor feature near TM5, while this distance is larger in the consensus 
hypothesis and in the hypotheses based on all other templates.
5.3.8.4. OPRM
Binding mode hypotheses for opioid receptors are described in literature and depict a 
pharmacophore with a phenolic site deep down a subpocket near TM5, a hydrophobic 
region near TM5 towards the extracellular loop and an anionic site related to residue 3.32 
[77-79]. The pharmacophore hypothesis based on the template 2VT4 seems to mimic 
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this binding mode best with a positive ionizable and polar feature related to 3.32 and two 
hydrophobic features near helix V. Therefore we included the pharmacophore hypothesis 
based on the 2VT4 template as well.
5.3.9. Compound sets
5.3.9.1. Pose prediction
A maximum of 100 3D conformations per molecule was  generated for all compounds 
depicted in Figure 2 of de Graaf et al. [55] using Corina [80] and Cyndi [81]. 
5.3.9.2. Target specificity
Compounds with activities better than 50nM were retrieved from Chembl02 for the 15 
targets and divided into training and test sets. The test set was selected using exclusion 
sphere clustering on BCI fingerprints and contained the 50 most chemically diverse 
compounds for each target. The ‘fake’ active sets of compounds with similar properties 
to the actives but different architectures were selected based on the same number of 
positive ionizable and negative ionizable features, acceptors, donors, hydrophobic atoms, 
aromatic atoms, heavy atoms, rotatable bonds and number of rings. For each known 
active compound in the test set the most similar (and presumed inactive) compound 
was chosen from all Chembl02 compounds that have not been tested in GPCR assays. 
‘Fake’ active compounds were selected with emphasis on the same ionizable features 
and polar groups, and with MACCS fingerprint similarities greater than 0.6 to all known 
actives. The 10.000 assumed inactive compounds used as decoys were selected from 
the 10.000 most diverse compounds from all Chembl02 compounds not tested in GPCR 
assays. This selection was carried out using the diverse molecule component with FCFP_4 
fingerprint as implemented in Pipeline Pilot [82]. 3D conformations were generated for 
all compounds using the procedure described to generate conformations for the pose 
prediction compound set. 
5.3.10. Method validation
5.3.10.1. Retrospective binding mode prediction
The performance of Snooker in reproducing protein-ligand binding hypotheses as 
reported in literature [55] was investigated for ADRB2. Compound poses matching 5 
or more pharmacophore features were minimized using sidechain optimizations and 
energy minimizations using the Yamber3 forcefield as embedded in YASARA [69]. First, 
a procedure of optimization of the sidechains of all residues with a distance less than 
10Å from the ligand pose using SCWALL [83] as implemented in YASARA followed by an 
energy minimization with fixed carbon atoms of the helix endings is performed twice. 
After this all sidechains with a distance less than 8Å from the ligand are again optimized 
using SCWALL. Finally, the complex is energy minimized without constraints using the 
Yamber3 forcefield. The resulting poses are then compared to corresponding reference 
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poses reported by de Graaf et al. [55], by calculating the RMS between all atoms within 
13Å of the Cα-atom of Ser5.46 in the reference structures and their counterparts in 
the pharmacophore guided poses.  Although the reference structures are obtained via 
a docking experiment in customized receptor models, the validity of these models is 
supported by their high similarity to the recently elucidated structures of the homologues 
ADRB1 receptor with several ligands [84].
5.3.10.2. Prospective binding mode prediction
PDB entry 2RH1 was used as a template to build the homology models. The structure was 
cleaned, the lysozyme protein was removed and the bound ligands retained. Residues 
in the loop between TM5 and TM6 (residues 218-317) were discarded in the modeling 
process for the DRD3 receptor. For CXCR4, residues in the loop between TM6 and TM7 
(residues 267-276) were discarded and the loop between TM4-TM5 was deleted (residue 
Y174-A198) and replaced with the loop TM4-TM5 from PDB entry 3EML (AA2AR_HUMAN, 
residues N144-N175). Homology modeling was performed using the Yasara program 
and its built-in modeling algorithm [85]. Subsequently, the initial models were manually 
refined and subjected to a final energy minimization step. Snooker pharmacophores were 
generated based on the custom built homology models by the procedure described in this 
manuscript. Finally, compound matches in all 5 feature pharmacophores for eticlopride 
in the DRD3 receptor and in all 4 feature pharmacophore for the CXCR4 receptor were 
optimized and scored using Fleksy [17]. 
5.3.10.3. Target specificity
The performance of Snooker with regard to target specificity was tested in a cross-
screening exercise. A virtual cross-screen of 15 pharmacophore hypotheses of different 
GPCRs and 10000 assumed inactive compounds plus 750 active compounds (50 for each 
GPCR) was therefore performed. After the virtual screen, compounds were first ranked 
according to the number of fitted features, and subsequently by their fit value. For each 
set of 50 actives and 10000 assumed inactives, the area under the semi-logarithmic 
receiver operating curve (pROC AUC) was calculated [86]. Finally, the 15 different 
pharmacophore hypotheses were ranked for each compound set using the pROC AUC. 
Since the pROC AUC emphasizes early enrichment we have chosen this value instead 
of the normal ROC AUC. To show that results are not biased towards the properties of 
the active compounds, 15 fake sets of active compounds were created and screened 
together with the 10000 assumed inactives.  To construct the fake sets, one compound 
which has not been tested in a GPCR assay and possesses similar properties to an active 
was selected per active molecule. The pROC AUC and ranking is subsequently calculated 
for each pharmacophore hypothesis and compound as described before. 
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5.3.10.4. Library enrichment
From all training set compounds poses we removed those which have at least one atom 
within 2.0Å of the backbone of the homology model. The pose which had the best volume 
overlap (calculated as the smallest average tanimoto shape distance) with all filtered 
training set poses was defined as the reference. Next, the volume overlap between the 
reference and all poses of the 10050 compounds (10000 compounds not tested in a GPCR 
assay and 50 actives for the GPCR of interest) which match the pharmacophore were 
calculated. A value for the volume overlap (as tanimoto shape distance) was set at the 
maximal  enrichment of training set actives versus decoys and including  at least 25% 
of training set actives. Subsequently, a shape cutoff was defined by adding 0.03 to this 
value. All poses of the test and decoy set with a tanimoto shape distance larger than 
the cutoff were removed and the remaining compounds were ranked according to the 
number of matching pharmacophore features, the number of actives in the training set 
which hit this same pharmacophore and finally the fit value. Lastly, the AUC, pROC AUC 
[86], enrichment at 0.5%, 1%, 2% and 5% of the compound set were calculated [87]. 
5.3.11. Pharmacophore screening. 
Pharmacophore searches were performed using custom code implemented in python 
and making use of RDKit [88]. First, ligand atoms were typed using the built-in definitions 
of RDKit. Second, all matches between pharmacophore features and ligand features were 
listed after which all possible matches between a ligand and a pharmacophore were 
calculated. Third, all ligand atoms which match features were transformed to minimize 
the RMS between the ligand atoms and the centre of the corresponding pharmacophore 
feature. Fourth, the distance from each atom to the centre of the feature it should match 
was calculated, and if this was larger than the pharmacophore radius, the weight of this 
pair was increased in the next transformation. This procedure is repeated three times and 
a hit was defined when the average RMS was smaller than the average pharmacophore 
radius, and when all ligand atoms were within 105% of the radius of the pharmacophore 
feature.
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5.4. Results and discussion. 
5.4.1. Retrospective binding mode prediction
The contributions of the different residues to the pharmacophore hypotheses deduced 
from the ADRB2 models derived from 8 different template structures as well as a 
consensus are depicted in Figure 5.3. The consensus pharmacophore hypothesis is 
derived from the overlay of the models based on the 8 different templates and contains 
the most robust features related to the residues identified as being important for ligand 
binding by multiple sequence alignment (MSA) analysis. Represented are for example 
known important interactions like the positive ionizable interaction of Asp3.32, the 
hydrophobic contact with Val3.33, the polar interactions with Asn7.39 & Asp3.32 
and with Ser5.42 & Ser5.46 [76]. The overlay of the 8 models represents all possible 
interactions hypothesized by the individual models. A weighted average of all these 
possible interactions defines which single interactions are considered most important 
based on MSA analysis and robust as indicated by their presence in the majority of the 
models. The consensus hypothesis is newly created by revisiting the interaction feature 
points and recalculation of the densities, thus pharmacophore features. For example, 
Ser5.46 has been shown to be important for the binding of agonists [76], but has only 
limited accessibility in the models based on the aminergic templates, probably due to 
the antagonist conformation in which the aminergic receptors have been crystalized. This 
same area of the receptor is much more accessible in the models based on the opsin 
and rhodopsin templates and promotes the use of models based on these templates to 
construct the consensus pharmacophore hypothesis. Ser5.46 is very well represented 
in the consensus pharmacophore hypothesis due to the inclusion of the rhodopsin 
templates (Figure 5.4).
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Figure 5.4: Contribution of the different residues to the different pharmacophore features 
(horizontal) for the pharmacophore hypotheses derived from the ADRB2 models based on the 
different templates as well as the consensus pharmacophore hypothesis (vertical). Coloring of the 
pie-charts is according to the transmembrane domain in which the residue is positioned. Templates 
corresponding to crystal structures of beta aminergic, bovine rhodopsin and the adenosine A2A 
receptors are colored blue, red and green, respectively.
The pharmacophore guided poses of 16 compounds matching a consensus (sub)
pharmacophore hypothesis of 5 or more features are shown in Figure 5.5 together with 
the reference as defined by de Graaf et al. [55]. The depicted poses are the most similar 
poses to the reference amongst all possible poses which satisfy a pharmacophore of at 
least 5 features. Since evolutionary pressure is mainly driven by endogenous agonists [89] 
and the fact that the Snooker procedure assigns weights to residues based on calculated 
entropies (reflecting evolutionary pressure) from a multiple sequence alignment 
comprising multiple species, it is to be expected that the method is more biased towards 
agonism than towards antagonism. This and the fewer specific contacts for antagonists 
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as suggested by mutagenesis experiments [90] might explain the relatively high number 
of antagonist experiments (9 out of 12 antagonists [red] compared to 1 out of 14 agonists 
[green]) for which no pose could be produced. 13 of the 16 ligands have at least one 
pose comparable to the reference (heavy atom root mean square deviation (RMSD) <= 
2.0Å). This indicates that Snooker pharmacophores represent the correct protein-ligand 
interactions for the majority of ADRB2 ligands which do fit a (sub)pharmacophore of at 
least 5 features.
Figure 5.5: Receptor structure of the reference structure (gray), reference pose (orange), most 
similar predicted pose (cyan) and structure-based consensus pharmacophore hypothesis of the 
human beta 2 adrenergic receptor. Pharmacophore features are colored cyan (hydrophobic), 
green (acceptor), magenta (donor) and blue (positive ionizable). Ligand names are colored red 
for antagonist/inverse agonist and green for agonist. The heavy atom root mean square deviation 
(RMSD) of each pose is indicated below each figure.
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5.4.2. Prospective binding mode prediction
Binding mode hypotheses largely based on Snooker pharmacophores are generated for 
the human DRD3 and CXCR4 receptor and submitted for evaluation in the GPCR dock 2010 
assessment [58]. Utilizing custom made homology models, Snooker pharmacophores and 
low resolution binding modes were generated and optimized by Fleksy. The dopamine 
DRD3 compound, eticlopride, fitted dominantly into one five feature pharmacophore and 
was consistently predicted in a binding mode similar to the pose depicted in Figure 5.5. 
Based on the five feature pharmacophore used to generate these poses, interactions 
with Asp3.32, His6.55, Tyr7.35, Thr7.39, Tyr7.43, Val3.33, Val5.39 and Phe6.51 can be 
assumed. The final poses as optimized by Fleksy indeed represent those interactions and 
all 5 submitted models ranked in the top 10 in the DRD3 assessment. The best model 
correctly predicted 36/65 atomic contacts and 12/15 residue contacts [58].
The default CXCR4 model did not show a pocket volume for the positioning of 
pharmacophore features due to bulky and inward directed residues in the upper part 
of the transmembrane domain. To generate a pocket volume the minimal edge length 
required for the removal of tetrahedra was reduced from 8.5Å to 8.0Å and 7.5Å. This 
resulted in two different subpockets in the minor binding pocket between TM2, TM3, 
and TM7[57]. Pharmacophores related to both subpockets were generated and screened 
resulting in two distinct sets of possible poses. IT1t poses in the first subpocket 1 
correlated to interactions with residues Glu7.39, Thr3.33, Phe2.57, Leu 2.61, Tyr3.32, 
Leu3.36 & Phe7.43 and poses in the second subpocket 2 represented interactions of 
the small molecule IT1t to residues Glu7.39, Tyr3.32, His3.29, Val3.28 & Leu2.61. Since 
the pharmacophore features from the first subpocket 1 are based on a larger number 
of residues originating from the transmembrane domain we optimized and submitted 
compound poses in this pocket for evaluation and ranked 14th, 17th, 28th, 29th and 33th 
out of 103 predictions in the GPCR dock 2010 assessment [58]. 
The pose prediction experiment of ADRB2 already indicated that antagonists and inverse 
agonists are likely to have less specific contacts as agonists. This and the observation that 
the co-crystalized peptide ligand in the CXCR4 crystal structure does occupy a large part 
of the major pocket indicates that other small molecules and agonists in particular might 
bind somewhere other than IT1t. Interestingly, retrospective analysis of the binding 
modes obtained in minor subpocket 2 (which was not submitted for the GPCR DOCK 
2010 assessment) show structures which resemble the CXCR4-IT1t crystal structure with 
interactions to residues Glu7.39, Tyr3.32, His3.29, Val3.28 & Leu2.61 (Figure 5.6B,D). 
Important interactions with W2.60 and D2.63 are however not predicted in these 
models, as the T2.56XP2.59 induced kink in TM2 was not correctly predicted based on 
the available set of GPCR crystal structure templates [58]. 
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Figure 5.6: Binding mode predictions of eticlopride in the human DRD3 receptor and 1t in the 
CXCR4 receptor. A: Human DRD3 pharmacophore and matching eticlopride pose. B: Human CXCR4 
pharmacophore and matching IT1t pose. C: Optimized eticlopride pose and corresponding receptor 
structure in yellow and orange and crystal structure pose and receptor structure in green and cyan. 
D: Optimized IT1t pose and corresponding receptor structure in yellow and orange and crystal 
structure pose and receptor structure in green and cyan.
5.4.3. Identification of receptor-specific ligands and ligand binding residues in cross-
screen. 
Consensus pharmacophore hypotheses are generated for 15 targets using default 
Snooker settings, as described in the Methods section. The residue contributions to 
the pharmacophore hypotheses for the different models are depicted in Figure 5.7. 
The significance of each feature for the identification of known actives for a model is 
indicated below the pie-chart. This significance has been calculated as the fraction of 
pharmacophores which contain the particular feature and match a conformation of a 
known active. Site-directed mutagenesis studies confirm that most of the pharmacophore 
features in the Snooker models relate to ligand binding residues. Most positively ionizable 
(and/or H-bond donor) pharmacophore features are associated with negatively charged 
residues which are determined to be essential for ligand binding to bioaminergic receptors 
ADA2B, ADRB2, DRD2, HRH3, and 5HT7R (D3.32) [76], EDNRA (D7.35) [75], GHSR (E3.33)
[91], MCHR1 (D3.32) [92] and OPRM (D3.32) [78]. Likewise, negatively charged (and/or 
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acceptor) features correspond to positively charged residues shown to be involved in 
ligand binding in AGTR1 (K5.42) [93], EDNRA (R6.55) [75], GHSR (R6.55) [91] and TA2R 
(R7.40) [94]. In addition, polar residues at positions T3.36/N6.55/S7.42 in AA2AR [67, 
95], 5.42/5.43/5.46 in the bioaminergic receptors [76] and Q3.22 in EDNRA [75] are 
associated with donor and acceptor features and indeed play key-roles in ligand binding 
for these receptors. The Snooker approach clearly allows an automated and fully protein-
based construction of experimentally supported pharmacophore models. Interestingly, 
valid pharmacophore models could not only be built for receptors with existing crystal 
structures (ADRB2 and AA2AR) and receptors which are related to crystallized GPCRs 
(5HT7R, ADA2B, DRD2, HRH3), but also for receptors with low sequence similarity to 
GPCR crystal structure templates (AGTR1, CLTR1, EDNRA, GASR, NPY5R, GHSR, MCHR1, 
OPRM, TA2R).
Despite the fact that all template structures have ligands with key interactions to helix V, all 
features of the GHSR receptor are almost exclusively related to residues in helix III, VI and 
VII. Site directed mutagenesis experiments confirm the importance of several residues 
(Q3.33/F6.51/R6.55/P6.58/N7.35) of helix III, VI and VII and the relative unimportance 
of helix V (M5.39/V5.42/S5.43/F5.46) for ligand binding [91], illustrating the ability of 
Snooker to presume different binding pockets by using similar template structures. The 
features of the CLTR1 pharmacophore hypothesis relate only to residues originating from 
helices III, VI and VII. This suggests a different binding mode for ligands of this receptor 
compared to e.g. the amine receptors (5HT7R, ADA2B, ADRB2, DRD2 and HRH3) which 
do have polar interactions with helix V [76]. The values below the features indicate the 
importance of those features in retrieving active compounds and it is remarkable to see 
that positive ionizable features play a crucial role in retrieving active compounds when 
present (as witnessed by the relatively high values). However, due to the limited number 
of negative ionizable residues and therefore positive ionizable features in the pocket, 
are often two positive ionizable features related to the same residue (AA2AR, ADA2B, 
ADRB2, AGTR1, HRH3, OPRM). Subpharmacophores which are identical except for the 
positive ionizable features are therefore likely to retrieve similar compounds by assuming 
almost identical ligand poses. The absence of a feature in pharmacophores retrieving 
active compounds gives the opportunity to drop such a feature in a pharmacophore for 
virtual library screening and will most likely increase the hit rate.
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Figure 5.7: Pie-charts visualizing the contributions of the different residues to pharmacophore 
hypotheses for 15 different GPCRs. The percentage of recognized active compounds by a 
subpharmacophore which contain a feature is indicated below the pie-chart of that particular 
feature. In a scenario where 60 out of the 100 actives are retrieved, and 30 of the actives are 
matched in a pharmacophore where feature X is involved, the number for feature X will be 50. 
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To validate the target-specificity of the generated pharmacophore hypotheses we 
performed a cross-screening experiment on 15 sets of active and decoy compounds using 
the 15 corresponding pharmacophore hypotheses. The enrichment of all sets of active 
compounds is calculated for all pharmacophore hypotheses. Enrichment values of the 
different hypotheses are ranked for each set of active compounds. Figure 5.8 shows the 
rank of the pharmacophore hypothesis of the target receptor which corresponds to the 
compound set of actives. The target consensus pharmacophore hypothesis ranks as one 
of the best 3 hypotheses for 10 of the 15 receptors. 
Figure 5.8: The rank in a list of 15 pharmacophore hypotheses at which a target pharmacophore 
hypothesis enriches a compound set of active molecules for that target. Blue indicates the rank of 
the consensus models and orange the rank of the adjusted models (see Materials and Methods). 
The average rank of the screen of the “fake” sets of actives is indicated with the red dashed line.
A shortcoming of the automatic homology modeling procedure is the accurate prediction 
of helix structure, for example when kinks are present, as observed in TM2 of the recently 
elucidated CXCR4 receptor structure [57]. Performance of the consensus pharmacophore 
hypotheses in the cross screening experiment is poor for 4 compound sets. Mutagenesis 
data and multiple sequence analysis [38, 72] indicate that minor model adjustments 
are required for those receptors. Gln3.32 is known to be important for ligand binding in 
the EDNRA receptor [75] and is not related to a pharmacophore feature in the original 
pharmacophore hypothesis. The hypotheses based on the 3CAP and 3EML template is 
tested for the EDNRA receptor because Gln3.32 correlates to a pharmacophore feature 
in these hypotheses. The modifications made to the NPY5R, TA2R and OPRM receptor 
are, respectively, the adjustment of the template due to an assumed sulfide bridge and 
the inclusion of the third ranked polar feature instead of the second ranked polar feature, 
adjustment of the multiple sequence alignment and selection of a template to enable 
exposure of residues which are likely to be ligand binding, and selection of a template 
due to correspondence of the resulting pharmacophore hypothesis with literature [77-
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79] (see Methods for details). The original consensus pharmacophore of those receptors 
show a reasonable amount of similarity to the modified pharmacophores and show 
major differences by 2-3 features (data not shown). 
Three of the manually adjusted pharmacophore hypotheses retrieve their corresponding 
compound set amongst the best 3 hypotheses in the earlier mentioned cross-screen. 
Thus, as in many other modeling procedures, knowledge-based input can also improve 
Snooker pharmacophore hypotheses [52, 55], but such input is not a prerequisite for this 
method.
 
All 15 generated pharmacophore hypotheses possess at least 2 acceptors, 2 donors and 
2 hydrophobic features and some are complemented with a maximum of 2 positive and/
or negative ionizable features. The presence of ionizable features in hypotheses could 
potentially lead to biased enrichment – the requirement for corresponding features on 
ligands might function as an effective 2D filter, independent of positions in the hypotheses. 
To address this problem, fake active sets of compounds with chemical properties 
similar to the active molecules were cross-screened to determine the target specificity 
accomplished by the correct spatial arrangement of features. The average rank of 7.0 
for the pharmacophore hypotheses corresponding to the fake active sets (compared to 
2.3 for the true actives) further indicates that features have indeed the correct spatial 
arrangement. Ideally, compound sets should be best recognized by the pharmacophore 
hypothesis based on the homology model of the receptor at which the compounds are 
active. However, polypharmacology against GPCRs is widely accepted and even occurs in 
known antipsychotics and antidepressants. The selected compound sets include the 50 
structurally most diverse compounds for each target and possibly contain a mix of partial 
and full agonists, antagonists and inverse agonists. Hierarchical clustering on compound 
fingerprints shows the similarity of compounds selected for the different targets. Some 
of the compounds show activity across multiple target receptors (Chembl02 compound 
id. 2214 has reported activity on the 5HT7R and DRD2 receptor, compound id. 1989 
has reported activity on the ADA2B and DRD2 receptor and compound id. 27397 has 
reported activity on the ADA2B and ADRB2 receptor). Although active compounds are 
only included in the test set of only one receptor, they are successfully retrieved by the 
pharmacophore hypotheses of the other targets on which they have reported activity 
(data not shown). Cross-activity inhibits the selection of sets of compounds uniquely 
active at only one receptor and it is of course possible that cross activity exists, especially 
within receptor sub-families, which is not yet reported in the literature. Snooker allows 
for the virtual screening of compounds against pharmacophores of all class A GPCRs. 
The outcome of such a virtual screen can be used to predict bioactivity profiles, design 
multi-target drugs, or to select a panel of GPCRs on which a compound should be tested 
to prohibit possible side effects at a later stage. 
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5.4.4. Library enrichment
The ultimate goal of 3D pharmacophore hypotheses is to predict the conformation of all 
and only active ligands exactly as observed in the crystal structure. Shape constraints are 
often added to pharmacophore hypotheses to improve the enrichment of active molecules 
in virtual screenings of compound libraries [24, 60]. Since only limited enrichment is 
observed in the cross-screening experiments we introduce a shape constraint derived 
from a reference pose of an active compound in the enrichment experiment to optimize 
enrichment factors. The reference pose is automatically extracted from a training set 
of active compounds and used to filter the decoys and test set on shape similarity to 
this reference pose (see Materials and Methods). The number of actives, decoys and 
enrichment factors for the filtered and unfiltered sets are listed in Table 5.2. 
 
Table 5.2: Retrospective virtual screening accuracies of 15 compound sets using pharmacophores 
with and without shape constraints.
Receptor Actives 
(unfiltered)
decoys 
(unfiltered)
shape 
cutoffa
actives 
(filtered)
decoys 
(filtered)
EF (unfiltered)b EF (filtered)c
5HT7R 16 3023 0.560 5 567 1.06 1.76
AA2AR 25 4170 0.555 9 884 1.20 2.04
ADA2B 30 5232 0.434 12 38 1.15 63.16
ADRB2 38 2253 0.576 21 452 3.37 9.29
AGTR1 22 1961 0.635 9 350 2.24 5.14
CLTR1 13 2823 0.514 2 20 0.92 20.00
DRD2 30 2918 0.560 12 845 2.06 2.84
EDNRA 44 5721 0.578 24 1917 1.54 2.50
GASR 11 1444 0.844 11 1230 1.52 1.79
GHSR 48 4439 0.588 17 508 2.16 6.69
HRH3 37 4762 0.570 19 1061 1.55 3.58
MCHR1 36 4386 0.603 13 802 1.64 3.24
NPY5R 14 1925 0.618 4 762 1.45 1.05
OPRM 24 3610 0.668 5 678 1.33 1.47
TA2R 25 675 0.538 5 1 7.41 1000.0
a Shape cutoff used to filter the test and decoy set (paragraph 5.3.10.4). 
b Enrichment factor (EF): ratio of “filtered actives / filtered decoys” to “all actives / all decoys”. 
c Enrichment factor (EF): ratio of “unfiltered actives / unfiltered decoys” to “all actives / all decoys”.
On average the shape constraint improves enrichment values by a factor ~2.0. The 
enrichment values for those targets with the most stringent shape criteria (ADA2B, 
CLTR1, TA2R) are improved best. In the case of ADA2B this is due to the small size of 
the reference molecule as well as ADA2B active compounds. Larger compounds have 
by definition a higher chance to fit a pharmacophore without shape constraints and are 
removed by the addition of this shape constraint. As a result, the average molecular 
weight of the filtered sets is reduced from 201 to 165 and 279 to 173 for the actives and 
decoys respectively. For TA2R the shape constraint selects almost exclusively poses which 
fit the pharmacophore consisting of features 1,2,6,7 and 8. This pharmacophore is rarely 
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present in poses generated for decoy compounds. A result of the stringent cutoff is that 
all remaining compounds after filtering contain the same scaffold. However it should be 
noted that an acceptor feature and a correct orientation of the varying R-group is required 
to fulfill the pharmacophore criteria and shape constraint. For CLTR1 very few actives or 
decoys were selected. Retrospective analysis of the training set shows a high similarity 
among the compounds in this training set explaining the stringent cutoff value and low 
number of selected compounds. Both selected CLTR1 actives also show relatively high 
similarity to the compounds in the training set, indicating that the automatic selection 
of a reference and cutoff value can sometimes result in high enrichment values but with 
less novelty in the resulting compound sets due to a suboptimal training set. Most shape 
filtered sets do however show chemically diverse active compounds as desired in typical 
virtual screening experiments. The training set of active compounds is used to derive 
the reference shape but also to rank the compounds which match a pharmacophore. 
Pharmacophores are therefore first ranked on the number of features and next on 
the number of training compounds which match the pharmacophore. Compounds are 
subsequently ordered on the pharmacophore in which they match and the fitvalue 
which is obtained in this pharmacophore. Using this approach we calculated 6 different 
performance measures for the enrichment and these are listed in Table 5.3. The high 
early enrichment values (at EF 0.5% and 1.0%) as compared to the enrichment values in 
Table 5.2 indicate that this ranking improves the result of the virtual screening.
Table 5.3: Retrospective virtual screening accuracies of 15 compound sets using Snooker 
pharmacophores and shape constraints. Enrichment factors (EF) above 3 and 10 are colored orange 
and green, respectively.
Receptor AUCa pROC AUCb EFc at 0.5% EFc at 1.0% EFc at 2.0% EFc at 5.0%
5HT7R 0.53 0.57 12 6 4 2
AA2AR 0.55 0.53 0 2 1 2
ADA2B 0.61 0.98 44 22 11 5
ADRB2 0.69 1.04 16 14 14 8
AGTR1 0.58 0.71 16 12 9 4
CLTR1 0.52 0.56 8 4 2 2
DRD2 0.59 0.76 16 10 8 5
EDNRA 0.66 0.90 16 8 5 5
GASR 0.56 0.62 4 10 5 3
GHSR 0.65 0.96 16 14 10 7
HRH3 0.64 0.82 8 6 4 6
MCHR1 0.60 0.72 8 4 6 4
NPY5R 0.50 0.43 0 0 1 1
OPRM 0.52 0.50 0 2 3 2
TA2R 0.54 0.71 16 8 4 2
aArea under the ROC curve; 
bArea under the semi-logarithmic curve; 
cEnrichment factor (EF): the ratio of true positive rates to false positive rates at increasing false positive rates (0.5%, 1%, 2% and 5%). 
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Virtual screening methods should enrich active ligands at least 10 fold to obtain a 
reasonable chance of finding a true hit [96]. According to this criterion, Snooker shows 
early enrichment for 8 and 6 of the 15 receptors at 0.5% and 1% false positive rates. 
Interestingly, high virtual screening enrichments are obtained not only for bioaminergic 
receptors (ADRB2, 5HT7R, ADA2B, DRD2), but also pharmacophore models based 
on receptors with low sequence similarity to GPCR crystal structures (AGTR1, EDNRA, 
GASR, GHSR, TA2R) yield high early enrichment results. This shows that Snooker is 
not necessarily dependent on the availability of high resolution structural data, and 
demonstrates the strength of the pharmacophore modeling approach. Although 
enrichment is mainly achieved by the additional shape restraints, this method results 
in a binding model of the compounds which is likely to reflect the true interaction of 
the compound with the receptor. Such information can be very useful in the design of 
experiments and compound optimization after the discovery of a new active compound. 
The relatively poor performance of the AA2AR pharmacophore hypothesis, partly based 
on structural information of the AA2AR crystal structure can be explained by the fact 
that the ligand binding site is for a large part located between the extracellular loops, 
currently not included in Snooker pharmacophore models. It should furthermore be 
noted that the test sets of 50 active compounds consist of compounds with different 
scaffolds and possibly different binding modes [97], explaining the generally low global 
virtual screening results (AUC). Such a diverse set of active molecules is possibly more 
difficult to describe with a combination of a single pharmacophore hypothesis and shape 
restraint and results therefore usually in less satisfying enrichments. The definition of 
multiple combinations of pharmacophores and shape restraints based e.g. overlays of 
different compound series available in the training set might improve enrichment scores 
but would likely limit the structural diversity of hits.
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5.5. Conclusion
In this paper, we present Snooker, a new structure-based approach to generate low 
resolution pharmacophore hypotheses for class A GPCRs. We show that Snooker generates 
ADRB2 pharmacophore hypotheses which retrieve 3/12 antagonists-inverse agonists 
and 13/14 agonists and assumes the correct binding mode for 3 and 10 compounds, 
respectively. All 5 submitted eticlopride binding mode predictions in the human DRD3 
receptor, which are largely based on the eticlopride matches in Snooker pharmacophore, 
showed to be in the top 10 of all submitted models in the GPCR dock 2010 assessment. 
The automated and fully protein-based construction of pharmacophore hypotheses 
is in line with experimental site-directed mutagenesis data on essential ligand binding 
residues for a diverse set of 15 class A GPCRs. For several of the more difficult targets, 
the default Snooker settings can be adjusted with target-based knowledge to obtain good 
results. Interestingly, valid pharmacophore models were built for not only 2 receptors 
with known crystal structures and 4 related receptors but also for 9 receptors with low 
sequence similarity to GPCR crystal structure templates. A virtual screening experiment 
using the Snooker pharmacophore hypotheses in combination with a shape constraint 
resulted in >10 fold enriched compound sets for 8 out of 15 targets. As such, the method 
is suitable to design focused compound libraries targeting a small subfamily of class A 
GPCRs. 
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Abstract
Recently the first community-wide assessments of the prediction of the structures of 
complexes between proteins and small molecule ligands have been reported in the so-
called GPCR Dock 2008 and 2010 assessments. In the current review we discuss the 
different steps along the protein-ligand modeling workflow by critically analyzing the 
modeling strategies we used to predict the structures of protein-ligand complexes we 
submitted to the recent GPCR Dock 2010 challenge. These representative test cases, 
focusing on the pharmaceutically relevant G Protein-Coupled Receptors, are used 
to demonstrate the strengths and challenges of the different modeling methods. Our 
analysis indicates that the proper performance of the sequence alignment, introduction 
of structural adjustments guided by experimental data, and the usage of experimental 
data to identify protein-ligand interactions are critical steps in the protein-ligand modeling 
protocol.
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6.1. Introduction
In the last few years, the disciplines involved in in silico protein structure prediction have 
greatly evolved. Not only have more tools and modeling programs become available, 
but also the amount of varying approaches to produce predictive models has increased. 
Structure prediction of protein-ligand complexes by comparative or homology modeling 
can be subdivided into the following major steps: (1) identification of homologue proteins 
for which a three-dimensional structure is available; (2) alignment of the target sequence 
with the sequence of the template structure; (3) building the coordinates of the three-
dimensional model of the target; (4) modeling the protein-ligand interactions; and (5) 
assessing ligand binding mode prediction accuracy by investigating ligand structure 
activity data or biological data [1, 2].
Critical assessments of in silico methods to predict the structure of proteins (CASP [3]) and 
protein-protein complexes (CAPRI [4]) have been established in the past years, and many 
comparative docking studies to predict the binding orientation of small molecule ligands 
in known protein structures have been reported [5]. Only very recently, however, the first 
community-wide assessments of the prediction of the structures of complexes between 
proteins and small molecule ligands have been reported in the so-called GPCR Dock 
assessments [6, 7]. The first was initiated in 2008 to predict conformation of the human 
adenosine A2A receptor in complex with the small ligand ZM241385 [7, 8]. The second 
was organized in 2010 [6] to predict the conformation of the dopamine D3 receptor 
in complex with the small ligand eticlopride [9], as well as the chemokine receptor 
CXCR4 bound to the small ligand 1t [10] or the cyclic peptide CVX15 [6, 10]. These 
assessments did not only give the protein modeling community the chance to objectively 
(and prospectively) test their methods to predict the structure of complexes between 
proteins and small (drug-like) ligands, but also offered a unique opportunity to identify 
the problems and pitfalls in the prediction of protein-ligand interactions. In the current 
review we will discuss the different steps along the protein-ligand modeling workflow 
by critically analyzing the modeling strategies we used to generate the structures we 
submitted to the GPCR Dock 2010 challenge. These representative test cases will be used 
to demonstrate the strengths and challenges of the different methodologies and their 
impact on modeling accuracy.
6.2. Experimental Section
6.2.1. GPCR Dock 2010
In spring 2010, the group of Stevens et al. challenged the scientific community to 
participate in the structure prediction assessment GPCR Dock 2010. The subject of 
the challenge consisted of three different crystal structures for which multiple models 
could be deposited. The first case encompassed modeling the dopamine D3 receptor 
co-crystallized with the antagonist eticlopride [9] (Figure 6.1). The dopamine D3 receptor 
is closely related to the adrenergic beta 1 and 2 receptors, for which a crystal structure 
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has already been elucidated [11, 12]. The aminergic receptor family possesses a high 
sequence identity for the residues involved in ligand binding, including D3.32, S5.43, 
S5.46, and Y7.43 [13-16]. Due to the functional similarity and identical binding sites 
of the target to the adrenergic receptors, it was considered as the easiest of the three 
challenges.
Figure 6.1: Chemical structures of eticlopride, 1t and CVX15. The first is co-crystallized with the 
dopamine D3 Receptor and the latter two with the chemokine Receptor CXCR4.
The second case encompassed constructing a model for the chemokine receptor CXCR4 
co-crystallized with a small ligand 1T [17] (Figure 6.1). The similarity of the chemokine 
receptor CXCR4 in sequence and function is distant compared to the GPCRs for which 
a crystal structure has been elucidated [10] and as such was expected to pose a more 
difficult challenge than the dopamine D3 receptor complex. The importance of certain 
amino acids for the binding of small ligands has been described [18-20], and the ligand 
in question is one from a compound series for which structure activity relationship data 
has been determined [17]. These data could be used to derive binding hypotheses for the 
ligand in the CXCR4 model. 
The third case involved building a model for the chemokine receptor CXCR4 co-crystallized 
with a large cyclic peptide, the antagonist CVX15 [21, 22] (Figure 6.1). Due to the large 
conformational space accessible to the ligand, it was considered the most difficult 
challenge in GPCR Dock 2010: none of the deposited models were able to predict any 
of the critical contacts between protein and ligand [6]. As the current review focuses on 
the prediction of interactions between proteins and small (drug-like) ligands, the CVX15 
modeling case will not be described in this review.
6.2.2. Modeling Approaches
Our two research groups have taken different approaches to construct the structural 
models for the challenge. The CDD-CMBI group contested in both small ligand challenges 
and ranked second for the dopamine D3 receptor and fourteenth for the chemokine 
CXCR4 receptor, whereas the VU-MedChem group only contested in the CXCR4-1t 
challenge for which they obtained first rank [6]. The CDD-CMBI group chose to combine 
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sequence conservation knowledge with the placement of a pharmacophore definition 
as a description for the protein-ligand interactions in space (Figure 6.2A). In parallel, 
a homology model was constructed based on a template structure, which was 
subsequently combined with the pharmacophore and flexible receptor docking to 
obtain a structural model for the protein-ligand interactions. The VU-MedChem group 
constructed a structural model after which literature data was used to determine the 
most likely protein-ligand interactions (Figure 6.2B). Each of the steps taken by our 
groups is graphically outlined below.
Figure 6.2A: Modeling workflow as used by the CDD-CMBI group in the GPCR Dock 2010 challenge. 
B: Modelling workflow as used by the VU -MedChem group in the GPCR Dock 2010 challenge.
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6.2.3. Sequence Analysis
6.2.3.1. Current Approaches
The construction of a multiple sequence alignment of the target sequence with a series 
of potential homologues is an important step in predicting the structure of the target 
protein [2]. Potential misalignments have a direct impact on the location of amino acids in 
the protein model, which in turn directly influences the models ability to correctly predict 
protein-ligand interactions. As such, the accuracy of the alignment should be optimized as 
much as possible. To accomplish this, common practice is to include sequences belonging 
to target family members in an attempt to identify important residues and sequence 
motifs that might point to a similarity in protein fold or function. Highly conserved 
amino acids indicate the conservation of the general protein function, three-dimensional 
fold and structural features. Amino acids that are very different between homologous 
proteins potentially indicate locations of specificity to binding partners such as small 
ligands or other proteins.
A G protein-coupled receptor contains seven transmembrane helices, each of which 
contains highly conserved residues and sequence motifs (DRY in TM3, CWxP in TM6 and 
NPxxY in TM7) likely related to generic receptor activation. Based on sequence and motif 
conservation, Ballesteros and Weinstein [23] developed a generic numbering scheme for 
GPCRs. This numbering scheme allows for consistent residue numbering across multiple 
proteins, independent of their sequential numbers. The underlying principle is that 
residues with the same general residue number have equivalent locations in their tertiary 
structures and consequently in the multiple sequence alignments. Residue numbers are 
in the format ‘X.Y’, where X indicates the TM helix, and Y the residue position with respect 
to the most conserved residue position in the helix, which gets the number 50. In addition 
to these conserved residues, most class A GPCRs also contain conserved cysteine residues 
in both TM3 (C3.25) and the extracellular loop 2 (C45.50) that together form a cysteine 
bridge. Resulting from these observations, the alignment of the structural aspects for 
GPCRs is most challenging for residues arranged outside of the transmembrane helices, in 
the N-terminus, intracellular and extracellular loops, and the C-terminus. However, most 
GPCR ligands are interact with the transmembrane domain [24], making the construction 
of a protein-ligand binding model feasible.
6.2.3.2. DRD3 Case
Of the crystallized GPCRs the adrenergic beta 2 receptor (ADRB2) has the highest 
sequence similarity with the dopamine D3 receptor, making this the most suitable 
template for modeling studies. The alignment of the dopamine D3 sequence with the 
ADRB2 sequence was based on alignments from the GPCRDB [25], with additional manual 
refinements in the loop regions. A sequence-based prediction of residues involved in ligand 
interaction was made for all transmembrane residues. Residues were scored according to 
ligand binding probability based on an analysis of Shannon entropies of residue positions 
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[26] of a multiple sequence alignment of around 7700 class A GPCR transmembrane 
domains. The alignment included 64 dopamine receptor D2 and D3 sequences of in total 
34 species. The most important ligand interacting residues were predicted to be D3.32, 
V3.33, S5.42, H6.55, Y7.35 and T7.39, which is corroborated by mutation data [14-16].
6.2.3.3. CXCR4 Case
In case of the CXCR4 challenge, the multiple sequence alignment study was supplemented 
with a literature study in order to investigate the target for conservation, specific family 
motifs and the importance of amino acids involved with ligand binding. A sequence 
alignment of all CXC chemokine receptors was constructed by sequence retrieval from 
the Uniprot database [27] and alignment with ClustalW [28]. The likelihood of cysteine 
bridges was assessed based on their sequence conservation (Figure 6.3). Similar to all 
other class A GPCRs, CXCR4 contains the cysteine residues C3.25 and C45.50. However, 
the sequence analysis also showed that all CXCR isoforms except for CXCR6 contain a 
cysteine residue both in the N-terminus as well as the extracellular loop 3. From these 
observations, it was concluded that for CXCR4 an additional cysteine bridge should be 
incorporated into the protein model between the N-terminus and ECL3. The presence of 
both cysteine bridges were indeed confirmed by the CXCR4 crystal structures [10].
Figure 6.3: Sequence alignment of the CXCR family including various species. Indicated are the 
conserved cysteine residues in the N-terminus and the extracellular loop 3 which are hypothesized 
to form a cysteine bridge.
N-terminus TM1 ECL3 TM7
CXCR1 Homo Sapiens ~ A D E D Y S P C M L E - T E T L N ~ ~ Q V I Q E S C E R R N N I G ~
CXCR1 Mus Musculus ~ T G D Y F I P C K R - - V P I T N ~ ~ H L I E D T C E R R N D I D ~
CXCR1 Rattus Norvegicus ~ T G E Y F S P C K R - - V P M T N ~ ~ H L I Q D T C E R R N N I D ~
CXCR1 Macaca Mulatta ~ T D E D Y S P C R L E - T Q S L N ~ ~ H L I K E S C E R R N D I G ~
CXCR1 Pan Troglodytes ~ T D E G Y S P C R L E - T E T L N ~ ~ Q V I Q E S C E R R N N I G ~
CXCR2 Bos Taurus ~ E D Y D Y S P C E I S - T E T L N ~ ~ H V I A E T C Q R R N D I G ~
CXCR2 Canis Familiaris ~ I P A D S A P C R P E - S L D I N ~ ~ Q A I E E T C Q R R N D I G ~
CXCR2 Homo Sapiens ~ F L L D A A P C E P E - S L E I N ~ ~ Q V I Q E T C E R R N H I D ~
CXCR2 Mus Musculus ~ I L P D A V P C H S E - N L E I N ~ ~ K L I K E T C E R R D D I D ~
CXCR2 Rattus Norvegicus ~ T L S D A A P C P S A - N L D I N ~ ~ K L I K E T C E R Q N E I N ~
CXCR2 Macaca Mulatta ~ S L P D V A P C R P E - S L E I N ~ ~ Q V I Q E T C E R R N H I D ~
CXCR2 Pan Troglodytes ~ F L L D A A P C E P E - S L E I N ~ ~ Q V I Q E T C E R R N H I D ~
CXCR3 Bos Taurus ~ F C C T S P P C P Q D F S L N F D ~ ~ G A L A R N C G R E S S V D ~
CXCR3 Canis Familiaris ~ S C C A S P P C P Q D I S L N F D ~ ~ G A L D R N C G R E S R V D ~
CXCR3 Homo Sapiens ~ S C C T S P P C P Q D F S L N F D ~ ~ G A L A R N C G R E S R V D ~
CXCR3 Mus Musculus ~ D F S D S P P C P Q D F S L N F D ~ ~ G V L A R N C G R E S H V D ~
CXCR3 Rattus Norvegicus ~ D F S D S P P C P Q D F S L N F D ~ ~ G V L A R N C G R E S H V D ~
CXCR4 Bos Taurus ~ Y D S M K E P C F R E E N A H F N ~ ~ E I I Q Q G C E F E S T V H ~
CXCR4 Canis Familiaris ~ Y D S M K E P C F R E E N A H F N ~ ~ E I I K Q G C E F E K T V H ~
CXCR4 Homo Sapiens ~ Y D S M K E P C F R E E N A N F N ~ ~ E I I K Q G C E F E N T V H ~
CXCR4 Mus Musculus ~ Y D S N K E P C F R D E N V H F N ~ ~ G V I K Q G C D F E S I V H ~
CXCR4 Rattus Norvegicus ~ Y D S N K E P C F R D E N E N F N ~ ~ E V I K Q G C E F E S V V H ~
CXCR4 Macaca Mulatta ~ Y D S I K E P C F R E E N A H F N ~ ~ E I I K Q G C E F E N T V H ~
CXCR4 Pan Troglodytes ~ Y D S M K E P C F R E E N A N F N ~ ~ E I I K Q G C E F E N T V H ~
CXCR5 Homo Sapiens ~ E N H L C P A T E G P L M A S F K ~ ~ K A V D N T C K L N G S L P ~
CXCR5 Mus Musculus ~ D S N F C S T V E G P L L T S F K ~ ~ K A V N S S C E L S G Y L S ~
CXCR5 Rattus Norvegicus ~ D S I F C S T E E G P L L T S F K ~ ~ K A V N S S C E L S G Y L S ~
CXCR6 Homo Sapiens ~ S F N D S S Q E E H Q D F L Q F S ~ ~ E Y Y A M T - - - - - S F H ~
CXCR6 Mus Musculus ~ N N S S D N S Q E N K R F L K F K ~ ~ E Y Y T I T - - - - - S F K ~
CXCR6 Macaca Mulatta ~ S F N D S S Q E E H Q D F L Q F R ~ ~ E Y Y A M T - - - - - S F H ~
CXCR6 Pan Troglodytes ~ S F N D S S Q E E H Q D F L Q F S ~ ~ E Y Y A M T - - - - - S F H ~
CXCR7 Canis Familiaris ~ I V V D T V L C P N M P N K S V L ~ ~ H Y I P F T C Q L E N F L F ~
CXCR7 Homo Sapiens ~ I V V D T V M C P N M P N K S V L ~ ~ H Y I P F T C R L E H A L F ~
CXCR7 Mus Musculus ~ I V V D T V Q C P T M P N K N V L ~ ~ H Y I P F T C Q L E N V L F ~
CXCR7 Rattus Norvegicus ~ I V V D T V Q C P A M P N K N V L ~ ~ H Y I P F T C Q L E N V L F ~
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6.2.4. Template Selection and Construction
6.2.4.1. Current Approaches
Template selection is mostly based on the sequence similarity between the template 
structure and the target sequence. If the sequence identity is low (<20%) and the 
structural aspects of the model are not highly conserved (alpha-helices and beta-sheets), 
it is very challenging to construct a predictive model for the protein fold [2] and residues 
interacting with potential ligands. For GPCRs, the crystal structures available for various 
proteins [8, 11, 12, 29] have shown only slight differences in the general arrangement 
of the seven transmembrane helices. The only marked differences were observed when 
comparing the activated [29] and inactivated [30] conformations of the rhodopsin 
structure. Here, a reorientation of amino acids in the central and intracellular regions 
of the TM region as well as a twisting of TM5 and TM6 are observed. Currently, novel 
insights in the conformational changes upon activation can also be derived from the 
activated AA2AR [31] and ADRB2 [32, 33] structures.
Due to the structural conservation, model construction based on any of the crystal 
structures would likely result in a preliminary model of the transmembrane region 
with most of the amino acids correctly pointing into the helical bundle [1, 24]. Minor 
adjustments can be made to the alpha helices in case gaps, insertions or helical kinks 
are expected. This holds particularly true for the occurrence of proline residues in 
helices combined with either serine or threonine TM residues [34, 35]. Adjustments of 
the template to accommodate these differences can be accomplished by constructing a 
custom template for the helix and using molecular dynamics or Monte Carlo simulations 
to predict the overall helical fold.
With regard to the loops, there are noticeable differences, especially in the second 
extracellular loop, which seems to show a different fold in all currently known protein 
families. In bovine rhodopsin this loop folds into a beta sheet structure, the adrenergic 
beta 1 and 2 receptors exhibit an alpha helical fold, and the adenosine A2A receptor 
shows a coil structure. Using experimental mutation data on the extracellular loop 
residues, one can produce a protein-ligand interaction model and restrain amino acids 
from the loop in the binding site while optimizing the rest of the loop structure [36-39]. 
However, when no data is available, it is advised to omit the modeling of the extracellular 
loops altogether and prioritize the modeling of interactions with residues in the TM 
bundle. Multiple template structures can be used as a basis for the construction of the 
final model, such as a combination of a template for the transmembrane domain and a 
template for the loop regions. 
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6.2.4.2. DRD3 Case
Since it has the highest similarity to the dopamine D3 receptor, the ADRB2 structure [11] 
(PDB code 2RH1) was chosen as the modeling template. Since the residues in the loop 
between TM5 and TM6 (residues 218-317) were not present in the crystal structure due 
to the insertion of T4 lysozyme, these residues were discarded in the modeling process. 
No additional modifications to the structure were deemed necessary based on the 
sequence.
6.2.4.3. CXCR4 Case
A structural assessment of available crystal structures of other G protein-coupled receptors 
was ensued following the alignment of their sequences to those of the chemokine receptor 
family. The structural alignment was performed with MOE2009.10 [40] and consisted of 
the structures of the human adenosine A2A Receptor [8] (PDB: 3EML), human adrenergic 
Beta 1 Receptor [12] (PDB: 2VT4), human Adrenergic Beta 2 receptor [11] (PDB: 2RH1) 
and the bovine opsin structure [29] (PDB: 3DQB). The selection and construction of 
a template structure posed several challenges. Overall, none of the sequences of the 
crystal structures possessed a significantly higher sequence similarity with the CXCR4 
sequence than another, and as such, the choice of a template structure seemed arbitrary. 
In the end, the crystal structure of ADRB2 was found to be a feasible template due 
to the importance of D3.32, N7.39 and Y7.43 in the binding of the antagonist carazolol [11], and 
the analogous involvement of residues at these positions in chemokine receptor binding 
by small ligands [20, 41-43]. From the sequence analysis and literature [44] it became 
clear that the chemokine receptor family possessed a unique TxP motif in TM2 which 
when aligned to the available crystal structures would produce a gap at the top of the 
transmembrane helix (Figure 6.4). A misalignment of this region would not put important 
amino acids into the TM bundle such as D2.63 [20]. To overcome this problem, we 
decided to customize the conformation of TM2 to accommodate the difference in amino 
acid rather than using an existing crystal structure as a template. In a manner similar to 
Govaerts et al. [44], a three-dimensional model of the helix was constructed to predict 
the helical bend of the TxP motif using the AMBER program [45] which was subsequently 
incorporated into the template. Lastly, TM1 of the template structure was oriented closer 
to TM7 since there is a spatial gap between these helices in the crystal structure due to 
the uncapped N-terminus of TM1. It was reasoned that the smaller residue at position 
7.40 in CXCR4 compared to that of in the ADRB2 structure (A vs. W, respectively) could 
accommodate the helical repositioning.
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Figure 6.4: Sequence conservation of the TxP motif in the CXCR family and the implication of a 
possible misalignment on the amino acids pointing into the TM bundle. Using the unadjusted TM2 
template of ADRB2 (orange ribbon and Cα spheres) would place W2.60 and D2.63 on the red Cα 
spheres, where the residues would not contact the ligand. In the CXCR4 crystal structure (yellow 
ribbon and Cα spheres), W2.60 and D2.63 are positioned on the green Cα spheres, indicating a shift 
from the ADRB2 template.
6.2.5. Homology Model Construction
6.2.5.1. Current Approaches
There are many homology modeling software packages available that allow the user 
to construct a three-dimensional model for their desired target sequence based on 
a template structure. Most packages work in a similar fashion. Residues that are in 
common between the template and the target are typically kept unaltered in the initial 
step of the model construction. Next, residues that differ are mutated and placed in 
an initial conformation based on a rotamer library [46, 47] that consists of the most 
commonly observed orientations of the residues throughout various crystal structures 
in the Protein Data Bank [48]. Residues are perturbed and reoriented whilst decreasing 
the amount of steric clashes and increasing the amount of stabilizing interactions. Finally, 
multiple different homology models are created and if desired optimized by the modeling 
program. It is recommended to investigate the predictive value of the model by identifying 
potential protein-ligand interactions as hypothesized by the user or as determined from 
literature data, as described below. 
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6.2.5.2. DRD3 Case
The template was prepared by a cleanup of the structure (removal of waters, sulfate ions, 
maltose, acetamide and butanediol), and removal of the T4 lysozyme protein. The lipids 
were retained for modeling. Using the alignment and the template as the starting point, 
modeling was performed with the Yasara program and its built-in modeling algorithm 
[49]. Side chains were added with Yasaras implementation of SCWRL [50], and then the 
model was subjected to an energy minimization with the Yasara2 force field as described 
previously [49]. WHAT CHECK [51] validation scores were used to score and rank the final 
models. The generated model was refined manually and a final energy minimization step 
was applied to relax the atoms of the DRD3 model. 
6.2.5.3. CXCR4 Case
Structural modeling of the CXCR4 structure was commenced with the TM bundle and most 
of the loop structures. Three structural regions were excluded from the initial model and 
were constructed later. These included the extracellular loop 2 (ECL2), the N-terminus, 
and the C-terminus. The extracellular loop 2 could not be modeled using any of the protein 
crystal structures available since the length of the CXCR4 loop is different and amino acids 
would either have to be added to or deleted from the (template) sequence. Different 
conformations of ECL2 were generated using MODELLER [52] and incorporated into the 
CXCR4 models, and one conformation was constructed based on the ECL2 of the opsin 
structure [29] (PDB: 3DQB). A structural model for the N-terminus could be retrieved 
from the crystal structure of the ligand CXCL12 [53] (PDB: 2K04) after positioning the 
arrangement on top of the TM bundle of the CXCR4 model. The C-terminus was modeled 
with a random arrangement since all atoms were requested for submission in the GPCR 
Dock assessment.
6.2.6. Ligand Interaction Modeling
6.2.6.1. Current Approaches
The prediction of protein-ligand interactions can be a challenging task for which the 
availability of experimental data is often beneficial. Many different experimental 
methods have been applied to identify GPCR ligand binding sites, and elucidate protein 
conformations and protein-ligand interactions, including site-directed mutagenesis 
studies [54], infrared probes [55], NMR spectroscopy [56], fluorescence measurements 
[57, 58], and the use of unnatural amino acids [59] and amino acid chelators [43]. 
Each of these tools provides information about amino acids interacting either with 
each other or with the ligand. In addition to these pharmacological and biophysical 
methods, a common method is the evaluation of other receptor binders and structural 
analogues of the ligand with regard to their interaction with the protein [17, 60] (and 
protein mutants if available). The majority of the methods allow the identification of 
residues interacting with the ligand thereby providing an anchor for the arrangement of 
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the ligand in the binding site. Thus model validation can be performed by investigating 
both structure activity relationships based on ligand analogues, but it can also utilize 
site-directed mutagenesis data. 
Molecular docking methods can be used to generate an initial binding pose of the 
small molecule ligand in the protein model. Docking programs rank the poses based 
on a scoring function that is knowledge-based, energy-based or empirical [5]. Since the 
scoring functions are optimized for protein-ligand complexes such as in the Protein Data 
Bank, one may assume that the results are precise. However, when little is known about 
the protein binding cavity or the rotamer conformations of the amino acids in the binding 
pocket, one cannot be certain that the docking program will generate or select the correct 
binding mode. In such case, it is helpful to post-process the binding poses using filtering 
schemes that prioritize specific residue interactions [1]. 
6.2.6.2. DRD3 Case
Ligand interactions were modeled using pharmacophore searches followed by flexible 
receptor docking. Structure-based pharmacophores derived from the transmembrane 
domains of the constructed homology models were built using the Snooker program 
[61]. In short, the Snooker method scores residue positions based on sequence 
conservation in a multiple sequence alignment, and deduces the key interacting 
residues from the derived statistics. Known DRD3 actives were retrieved from 
Chembl [62] using a 50nM activity cutoff. Conformations of the ligands were generated 
using Cyndi [63]. A pharmacophore search was performed to identify the structure-based 
pharmacophore complementary to most of the active compounds. The donor and positive 
ionizable features in the resulting pharmacophore originate from D3.32, the acceptor 
feature from T7.39, and the hydrophobic features from F6.51, F6.52, H6.55 and F7.35. 
Subsequently, eticlopride was matched in this structure-based pharmacophore (Figure 
6.5A,B). The low-resolution binding modes obtained from Snooker were used to guide 
high-resolution molecular docking by the Fleksy program [64]. The various orientations 
of eticlopride in the DRD3 receptor model were used as anchors to guide induced fit 
docking using the Fleksy protocol. The generated poses were optimized in the homology 
model (Figure 6.5C) and ranked using a consensus scoring function which utilizes docking 
scores, geometrical quality indicators and molecular dynamics force field interaction 
energies. All final poses contained the charged interaction of the basic amine with D3.32 
and the hydrophobic interactions with TM3, TM5, TM6 and TM7 similarly to carazolol in 
the ADRB2 receptor complex and timolol in the ADRB1 receptor complex. A retrospective 
comparison to the DRD3 crystal structure revealed that the polar interaction with D3.32 
was correctly predicted, as well as the hydrophobic contacts to V3.33, V5.39, V5.39, 
H6.55, F7.35, T7.39 and Y7.43 (Figure 6.5C,D). Many of these residues are in agreement 
with the pharmacophore features defined by the Snooker protocol.
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Figure 6.5: Binding pose as predicted by CDD-CMBI using Snooker and Fleksy compared to the X-ray 
structure.
The final GPCR Dock 2010 assessment of the five submitted models placed each of them in the 
top 10 of all 117 submitted models with the best model ranking second. Despite 
a relatively high receptor model RMSD the submitted models were able to 
capture a large part (35% to 57%) of the receptor-ligand atomic contacts, 
including the hydrogen bond with D3.32 and the hydrophobic interactions with 
F6.51, F6.52, H6.55 and F7.35. The best binding mode was able to capture 36 of 
65 atomic contacts as well as 12 of 15 residues directly interacting with the ligand. 
Interestingly, the accuracy of the five submitted DR3D models is in excellent agreement 
with the ranking generated by the Fleksy consensus scoring function [6] (Figure 6.6). 
This highlights the potential of knowledge based scoring functions in the identification 
of near-native receptor-ligand complex geometries. The scoring function performs 
less well in ranking the much less accurate solutions generated by CDD-CMBI 
for the CXCR4 target (Figure 6.6), but does correctly assign them a worse score compared to the 
DRD3 solutions.
  
(A) Snooker pharmacophore (B) Snooker pharmacophore fit 
  
(C) Submitted rank 1 Fleksy docking pose (D) X-ray conformation 
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Figure 6.6: Ranking of the submitted models by the Fleksy consensus score. The five submitted 
models for DRD3 are shown in green, for comparison the five submitted models by CDD-CMBI 
for CXCR4 are shown in red. The consensus complex score (lower is better) is plotted against the 
percentage of correct contacts as determined in the final GPCR dock 2010 assessment. The final 
rank in the GPCR dock 2010 assessment is indicated for each of the solutions.
6. 2.6.3. CXCR4 Case
Wong [20] and Rosenkilde [43] determined that negatively the charged residues D2.63, 
D4.60, D6.58 and E7.39 play a role in the CXCR4 binding of several antagonists. Based 
on the physico-chemical properties of ligand 1T (Figure 6.1), it seemed likely protonated 
on one of the thiourea moieties. As such, the negatively charged residues were the first 
candidates for an anchor point of the ligand in the TM bundle of CXCR4. Eight possible 
binding poses were conceived in which the ligand is sandwiched between two negatively 
charged residues that interact with either of the thiourea moieties (D2.63 was only 
able to combine with E7.39). From these poses, the five poses that corroborated the 
structure-activity relationships as described by Thoma et al. [17], were chosen for the final 
models. The ligands were docked into the models using GOLD [65] using the restraints 
of ionic interactions. Both binding modes interacting with D2.63 and E7.39 were among 
those chosen for submission to GPCR Dock 2010 (Figure 6.7A,B). The final models were 
optimized using AMBER molecular dynamics simulation including the ionic interactions, 
followed by an unconstrained energy minimization and molecular dynamics to optimize 
the overall structure. Model ranking was performed by visual inspection.
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Compared to the crystal structure, the 5th ranked model possessed the most similar 
binding mode in the CXCR4 structure. In total, 19 of 64 atomic contacts from five of 13 
residues were correctly predicted by the model. Although this might seem a low amount, 
the model did capture the hydrophilic interactions of the ligand with D2.63 and E7.39 
(Figure 6.7B,C), and the fraction of the pocket that was predicted correctly reached 45% 
[6]. The major discrepancy between model and crystal structure is the folding of ECL1 and 
ECL2 to place the correct residues in the binding cavity. 
Figure 6.7: Binding poses as predicted by VU-MedChem using GOLD compared to the 
X-ray structure.
The other research groups that participated in the GPCR Dock 2010 were able to 
reproduce the interaction of 1t with either D2.63 or E7.39, but were unable to produce 
a pose that interacted with both ionic residues. The explanation for this observation 
can be twofold. Firstly, the location of the ligand 1t in the transmembrane domain is 
new, namely, inside the minor pocket [24], whereas all potential template structures 
portrayed their ligand in the major pocket. Secondly, the correct spatial construction of 
the binding cavity is dependent on the sequence alignment and resolving the influence 
of the TxP motif on TM2, as well as the positioning of TM1 due to the presence of the 
cysteine bridge between the N-terminus and ECL3 [10]. The VU-MedChem group was 
able to capture the correct interactions in the binding cavity because they focused their 
attention on these particular regions. 
6.2.6.4. Water Molecules
Although none of the modeling attempts have included the prediction of protein-water or 
ligand-water interactions, it should be noted that conserved water clusters 
have been identified for class A GPCRs between TM1, TM2, TM6 and TM7. 
These conserved waters are suggested to be involved in receptor activation 
[66] and can in principle be included in GPCR modeling procedures [67]. 
However, none of these water molecules is directly involved in water-mediated protein-
ligand interactions. In the AA2AR crystal structures, water molecules are included in 
protein-ligand hydrogen bonding networks [8] and consideration of some of these water 
   
(A) VU alternate pose (B) VU most accurate pose (C) Xray pose 
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molecules has been shown to improve structure-based virtual screening accuracy [68]. In 
the ADRB1, ADRB2 and DRD3 crystal structures, no water molecules have been resolved 
in the vicinity of the ligand, and none of the crystallographic water molecules in contact 
distance of the ligand in the CXCR4 structure mediate polar protein-ligand interactions. 
Moreover, given the hydrophobicity of the CXCR4 pocket, it is unclear to which extent 
the water molecules influence ligand binding; hence it would have been difficult to 
predict the position of the water molecules in the pocket. Finally, the need to include 
water molecules in the prediction of protein-ligand interactions is target-dependent, as 
demonstrated by comparative docking studies [69, 70].
6.3. Conclusions
Structure-based modeling and design can aid in understanding and optimizing protein-
ligand interactions and as such has proven a valuable tool in modern drug discovery. 
The approaches to structure-based modeling have evolved to include prior knowledge, 
which greatly aids the identification of ligand binding cavities as well as the validation 
of generated ligand binding poses. In the GPCR Dock 2010 challenge, our groups 
used different approaches to obtain predictions for the protein-ligand interactions of 
eticlopride and 1t in the DRD3 and CXCR4 crystal structure, respectively. 
The largely automated use of extensive sequence analysis in the derivation of the 
structure-based pharmacophores followed by the selection of the structure-based 
pharmacophore best correlating to a large number of known actives, resulted in a 
pharmacophore definition which correctly encoded the crucial protein ligand interactions 
for DRD3. The simultaneous optimization of protein-ligand interactions and the protein 
and ligand structure themselves in a restraint docking procedure allowed that correct 
atomic contacts were produced and that these predicted contacts were optimized. 
Importantly, the applied knowledge based scoring function was able to correctly identify 
and assign the highest rank to the best near-native complex geometry without manual 
intervention.
Resulting from a knowledge-based investigation of the CXCR sequence, the CXCR4 
model required a template adjustment in TM1 and TM2 to accommodate an expected 
cysteine bridge in the N-terminus as well as a kink in TM2. Inclusion of such detail 
resulted in a highly customized CXCR4 model which was able to correctly capture the 
most important protein-ligand interactions as observed in the crystal structure. Without 
in depth sequence analysis, experimental receptor knowledge and knowledge on ligand 
analogues to validate and refine the ligand binding prediction, the result would not have 
been as successful.
From this study we conclude that the integration of experimental target data and 
in silico studies in iterative cycles is of prime importance for the accurate prediction 
of the protein architecture as well as ligand binding modes therein. Even then, 
the elucidation of a ligand binding mode is not always clear cut, since symmetry 
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in the ligand (such as for 1t) or binding pocket increases modeling difficulty. 
In the future, the inclusion of experimental data and further development of more 
automated procedures will help to fill the gaps that still exist in the GPCR structural 
landscape, even when GPCRs belonging to different subfamilies are being resolved by 
crystallography in rapid succession (http://gpcr.scripps.edu/) [31-33, 71].
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Abstract
For the first time, and prospectively, we investigated the performance of a receptor-
based and a ligand-based virtual screening approach against a set of three G Protein-
Coupled Receptors (GPCRs), namely the Beta-2 Adrenoreceptor (ADRB2), the Adenosine 
A2 Receptor (AA2AR) and the Sphingosine 1-Phosphate Receptor (S1PR1). This study aims 
to evaluate ligand- and structure-based approaches to make most use of information 
available today. In order to also evaluate cross-reactivity of ligands, all 900 compounds 
selected for any of the receptors (300 each) were also screened against the two other 
receptors that formed part of this study. Novel bioactive compounds could be identified 
using a consensus scoring procedure combining ligand-based and structure-based 
tools. The success of retrospective ligand-based and prospective ligand-protein based 
screening appeared to be dependent on the chemical diversity of the ligand training set 
used to validate and optimize the ligand- and protein-based models. While the diverse 
AA2AR ligand training set facilitated the construction of a robust ligand-based model 
superior to the protein-based model, a combination of ligand- and protein-based ADRB2 
models gave the best results in retrospective screening runs. Furthermore, our in vitro 
screening studies suggest to be careful with restrictive in silico compound similarity filters 
to identify novel ligands. Finally, we found that there was a striking degree of activity 
of ligands that were selected for one receptor, and identified to be active on another 
receptor of the set. This effect could be partly explained by the fuzziness and overlap 
of protein-based pharmacophore models. Overall, this is one of the first prospective 
chemogenomics  studies available in the literature in which all in silico hits are measured 
against all protein targets . The lessons learned from this exercise can be used to guide 
future virtual ligand library design efforts. 
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7.1 Introduction
Chemogenomics is a new research area aimed at systematically studying the biological 
effect of a wide variety of  small molecules (ligands) on a wide variety of macromolecular 
targets (gene products) [1-4]. Experimental measurements of large quantities of 
ligands and targets are time consuming and cost intensive and are therefore often 
complemented by high-throughput in silico chemogenomics approaches. These methods 
are typically divided in ligand- and target-based approaches and profile either a ligand 
against a set of diverse proteins, or a set of ligands against one specific protein target 
[5, 6] Both methods have been successfully applied in virtual screening experiments [5, 
6] to guide rational drug discovery and design [7-10]. However, the applicability domain 
of these in silico chemogenomics approaches depends on the quality and completeness 
of the training sets used for model construction and validation [11]. Data on small 
molecules is often incomplete since molecules are usually not screened systematically 
through a large panel of protein targets but only on a few pharmacological interesting 
targets [12]. Furthermore, most scientific studies focus on the presentation of “active” 
molecules and usually are (potentially) “inactive” molecules  not synthesized/tested 
(e.g., in hit optimization studies) or not reported [12]. Even in target annotated ligand 
databases such as CheMBLdb [13], DrugBank [14], BindingDB [15-17], PDBBind [18, 19], 
MOAD [20, 21], WOMBAT [22] and Glida-DB [23], protein-ligand interaction matrices 
are incomplete [12]. Computational methods have however been successfully used 
to fill the gap in experimental ligand-target affinity matrices[24], and to identify new 
drug-target associations [5, 25]. Furthermore, the high number of active molecules in 
target annotated chemical databases allows the identification of molecular features that 
determine binding to specific proteins and protein classes [26].
Ligand-based virtual screening methods like substructure mining [26], molecular 
fingerprint similarity searches [29] and ligand-based pharmacophore models [30] 
are generally faster than target(-ligand interaction) based methods such as molecular 
docking [31] and protein structure-based pharmacophore models [32]. Structure-based 
methods on the other hand are more suitable to find novel ligands and offer insight in the 
atomic details of protein-ligand interactions in 3D. The latter methods are therefore more 
suitable for the design of novel and diverse sets of bioactive molecules, but are generally 
too slow for efficient navigation of chemogenomics space. The recent elucidation of 
GPCR structures enables in silico screens based on structure-based approaches for this 
protein family [33], including protein-based pharmacophore screening methods that use 
the spatial arrangement of key chemical features required for protein-ligand binding, to 
identify new ligands and predict their binding mode in the protein target [34].  
The research project described in this paper is an effort to merge the current 
chemogenomics thinking of multi-target bioactivities with the increased availability 
of X-ray structures of GPCRs  as well as the increased availability of chemogenomics 
databases such as ChEMBL. Accordingly, we applied two different virtual screening 
147Compound library design
 
Ch
ap
te
r 7
approaches, one based on the recently elucidated receptor structures and one based on 
ligand bioactivity information, in order to select potentially bioactive compounds against 
a panel of three receptors, namely the Beta-2 Adrenoreceptor (ADRB2), the Adenosine 
A2 Receptor (AA2AR) and the Sphingosine 1-Phosphate Receptor (S1PR1). While ADRB2 
plays an important role in cardiovascular disorders [35] and asthma [35] , AA2AR is 
involved in coronary disease [35]  and parkinson’s disease [36], and S1PR1 is an important 
target in the treatment of autoimmune diseases [35]  and potentially cancer [37]. ADRB2 
and AA2AR were the first druggable GPCRs for which crystal structures were solved [38, 
39], while the first crystal structure of S1PR1 was announced recently  [40]. Hence, we 
selected this receptor set due to a combination of biological relevance, the availability of 
crystal structure information  (X-ray structures for ADRB2 and AA2AR, not yet for S1PR1) 
as well as the availability of known bioactive ligands (large, chemically diverse (AA2AR), 
large, chemically similar (ADRB2), and small, chemically similar (S1PR1) ligand sets), and 
also due to our ability to perform experimental assays for those targets to validate our 
models.
We selected a large number of compounds (300 per receptor) in a prospective manner 
and tested them for bioactivity against their intended target, but also against the other 
receptors in the study. This approach allowed us to compare structure-based and ligand-
based screening approaches in the context of currently available structural and bioactivity 
information; the degree of cross-reactivity of ligands against the set of receptors; and 
to explore whether information from related receptors might be useful in a practical, 
prospective virtual screening setting.  
7.2 Methods
7.2.1. Pharmacophore Screening
Figure 7.1 depicts a schematic overview of the applied virtual screening protocol. Structure 
based pharmacophores describing the negative image of the pocket, situated in between 
the transmembrane helices, were generated for all three GPCRs with Snooker [41]. For 
AA2AR and ADRB2 a consensus model of eight different templates was constructed 
whereas for S1PR1 a model was generated based on an experimentally validated agonist-
bound homology model [42]. To gain specificity, directionality was added to the polar 
pharmacophore features as the average vector between the polar feature centre and the 
Cα-atom of the residues which constitute the respective features.
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Figure 7.1: Virtual screening flowchart. Numbers indicate the number of compounds which pass 
the respective structure-based and ligand-based bioactivity models, bold numbers indicate the 
number of actives included in the selections. Note that out of the 300 compounds selected for 
each of the targets, some overlap between the hit lists had to be removed and not all compounds 
were available as physical samples, leading to slight modifications of the hit lists suggested by the 
virtual screening methods.
7.2.2. Ligand training set used for pharmacophore generation
Known active compounds for the three target proteins investigated in this study, 
namely the Beta-2 Adrenoreceptor (ADRB2), the Adenosine A2 Receptor (AA2AR) and 
the Sphingosine 1-Phosphate Receptor (S1PR1), were extracted for all species from 
the ChEMBL database (Release August 2009)[13] independently of the functional class 
(agonist, partial agonist, antagonist, inverse agonist) using an activity cutoff on Ki, 
IC50, or  EC50 of less than 50nM. To reduce the bias introduced by the deposition of 
compound series, diverse subsets of 50 compounds were generated for the AA2AR and 
ADRB2 receptor by exclusion sphere clustering on Tanimoto distances between the BCI 
fingerprints of the compounds. For the S1PR1 receptor all 43 compounds reported in 
ChEMBL were used as training set.
7.2.3. Pharmacophore model generation and training
Structure-based pharmacophores for all three targets were subsequently trained  with 
their corresponding sets of known actives. In this training, the subsets of pharmacophore 
features were ranked first according to the number of features in the pharmacophore 
and next according to the number of known actives that they were able retrieve. Finally, 
shape restraints were defined by the Tanimoto distance of the compounds matching the 
ADRB2 and AA2AR pharmacophores to carazolol and ZMA, respectively, which are co-
crystallized in their respective receptors [38, 39]. For S1PR1, shape restraints included 
the Tanimoto distance of compounds matching the pharmacophore to the average pose 
of training set actives in this pharmacophore. Last calculated as the pose with the lowest 
average Tanimoto distance to all poses matching the pharmacophore. Tanimoto distance 
cutoffs were set at those values at which the enrichment of known actives over the 50308 
database compounds was optimal.
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7.2.4. Pharmacophore screening settings 
Pharmacophore screening was performed with RDKit using the procedure described by 
Sanders et al. [41]. Projected points were also calculated with RDKit and handled just 
as the other feature types, with the exception that a heavy-atom – projected-point pair 
cannot be separated and has to match a feature projected-feature pair. The angular 
difference between the vectors describing the heavy-atom projected point pair and the 
feature projected feature pair has to be within 45 degrees.
7.2.5. Preparation prospective pharmacophore screening library
The compound library used for screening (paragraph 7.2.10) was prepared as follows. 
Initial three-dimensional conformations were generated with Corina [43] and multiple 
3D conformations were created with a genetic algorithm, Cyndi [44], which was ran with 
a population size of 200 and final output of 100 conformations per molecule. Given that 
the algorithm used here is designed for screening millions of compounds of typical in-
house or vendor libraries, no further force-field minimization of compounds has been 
performed.
7.2.6. Frequent substructure ranking
For the ligand-based screening part, the substructure-based screening method of van 
der Horst et al. [45] has been employed in the current study. This method performs 
screening by searching library compounds for the occurrence of specific substructures. 
These substructures are derived from existing ligands of the target under study and are 
selected for their ability to distinguish ligands for this target from other molecules. 
To assemble sets of ligands (the source sets) for the human adenosine A2A receptor 
(AA2AR), β¬2 adrenoceptor (ADRB2), and the S1P¬1¬ lysophospholipid receptor (S1PR1), 
ligand structures and activity data were retrieved from the ChEMBL database [46], selecting 
compounds with activity, i.e. a Ki, IC50, or EC50, of 10nM or less for the adenosine A2A 
receptor, and 10µM or less for the other two receptors. The 43 reference ligands used 
for fine-tuning the structural models of the S1PR1 receptor were also included in the 
training sets. Subsequent manual inspection was performed to ensure further removal 
of any alleged agonists, for instance, compounds that were highly similar to adenosine. 
All source sets were split into a training set and a test set using Pipeline Pilot’s Diverse 
Molecules component (30% test set and FCFP_4 fingerprints). The set sizes are provided 
in Table 7.1. For analysis of the substructures, all training sets were contrasted against 
a background set of ‘average’ compounds (the background set). The background set 
consisted of 10,000 randomly selected compounds from the drug-like subset of the ZINC 
database (accessed: February 12, 2010), a collection of all available chemical compounds 
[47]. Chemical structures were represented as graphs using a special type for aromatic 
bonds. Elaborate chemical representations, described in detail in the work of Kazius et al. 
[48] and van der Horst et al. [26] were not used. 
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Table 7.1: Number of molecules in training and test set for each receptor for the 
substructure-based compound ranking method.
Training set Test set Total
AA2AR 179 76 255
ADRB2 301 129 430
S1PR1 172 74 246
7.2.7. Generation of Frequently Occurring Substructures
Frequent substructure sets were generated using the frequent graph miner Gaston which 
finds all possible frequently occurring substructures in a set of molecules [49]. For each 
substructure, the number of molecules the substructure occurred in was calculated. The 
difference between the relative occurrence (fraction) of a substructure in the antagonists 
set and the background set is the score contribution of that substructure. Substructures 
were ranked according to the score contribution in descending order. The top 50 best 
substructures were selected for the screening model.
7.2.8. Substructure-based Virtual Screening – Ranking of Compounds.
To rank compounds in order of likelihood to display receptor binding, a score was 
calculated based on the previously generated substructure set. The score for a compound 
was calculated as follows: for each substructure in the set, presence in the compound was 
determined. For the substructures that occurred in a compound, the score contribution 
was summed to calculate the final score for that compound. 
7.2.9. Small Scale Benchmark Screening. 
All screening models were benchmarked using the test sets that were reserved earlier. 
Receiver operator curves (ROC) were plotted and the area under the curve (AUC) was 
calculated with Pipeline Pilot 6.1.5.0 Student Edition. The substructure set and score 
calculation  that resulted in the highest AUC, was selected for the large-scale virtual 
screening.
7.2.10. Virtual Screening Library
A diverse subset of the MSD in-house library of 50,308 compounds was used for virtual 
screening. In order to characterize the library, the overlap of the MSD in-house library 
with the ZINC purchasable compound set (~23,7M) was determined. The latter consisted 
of compounds from 26 commercial vendors, with a MW ≤ 500 Dalton. To determine 
the overlap between the two sets, structures were converted into unique hash codes 
without considering stereochemistry. From the 50,308 MSD compounds, 85% occurred 
in the 23,691,219 ZINC [47] compound database and 60% occurred in the 6,981,556 
CoCoCo [50] compound database. The MSD compounds possess similar physico-chemical 
properties to those within the ZINC and CoCoCo compound databases, placing emphasis 
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on druglikeness [51, 52] (data not shown). Compounds that occurred in the training or 
test sets were removed from the screening library, as well as compounds that had already 
been tested against one of the targets (for human, mouse, and rat).  In addition, for the 
AA2A receptor, compounds with a typical AR ligand scaffold, such as xanthines, were 
removed. 
7.2.11. Compound selection
To focus on new chemical entities we removed for each selection the compounds with 
a similarity in ECFP_4 / Tanimoto space > 0.5 to a known active as well as compounds 
with known AA2AR scaffolds in the AA2AR selection. A selection of 300 compounds for 
each receptor was made after determination of the average rank of each compound 
which matched a pharmacophore and had a positive score in the frequent substructure 
procedure. In case that compounds were not available for testing, the next best compound 
was selected.
7.2.12. Experimental validation
7.2.12.1. Adenosine A2A Receptor
HEK293 cells stably expressing the human AA2AR receptor (gift from Dr. Wang, Biogen, 
Cambridge, MA) were used to determine the affinity of compounds in a radioligand 
binding assay with [3H]ZM241385 as the radioligand. Membranes containing 40 µg protein 
were incubated in a total volume of 100 µL Tris•HCl (50 mM, pH 7.4) and [3H]ZM241385 
(final concentration 1.7 nM) for 2 h at 25 oC in a shaking water bath. Nonspecific binding 
was determined in the presence of 100 µM CGS21680. The incubation was terminated by 
filtration over pre-wetted Whatman GF/B filters under reduced pressure with a Brandel 
harvester. Filters were washed three times with ice-cold buffer and placed in scintillation 
vials. Emulsifier Safe (3.5 mL) was added, and after 2 h radioactivity was counted in a 
TriCarb 2900TR liquid scintillation counter. Compounds that inhibited binding by ≥ 50% at 
10 μM were subject to testing in concentration-response curves.
7.2.12.2. Beta-2 Adrenoreceptor Assay
HEK293T cells were cultured and transiently transfected with 2.5 μg ADRB2-pcDNA3.1+ 
(obtained from the Missouri S&T cDNA Resource Center ) per 106 cells using 12 μg 
linear 25-kDa polyethylenimine (Polysciences, Warrington, PA, USA ) as described 
previously[53]. Cells were harvested 48h after transfection and membrane fractions 
were prepared as described previously[53]. ADRB2-expressing membranes were 
incubated at room temperature in 96-well plates in binding buffer (50 mM HEPES – pH 
7.4, 1 mM CaCl2, 5 mM MgCl2, 100 mM NaCl, and 0.5% (w/v) BSA) with 1 nM [3H]-
dihydroalprenolol (DHA; 104.4 Ci/mmol from PerkinElmer Life Sciences), and 10 μM or 
increasing concentrations of compounds. After 1h, incubations were terminated by rapid 
filtration through Unifilter GF/C plates (PerkinElmer Life Sciences) presoaked in 0.5% 
152    Chapter 7
polyethylenimine and washed with ice-cold binding buffer supplemented with 500 mM 
NaCl. Radioactivity was measured using a MicroBeta Trilux (PerkinElmer Life Sciences). 
Nonlinear regression analysis of data and calculation of Kd and Ki values was performed 
using GraphPad Prism 4 software.
7.2.12.3. Sphingosine-1-Phosphate Receptor
The assay was performed using the Pathhunter™ Enzyme Fragment Complementation 
β-arrestin recruitment technology as described previously for the S1PR1 receptor.[54] 
The PathHunter™ CHO-K1 EDG1 β-arrestin EFC cell line was purchased from DiscoveRx 
(Fremont, CA). Cells were cultured in Dulbecco’s modified Eagles medium F-12 (Invitrogen, 
Garlsbad, CA), supplemented with 10% heat-inactivated fetal calf serum (Cambrex, 
Verviers, Belgium) , 100 U/mL penicillin, 100 μg/mL streptomycin, 300 μg/mL hygromycin 
B and 800 μg/mL geneticin (Invitrogen). Cells were seeded at a density of 10,000 cells per 
well of a 384 wells culture plates (PerkinElmer, Boston, Massachusetts) in 20 μL OPTI-
MEM (Invitrogen). After overnight incubation at 370C in a humidified incubator (5% CO2, 
95% humidity), 4 μL of compound dilution was added to cells and the plate was returned 
to the incubator for 2 hours, followed by incubation at room temperature for 1 hour. Cells 
were lysed using 8 μL PathHunter™ detection reagent (DiscoveRx). Plates were incubated 
in the dark for 2 hour at room temperature before measurement of β-galactosidase 
activity (chemiluminescence) on an Envision multilabel plate reader (PerkinElmer Life 
Sciences). Compounds that induced ≥ 30% β-arrestin recruitment compared to the 
reference compound AUY954 were selected and tested in dose response curves.
7.3. Results and discussion
This aim of the current study was to evaluate the performance of (combined) ligand- and 
structure-based virtual screening approaches (Figure 7.1), optimized using retrospective 
screening simulations (Figure 7.2 and 7.3), and applied in prospective all-against-all GPCR 
chemogenomics studies  (Figure 7.4 and 7.5, Tables 7.1 and 7.2). 
7.3.1. Chemical diversity ligand training sets
A large diversity space of active compounds is desired in drug design projects because it 
allows the selection and synthesis of drug-like compounds with good solubility, ADMET 
properties, selectivity towards the targets and a strong intellectual property position. The 
diversity of the 50 most dissimilar compounds for AA2AR and ADRB2 in BCI fingerprint 
space is presented in Figure 7.2. ADRB2 compounds show to be more similar to each 
other (average Euclidean distance ~11) and form a tight cluster as compared to AA2AR 
compounds (average Euclidean distance ~14). This indicates that the chance of finding 
novel compounds for the AA2AR receptor is larger than for the ADRB2 receptor, especially 
if we take into account that all compounds that are similar to known actives have been 
removed.
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Figure 7.2: Visualization of ligand similarities for the known actives on the adenosine A2A and 
the beta-2 adrenergic receptor. While, on average, beta-adrenoceptor ligands are more similar to 
each other, also some atypical ligands can be found which resemble compounds active on the 
adenosine A2A receptor. We will revisit this similarity of bioactivity classes later in the text, when 
we discuss the surprising degree of cross-reactivity of ligands selected for one receptor, but found 
to be bioactive also (or solely) against other receptors of the set.
 
7.3.2. Pharmacophore models match experimentally supported ligand binding modes
Several polar residues, namely T3.36, Q3.37, N6.55,  E45.53 and S7.42 make H-bond 
interactions with co-crystallized AA2AR ligands in crystal structures[39, 55] , and are 
shown to be important in agonists and xanthine antagonist binding based on site-directed 
mutagenesis studies.[56, 57], [58], [59], [39, 60] The structure-based pharmacophore 
model of AA2AR used in our virtual screening studies includes interaction features 
derived from three of these polar residues, namely T3.36, N6.55 and S7.42 (Figure 7). 
ADRB2 ligands share an essential positively charged amine as well as an aromatic ring 
separated by circa 5Å (partial and full agonists) to 7Å (inverse agonists and antagonists). 
The ADRB2 crystal structure [38] shows protein-ligand interactions to residues D3.32, 
S5.42, N7.39 and F6.52, which is in line with site-directed mutagenesis studies.[61, 62], 
[63], [64] Furthermore, mutation of residues S5.43, S5.46, N6.55, and Y7.35 have been 
shown to affect partial and full agonist binding[65-67], 35. The ADRB2 pharmacophore 
model indeed contains a hydrophobic contact with V3.33 and polar interactions with 
N7.39, D3.32, S5.42 and S5.46 as supported by ligand co-crystallized ADRB2 crystal 
structures and site-directed mutagenesis studies (Figure 7.6 and 7.7).  S1PR1 receptor 
ligands are characterized by the presence of a polar head which contains negatively and 
positively charged groups and a long hydrophobic tail[68]. Based on these chemical ligand 
properties computational modeling and site-directed mutagenesis studies have identified 
important S1PR1 receptor-ligand interactions including ionic interactions between the 
negatively charged phosphate oxygens of S1P and R3.28, and between the protonated 
amine of S1P and the E3.29.[69, 70]  In addition, Y5.39 has been identified as a conserved 
feature to influence selectivity for the lysophosphatidic acid receptor subtypes [71]. The 
structure-based pharmacophore model for S1PR1 indeed includes features for R3.28, 
E3.29 and Y5.39 as supported by site-directed mutagenesis studies (Figure 7.6 and 7.7).
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7.3.3. Retrospective virtual screening validation
A retrospective virtual screen based on the ligand-based, structure-based and the 
combined compound selection method of the 50 diverse actives for AA2AR and 
ADRB2 versus the 50308 assumed inactive compounds of the used compound library 
showed significant early enrichment (Figure 7.3). Retrospective enrichment for AA2AR 
is poor for the structure-based method. Probably due to the fact that a large portion 
of AA2AR ligands bind in the extracellular domain that is not  represented in Snooker 
pharmacophores, and because it is likely that the A2A adenosine receptor has no family 
conserved receptor binding pocket[39]. The ligand-based method on the other hand has 
an excellent performance for this target receptor, but might be biased towards known 
chemistry. A combination of both methods is likely to result in a reduced number of 
identified actives as compared to only the substructure method, but might contain the 
desired novelty amongst identified actives, containing novel scaffolds and potentially a 
different set of interactions with the receptor than training set molecules. In contrast 
to AA2AR ligands, the ADRB2 ligands bind largely within the TM domain and share a 
common binding mode within a buried pocket. Therefore, structure based searches 
perform better on ADRB2 than on AA2AR. They are not only able to capture the actives 
faster, but also retrieve a higher percentage of actives. A combination of structure-based 
and ligand-based methods for this receptor outperforms both individual methods (Figure 
7.3).
  
Figure 7.3: Receiver Operating (ROC) curves for the ligand-based and structures based virtual 
screening methods employed in this work. While the substructure-based method, on average, is 
able to achieve higher enrichment than the structure-based method employed, the extent of this 
difference is very much dependent on the target considered, with the adenosine A2A receptor 
showing significantly higher retrieval of active compounds than the beta-2 adrenoceptor. Consensus 
scoring outperforms each individual method in case of the beta-2 adrenoceptor.
7.3.4. Prospective cross-screening 
Using each of the three bioactivity models a total of 300 compounds were selected. 
Duplicates were removed and in case the selected compound was not available any-
more, the next compound in the list was selected. The final selection of compounds is 
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visualized in Figure 7.4 and shows that the ADRB2 model and the S1PR1 models select 
the same compounds more often than other pairs of predictive models. Hence, overlap 
between all three bioactivity classes could be anticipated also in compound selection 
space; however, correlation between overlap in ‘selection space’ and experimentally 
confirmed cross-reactivity between receptors was not entirely correlated as described 
in more detail below.
Figure 7.4: Distribution of compounds selected for experimental screening by each of the in silico 
bioactivity models. It can be seen that the beta-2 adrenoreceptor model and the sphingosine-1-
phosphate receptor model select  the same compounds more often than other pairs of activity 
models given the fact that 3780, 810 and 1205 compounds are scored for the AA2AR, ADRB2 and 
S1PR1 receptor model, respectively.
 
Using our combined ligand- and structure-based virtual screening approach, we have 
successfully identified 18 AA2AR, 6 ADRB2 and 3 S1PR1 ligands (Figure 7.5). Structures 
of the new compounds are visualized in Table 2 and plots of compound ranks versus 
receptor activity are displayed in Figure 7.5, also distinguishing between the in silico 
models used to select each bioactive compound identified in this study.
Figure 7.5: Novel active compounds 
found using the respective models 
for the three receptors in this study 
(adenosine A2 receptor, beta-2 
adrenergic receptor and sphingosine-
1-phosphate receptor). The title of the 
plot shows the receptor for which the 
ligands were experimentally found to 
be active against, while the bottom 
of the plot shows the model that was 
used in silico to select each respective 
compound. 
156    Chapter 7
Table 7.2: Identified active compounds for the AA2AR, ADRB2 and S1PR1 receptor. The last 
column of the table lists the closest available compound reported in the ChEMBL database 
(as calculated using the Tanimoto distance in combination with ECFP_4 fingerprints). 
 40 
Compound Molecular 
Weight (Da) 
Rank 
AA2AR 
Rank 
ADRB2 
Rank 
S1PR1 
Activity 
on 
receptor 
Binding 
affinity 
(pKi) / 
potency 
(pEC50)a 
Most similar compound in  
ChEMBL 
 
475 2285 - 160 AA2AR 6.7 
 
0.26 
 
388 347 - - AA2AR 6.2 
 
0.29 
 
310 247 - - AA2AR 5.9 
 
0.26 
 
433 254 - 1110 AA2AR 6.0 
 
0.26 
 
344 405 - - AA2AR 5.8 
 
0.32 
 
445 - - 255 AA2AR 6.0 
 
0.25 
 
367 121 - - AA2AR 5.8 
 
0.27 
 
385 59 - - AA2AR 5.3 
 
0.28 
 
452 19 - - AA2AR 5.2 
 
0.23 
 
370 9 - - AA2AR 5.4 
 
0.26 
 
353 - - 387 AA2AR 5.6 
 
0.27 
 
453 657 415 137 AA2AR 5.4 
 
0.24 
 
354 166 - - AA2AR 5.3 
 
0.23 
 
387 3636 - 38 AA2AR 5.6 
 
0.28 
 
299 194 - - AA2AR 6.2 
 
0.28 
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a For AA2AR and ADRB2 pKi values are reported obtained from competition binding assays measuring radio ligand displacement. For S1PR1 pEC50 
values are reported obtained from functional assays by measurement of the chemiluminescense due to β-galactosidase activity.
 42 
 
Compound Molecular 
Weight (Da) 
Rank 
AA2AR 
Rank 
ADRB2 
Rank 
S1PR1 
Activity 
on 
receptor 
Binding 
affinity 
(pKi) / 
potency 
(pEC50)a 
Most similar compound in  
ChEMBL 
 
351 104 - - AA2AR 5.3  
 
0.27 
 
340 276 - - AA2AR 5.3 
 
0.26 
 
365 - 45 - AA2AR 5.3 
 
0.22 
 
291 - - 40 ADRB2 6.1 
 
0.38 
 
263 - - 171 ADRB2 5.7 
 
0.33 
 
336 - 624 59 ADRB2 4.4  
 
0.36 
 
355 - - 62 ADRB2 4.4 
 
0.20 
 
353 - - 308 ADRB2 3.1 
 
0.26 
 
205 48 - - ADRB2 4.6  
 
0.23 
 
376 1 - - S1PR1 4.7 
 
0.22 
 
547 - - 175 S1PR1 4.5 
 
0.18 
 
444 323 - - S1PR1 4.3 
 
0.16 
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The AA2AR selection method was very successful and selected 12 out of the 18 active 
compounds for this receptor (including compound 3, for which the proposed binding 
mode in AA2AR is depicted in Figure 7.6). Another 3 compounds were ranked for this 
receptor but tested because they had a better rank in another receptor. The existence of 
GPCRlike compounds[72] (less flexible, less polar and more hydrophobic) and privileged 
scaffolds is well-known and is probably also reflected in our selection procedure since 
actives were retrieved for AA2AR in as well the ADRB2 and S1PR1 compound selection. 
For the ADRB2 receptor only 6 compounds were identified (including compound 21, for 
which the proposed binding mode in ADRB2 is shown in Figure 7.6), a much smaller number 
than for AA2AR. This is in agreement with the earlier observed restricted topological 
structure space of compounds for this receptor compared to the AA2AR receptor. The 
active compounds that were identified as ADRB2 bioactives in this study resulted from 
the compound selection for the AA2AR and S1PRR targets.  The fact that we did not find 
any ADRB2 ligands from the ADRB2 test set might relate to the fact that all compounds 
similar to known ADRB2 actives were excluded from the compound set. Remarkably, 5 of 
the ADRB2 bioactives were retrieved with the S1PR1 receptor pharmacophore. Important 
hydrogen bonding and charged interactions are in both SBPs related to interactions in 
TM3 and TM5 and hydrophobic interactions originate in ADRB2 mainly from Val3.33 and 
in S1PR1 from 5.39 and 6.55 but are in both cases located at fairly similar positions. The 
match of compound 21 in the S1PR1 pharmacophore is shown in Figure 7.7 including a 
fit of the crystal structure conformation of carazolol of the ADRB2 receptor[38] in this 
pharmacophore. The complementarities of the S1PR1 pharmacophore to known ADRB2 
binders and high similarity of the S1PR1 pharmacophore to the ADRB2 pharmacophore 
explains the ability of the S1PR1 SBP to retrieve ADRB2 actives. 
For S1PR1, three agonists were identified of which one was in the S1PR1 compound 
selection (including compound 26, for which the proposed binding mode in the S1PR1 
binding pocket is presented in Figure 7.6). Like the known bioactives, the novel hits 
are elongated compounds with physico-chemical properties similar to the endogenous 
ligand. Overall, two of the three compounds active against S1PR1 were actually selected 
by the AA2AR model, indicating a degree of cross-reactivity in the current study. 
The chemical similarity of the bioactives identified in our study to known inhibitors is 
portrayed by the ECFP4 closest similarity calculation in Table 7.2. The ECFP4 similarity 
thresholds for chemical novelty lies at values of 0.26 (strict) [73] and 0.4 (loose) [74]. 
From this we can surmise that many of our hits can indeed be considered as novel.
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Figure 7.6: The important interacting residues for the different receptors with the pharmacophores 
and fitted compounds. AA2AR: related to acceptor features: 5.42 & 6.55, 3.36 & 7.42, to donor 
features: 5.42 & 6.55, 3.36 & 7.42, hydrophobic feature: 3.32 & 3.33. ADRB2: acceptors: 
5.38&5.42&5.46, 7.39, donors: 3.32, 5.38&5.42&5.46, hydrophobic: 3.33. S1PR1: acceptors: 3.28, 
5.39, donor: 3.29 and hydrophobics: 5.39&6.55, 5.39&6.55.
 
 
 
 Figure 7.7: Structure-based pharmacophore for S1PR1 with a) compound 21 and b) carazolol in 
the conformation as found in the crystal structure of ADRB2[38].
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7.4 Conclusions
We performed compound selections for three receptors based on a combined ligand- 
and structure-based approach.  Retrospective analysis of both separate methods on 
the AA2AR and ADRB2 receptor indicated that the results depend on the chemical 
diversity amongst active compounds for a target. The diverse AA2AR ligand training 
set facilitated the construction of a robust ligand-based model superior to the protein-
based model, while a combination of a ligand- and protein-based model gave the best 
results for ADRB2.  Using a consensus scoring procedure combining the ligand-based 
and structure-based tools, we performed one of the first large-scale in-vitro prospective 
chemogenomic screening exercises, experimentally testing all in silico hits selected for 
all investigated targets. Out of the total of 900 compounds screened, hit rates varied 
from 2% (at the AA2A receptor), over 0.7% (at the ADRB2 receptor) to 0.3% (at the S1P1 
receptor). While these variations in hit rates might not be surprising by themselves, 
what is certainly surprising is the high degree of cross-reactivity encountered: In several 
cases, compounds were not found to be active against the receptor they were selected 
for, but rather against a different member of the panel. As a conclusion of practical 
relevance, which is supported also by the results obtained in this current work, the 
authors advocate more ‘fuzzy’ virtual screening setups to be considered as an alterna-
tive to in particular very specifically defined pharmacophores – since as we have seen in 
this work, also information from bioactive compounds (or receptors) of related proteins 
may very well be relevant to identify novel bioactive chemical matter. While the screens 
performed here, generating thousands of bioactivity data points, is relatively large for 
academic setups, it still considers only a relatively small number of receptors. Ideally, 
the chemogenomics approach presented here should be extended with more com-
pounds and a larger panel of targets and should preferably be tested using the same 
assay technology. Such endeavors are already frequently employed for other protein 
families, like for kinases and will provide more complete information to medicinal and 
computational chemists to optimize screening hits and leads and design better screen-
ing libraries than single-target screens can.[75]
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Abstract 
The pharmacophore concept is very important in Computer-Aided Drug Design (CADD) 
mainly due to its application in High-Throughput Virtual Screening (HTVS). With many 
pharmacophore screening software available, it is of the utmost interest to explore the 
behavior of these tools when applied to different biological systems. In this work we 
present a comparative analysis of eight pharmacophore screening algorithms (Catalyst, 
Unity, LigandScout, Phase, Pharao, MOE, Pharmer and POT) for their use in typical HTVS 
campaigns against four different biological targets. The results herein presented show 
how the performance of each pharmacophore screening tool might be specifically 
related to factors such as the characteristics of the binding pocket, the use of specific 
pharmacophore features and the use of these techniques in specific steps/contexts of 
the drug discovery pipeline. We conclude that algorithms with overlay-based scoring 
functions are generally slower than RMSD-based scoring functions but have a better 
performance in compound library enrichment. This observation together with other 
findings can be used to choose the most appropriate algorithm for specific virtual 
screening projects. We also analyzed how pharmacophore algorithms can be combined 
together in order to increase the success of hit compound identification. Furthermore, 
this study provides a valuable benchmark set for further developments in the field of 
pharmacophore search algorithms e.g. by using pose predictions and compound library 
enrichment criteria as described in this work.
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8.1 Introduction
In the field of drug design, high-throughput virtual screening (HTVS) methods encompass 
a valuable set of computational approaches for the analysis of large chemical structure 
libraries with the purpose of identifying hit compounds capable of interacting with a 
biological target of interest [1]. While combinatorial chemistry and high throughput 
screening (HTS) procedures over the last few decades have represented an important step 
in drug discovery to accumulate large amount of data, the global importance of in silico 
techniques is vice versa ascribable to reduced costs and the increased time-efficiency to 
unveil new potential active compounds [2, 3]. Among all computational approaches that 
can help to guide drug discovery, the so-called structure-based (SB) design approaches, 
which use the three-dimensional information of the biological target, are among the most 
popular [4-6]. However, despite the existence of large numbers of apparently different 
computational approaches, recent studies emphasize the usage of simple and already 
established techniques for the successful disclosure of important information towards 
the selection of novel bioactive compounds [7, 8]. In this context, some seemingly old 
concepts, such as that of the pharmacophore, have proven to be extremely useful over the 
past 30 years and it is surprising that many of these concepts are regaining momentum [9-
11]. For pharmacophore modelling, in particular, this renaissance has also been fostered 
by the current possibility to generate hypotheses directly from crystallographic, NMR or 
computational models of protein-ligand complexes [9, 10, 12]. Together with the fact 
that nowadays three-dimensional structure of biological receptors and enzymes become 
available much more frequently than in the past, one would theoretically need few steps 
in order to rapidly setup pharmacophore screening campaigns towards the selection of 
novel molecular entities for biological testing and/or lead optimization purposes. 
Beside the increased availability of structural information on pharmacological targets, 
advances in computing power and improvements in screening algorithms, presently 
pharmacophore screenings are also further stimulated by the increasing number of 
academic services and chemical vendors that offer large databases of commercially 
available compounds and virtual libraries for this purpose [13-17]. Some of these 
databases allow the circumvention of typical preparation steps such as hydrogen addition, 
tautomer and stereoisomers enumeration and, most importantly, conformer generation 
[17]. From the practical point of view, pharmacophores can be used to screen millions of 
high quality compounds structures within a reasonable amount of time, particularly when 
approximations such as a rigid pharmacophore fitting procedure are used. Like molecular 
docking, pharmacophore search algorithms should not only discriminate between active 
and inactive compounds but should also correctly orient the ligand in the protein-binding 
region [18, 19]. 
While many studies typically focusing on the accurate reproduction of binding modes 
and compound library enrichment have been published in the last year to assess docking 
screening algorithms [5, 20, 21], the pharmacophore concept, introduced above, has 
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been the object of few comparative studies assessing the performance of pharmacophore 
screening tools [9, 12, 19, 22, 23].
Here we will present an assessment of eight free and commercial software packages 
for pharmacophore screening. In order to ensure a fair comparison of the screening 
algorithms, we have chosen to manually curate pharmacophores extracted from X-ray 
structures, and to perform the virtual screens on rigid compound structures of pre-
calculated conformers using default settings. Four biological targets were analyzed, for 
which the locations of a large number of ligands elucidated by X-ray crystallography were 
collected from the literature, and were used to derive structure-based pharmacophores 
and evaluate pharmacophore screening performance.
The accuracy of the predicted binding modes as well as library enrichments for the 
different pharmacophore search algorithms is analyzed to elucidate how different factors, 
e.g. pharmacophore hypotheses and conformational states, may influence the outcome 
of high-throughput screenings. 
8.2 Methods
Figure 8.1 shows the computational protocol that was applied to each biological target. 
Full details of each step are discussed in the next paragraphs.
Figure 8.1: Flow diagram of the dataset preparation protocol and computational procedures. 
Yellow boxes indicate procedures in which all co-crystallized ligands are used, green boxes indicate 
procedures where the unbiased active and decoy set is used. 
170    Chapter 8
8.2.1. Pharmacophore definition 
8.2.1.1. Target selection
Four datasets corresponding to different biological targets were used in this study, 
namely CDK2 (Cyclin-dependent kinase 2), Chk-1 (Checkpoint kinase 1), PTP-1B (Protein 
tyrosine phosphatase 1B) and Urokinase. The last three protein targets were chosen in 
order to take advantage of published data from Brown et al. [24] while the CDK2 dataset 
was created from crystal structures retrieved from the Protein Data Bank [25]. All the 
biological targets have been selected for their important roles in different biological 
processes. CDK2 is a well-known protein kinase involved in the control of the cell cycle 
[26]; Chk-1 is a kinase required for checkpoint mediated cell cycle arrest in response to 
DNA damage or the presence of unreplicated DNA [27]; PTP-1B, is a regulator involved in 
insulin signaling and has been implicated as a potential therapeutic target for treatment 
of type II diabetes [28]; Urokinase, is a serine protease that circulates in plasma and that 
has been implicated in a number of tumor-related activities [29]. 
8.2.1.2. Structure retrieval
 Ligand coordinates for PTP1B, CHK1 and Urokinase datasets were obtained from Brown 
et al. [24] and were aligned with the PDB IDs 1NZ7, 2YWP and 1OWK, respectively. CDK2 
was selected because of the high number of complexes with different co-crystallized 
ligands available for the biological target in the Protein Data Bank [25, 26]. Reference 
X-ray structures were obtained from the PDB (accessed November 2010)[25] by using 
the human CDK2 Uniprot [30] Accession ID: P24941. The collected CDK2 complexes 
were filtered in order to retrieve proteins with bound ligands and no modified residues 
resulting in a set of 107 CDK2 complexes. These complexes were visually inspected and 
discarded in cases where ligand atoms were missing or multiple ligand conformations 
were present in a single PDB entry. Any duplicate entries were removed which resulted in 
a non-redundant set of 80 complexes (a full list is available as supplementary material). 
Finally, all complexes were superimposed with Sybyl [31] and the ligands were extracted.
8.2.1.3. Ligand preparation
After manual correction of ligands for all targets (e.g. bond orders, aromaticity and 
charges), Epik software [32] was used to calculate physiological protonation states. 
A visual inspection of the ligand embedded in the original protein PDB structure was 
performed to check for correct tautomeric forms. 
8.2.1.4. Pharmacophore derivation
Ligand structures were given appropriate atoms-types using an in-house rule-based 
classification system developed at Organon NV and pharmacophore features were 
generated after application of Renner’s fuzzy pharmacophore algorithm with an Rc-value 
of 2.0Å [33]. Manual inspection and combination of features shared by most ligands 
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resulted in the final pharmacophores that are depicted in section 8.3. Excluded volume 
features were added by an iterative procedure. Starting with the addition of an excluded 
volume feature at the position of the closest atom in the protein to a co-crystallized 
ligand atom, the algorithm continues to add excluded volumes until all protein atoms 
are considered. This addition is recursively performed for atom distances between 3.0Å 
-6.0Å from the co-crystallized ligands and that are at least 1.0Å from the nearest excluded 
volume feature. In contrast to most algorithms, which use the atom centre to evaluate if 
a pose is inside the excluded volume, Phase rejects ligand poses with an overlap of the 
ligand VDW radius with the excluded volumes. To be more consistent with the other used 
algorithms we therefore reduced the excluded volume radii of Phase pharmacophores 
with 1.7Å (approximately the VDW radius of a Carbon atom). 
8.2.2. Benchmark compound sets
8.2.2.1. All-actives set
The compound sets comprising all active compounds of each respective target (Table 8.1) 
were used to assess how well each individual algorithm performs in the reproduction of 
the crystal structure pose by means of RMSD calculation. 
8.2.2.2. Maximum unbiased validation sets of active and decoys
In order to assess the compound library enrichment of the different pharmacophore 
screens, data sets of actives and decoys were designed so as to avoid analogue bias 
(overrepresentation of certain scaffolds or chemical entities), and artificial enrichment 
(classification is caused by differences in simple physicochemical descriptors like 
molecular weight, number of bonds and acceptors, donors, rather than correct 
representation of the protein-ligand interactions). First, for each target, a set of assumed 
inactives compounds was prepared from the CoCoCo database [14, 17] by selecting 
compounds with a BCI-Tanimoto fingerprint similarity [34] of 0.5  or less to at least one 
ligand reported in the ChEMBL [35, 36] for that particular target. Second, the maximum 
unbiased validation (MUV) sets protocol [37] was used to select 30 actives and 15,000 
decoys (consistent with the set sizes available on the MUV website [38]) per biological 
target from each subset of the CoCoCo database. This protocol ensures an unbiased 
validation set by maximizing “active-active distances” G(t) and “active-decoy distances” 
F(t). Numerical integration of both distribution functions enables computation of global 
figures for data set self-similarity (ΣG) and the separation between active and decoys (ΣF). 
A parameter describing the “data set clumping” S(t), and its numerical integral ΣS can be 
calculated by subtraction of  G(t) from F(t).  Negative values of ΣS indicate clumping of 
actives, while positive values indicate dispersion of actives and clumping of small clusters 
of decoys with single active compounds, and values near zero indicate a spatially random 
distribution of actives and decoys [37]. The data sets generated with the MUV protocol 
will be used for the compound library enrichment studies and will be referred in the text 
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as MUV-active or MUV-decoys. 
For all compound data sets (All-actives, MUV-actives and MUV-decoys) of the four 
biological targets, three-dimensional conformations were generated with the Confgen 
software using the comprehensive algorithm [39].
Table 8.1: Overview of datasets included in the present study. All files in single- and multi-
conformation are available in supplementary materials.
Target All-actives All-actives 
Conformations
MUV-decoys MUV-decoys 
Conformations
MUV-actives MUV-actives 
Conformations
CDK2 80 992 15000 248250 30 352
CHK1 123 1913 15000 287203 30 457
PTP1B 110 4634 15000 405398 30 1123
Urokinase 75 703 15000 268646 30 192
8.2.3. Screening and Scoring 
8.2.3.1. Screening 
Screens were performed using eight different software tools as shown in Table 8.2 below. 
To mimic the scenario in which non-experts might apply pharmacophore screens and in 
order to avoid artificial bias towards certain algorithms, we ran all algorithms with default 
parameters with the exception of Pharao and Pharmer. For Pharao we used the tversky_
ref score instead of the Tanimoto score as the paper indicated that this score was most 
suitable for scenarios where it is important that as many features of the pharmacophore 
are matched as possible.  Since Pharmer cannot handle excluded volume features, we 
post-processed the Pharmer poses with POT with use of only the excluded volume 
definition and without a fitting. As the virtual screens were performed in different labs 
and using different hardware and software systems we decided to focus entirely on the 
quality of the produced results by the different algorithms and to disregard the CPU-
timing which is required for the presented pharmacophore searches.
8.2.3.1. Scoring
Internal molecular symmetries were considered by calculation of the Root Mean 
Square Deviations (RMSD) of all possible structural matches of fitted conformations and 
corresponding co-crystallized reference poses using RDkit [40] functionality. The lowest 
RMSD value, corresponding to the best fit, was reported for each pose and used for all 
further analysis.  Receiver Operator Characteristic (ROC) curves, Area Under the ROC 
Curves (AUC) and enrichment factors were calculated after ranking compounds from the 
MUV-active and MUV-decoys set based on the score values as reported in Table 8.2. 
Enrichment factors (EF) after x% of the library screened were calculated according to the 
following formula (N
experimental
 = number of experimentally found active structures in the 
top x% of the sorted database, N
expected
 = number of expected active structures, N
active
 = 
total number of active structures in database).
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Table 8.2: List of pharmacophore screening algorithms used in this study.
Tool Version Scoring algorithma Scoring methodb Bestc Tool availability Reference
Catalyst Discovery Studio v2.5.5.9350 FitValue d Overlay High Commercial [41]
Pharmer - RMSD RMSD Low Open-source [42]
POT - RMSD RMSD Low Open-sourcee [43]
Pharao 3.0.3 Tversky_reff Overlayf High Open-source [44]
MOE 2010.10 (date) RMSD RMSD Low Commercial [45]
Unity Sybyl X1.1.1 QFITg Overlay High Commercial [31]
LigandScout 3.02 Pharmacophore Fith Overlay High Commercial [46, 47]
Phase 3.3 Fitnessi RMSDi High Commercial [48]
a Scoring algorithm refers to the tool routine that was used in the present study to score ligand poses.
b Scoring method refers to the methodology class of scoring algorithm. RMSD-based methods check the distance of the feature group of the 
compound to the pharmacophore feature center. Overlay methods take the radii of the features and/or atoms into account and use this to assess 
how well a feature is matched. 
c Best refers to the score value (high/low) which is used to select the best match.
d FitValue evaluates for each molecular feature the distance to the center of the pharmacophore feature with respect to the pharmacophore feature 
radius. 
e Will be made available soon.
f Tversky_ref evaluates the volume-overlap of features of the pharmacophore and compound with respect to the volume of the pharmacophore. Pharao 
uses Gaussian overlaps of pharmacophore features and ligand atoms and does not require that all features are matched. Poses with a lower number 
of matched features are able to get as high scores as poses with more matched features. 
g QFIT is intended to compare alternate mappings of a single compound to the query and choose the best match. While Unity reports hits as soon as 
they fulfill the query, post processing options to relax and tighten hits to more closely match the query are available within Sybyl package.
h Pharmacophore Fit is a simple geometric scoring function that takes into account only chemical feature overlap. Other scoring functions are 
available within LigandScout package. 
i Fitness score of Phase is based on an RMSD term, vector term and a term describing the overlay of the produced pose with a reference pose. No 
vector features and no reference pose were considered in the present study, thus the resulting score is purely RMSD-based.
8.2.4. Data analysis 
8.2.4.1. Pose reproduction 
Pharmacophoric poses were generated by application of the 8 screening algorithms to the 
4 datasets, and the results were analyzed with respect to the accuracy of experimental 
binding mode reproduction and compound library enrichments. For each molecule, both 
the pose with the lowest RMSD to the reference structure and the RMSD of the pose with 
the best score were reported. The cumulative percentage of poses below a certain RMSD 
was calculated for both X-ray structures and the multi-conformational datasets of actives 
previously generated. For CHK1, PTP1B and Urokinase multiple pharmacophores are 
defined which recognize different subsets of active molecules. To evaluate the combined 
performance for CHK1, PTP1B and Urokinase we also merged the outcomes of the 
individual pharmacophores searches for these targets. To evaluate the performance of 
each algorithm in respect of compound library enrichment, the percentage of retrieved 
actives (sensitivity) versus the percentage of retrieved decoys (specificity) was calculated 
using the ranking of MUV data sets (actives and decoys) as deduced from their respective 
score values and visualized in receiver operator curves (ROC). Corresponding area under 
the ROC curves (AUC) and enrichment values at 0.5%, 1.0%, 2.0% and 5.0% are calculated 
and reported.
=
%
%  =  
%
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8.2.4.2. Compound library enrichment
To assess the cooperative behavior of different algorithms we calculated the improvement 
in enrichment factors for each pharmacophore algorithm when combined with another 
algorithm. This is calculated as the enrichment of the set of compounds which match in 
algorithm XY (Y after X) divided by the enrichment of the set of compounds which match 
in algorithm Y. Such analysis can be useful to identify the combination of algorithms that 
results in the best enrichment, but also might suggest how fast algorithms can be used 
as a pre-filter for the slower, but more accurate, algorithms. The heatmaps generated 
from this analysis (paragraph 8.3) show not necessarily which algorithms have the 
best enrichment, but illustrate the gain in performance achieved by pre-screening 
with another algorithm. In particular, values below 1.0 indicate that pre-screening with 
another algorithm will result in worse enrichment, while values above 1.0 indicate that 
pre-screening is beneficial for the final enrichment value. A value of 1.0 denotes no 
influence of the second algorithm.
8.3 Results and discussion
8.3.1. CDK2 dataset
8.3.1.1. Pharmacophore perception. 
CDK2 is a protein kinase whose pharmacophore features, delineating ligands that target 
the ATP-binding site, are well described in the literature [49]. Ligand sites typically include 
a hydrogen bond donor (HBD) and a hydrogen bond acceptor (HBA) representing a pair 
of key intermolecular interactions occurring with the hinge backbone (feature 1 and 2, 
Figure 8.2A). The importance of these features is exemplified by the fact that almost 
all the active compounds match those features (Figure 8.2B). A second HBA feature is 
common to most of the active compounds and represents interaction with the gatekeeper 
residue Glu81 or for bridging water molecules with catalytic Lys33. The hydrophobic 
feature labeled 4 in Figure 8.2A usually matches halogen-substituted aromatic rings that 
occupy the hydrophobic pocket of the CDK2 ATP binding site.
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Figure 8.2: CDK2 dataset. A: pharmacophore depiction as used in this study on top of PDB entry: 
1FVT (note that 1FVT with its co-crystallized ligand is used as a reference and does not contain the 
donor feature which is present in most ligands co-crystallized with CDK2). B: list of pharmacophore 
features with corresponding matching compounds in the set of actives. C: Two dimensional 
illustration of active compound similarities created using stochastic proximity embedding (SPE) 
with euclidean distances of BCI fingerprints [50-52]. Green dots represent compounds that match 
the pharmacophore according to the observed ligand alignment in the crystal structures; red dots 
are the compounds that do not match the pharmacophore.
8.3.1.2. Retrospective compound set analysis
The 45 compounds statisfying all pharmacophore constraints, in the conformations 
and positions observed in the crystal structure, are scattered over the chemical space 
represented by the 80 compounds included in the reference set of actives (Figure 8.2C). 
Most compounds match three of the four features including the acceptor and donor 
features required for the hydrogenbonding to the hinge region of the CDK2. 
8.3.1.3. Prospective binding mode reproduction.
The percentage of compounds for which a binding mode is predicted exceeds the 45 
compounds (56%) that were found to fulfill the pharmacophore criteria for all algorithms 
except Catalyst, LigandScout and Unity. Scoring seems to be problematic for most 
algorithms as only ~20-40% of compounds have a RMSD to the co-crystalized reference 
pose below 3.0Å for the best scored pose (Figure 8.3A). This behaviour appears to be 
partly caused by the number of conformers that are used as inputs for benchmarking the 
different algorithms, as performance is better if the best scored pose amongst the X-ray 
conformation active set is evaluated (Fig 8.3B,D). 
An analysis of the best reported RMSD of all matched poses for each molecule reveals 
that ~40% of compounds are predicted with a RMSD below 2.5Å, with the majority of 
those even below 2.0Å (Figure 8.3C). MOE even reaches almost 56% percent. Again, 
we find that pose prediction is more accurate if only the co-crystalized conformation 
of the ligand is used for the pharmacophore search (Fig 8.3D). However, the increase of 
compounds predicted below RMSD 2.5Å is only minor (Figure 8.3C,D), indicating that 
the multiple conformation generation protocol used includes at least one conformation 
representative for the co-crystalized conformer. 
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Figure 8.3: RMSD ranges of matched compounds from the co-crystallized ligand in four different 
scenarios. A: the best ranked pose from the ligand set  in their multi-conformational format; B: the 
best ranked pose from the ligand set in X-ray conformation; C: lowest RMSD from all poses from 
the ligand set  in multi-conformational format. D: lowest RMSD from all poses in the ligand set in 
their X-ray conformation.
8.3.3.4. Compound library enrichment. 
Receiver Operator Characteristic curves (ROC) are generated from the results of the 
pharmacophore searches of the MUV-actives and MUV-decoys sets. Most algorithms 
retrieve less then 70% and 50% of actives and decoys, respectively, as indicated by 
the endpoints of the lines in Figure 8.4A. The AUC calculation returns values between 
0.5 and 0.6 for most algorithms, indicating that the overall enrichment is only slightly 
better than could be expected from a random selection (Figure 8.4A,B). This seems 
to be mainly because of the relatively low number of active compounds retrieved by 
the pharmacophore. In particular, LigandScout retrieves only 3 out of 30 actives by 
matching those actives amongst the first 0.5% of the screened database and reaching 
an enrichment factor (EF) of 13.33 with  AUC of 0.527 (Figure 8.4B). Most algorithms 
show decreasing enrichment factors at higher false positive retrieval rates, indicating that 
the scoring measures used to rank the compounds that match a pharmacophore are 
relatively succesful for CDK2 ligand in a compound library enrichment experiment (Figure 
8.4A,B). The analysis of algorithm combinations (Figure 8.4C) shows that LigandScout, 
Unity and POT are capable of improving enrichment of other algorithms. In particular, 
LigandScout and POT seem to be complementary as there is an improvement of both 
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enrichment factors if they are used in a consecutive screening pipeline. Without any 
prescreening, LigandScout matches 3 out of 30 actives and 711 out of 15,000 decoys 
resulting in an enrichment factor of 2.1, while POT matches 20 out of 30 actives and 7571 
out of 15,000 decoys resulting in an enrichment factor of 1.3. When combined, these 
algorithms retrieve 3 actives and 471 decoys and have an enrichment factor of 3.2. This 
is an improvement in enrichment of a factor 1.5 for LigandScout and 2.4 for POT (Figure 
8.4C).  Only few values below 1.0 are observed, indicating that most algorithms can be 
combined with others without adversely affecting enrichments. This is an important 
observation that suggests the use of fast algorithms as pre-filtering steps for large 
compound collections before more accurate and computationally expensive algorithms. 
Figure 8.4: Enrichment analysis of CDK2 MUV-dataset. A: ROC curves showing the enrichment of 
CDK2 actives/decoys (dataset created with MUV, see Table 8.1).  B: AUC and enrichment values at 
0.5%, 1.0%, 2.0% and 5.0% false positive rate; green indicates an enrichment factor (EF) above 10.0 
and orange indicates EF above 5.0. C: Heatmap showing the improvement in enrichment factor of 
the algorithms on the Y-axis if pre-screening with the algorithm on the X-axis is performed. 
8.3.4. CHK1 dataset
8.3.4.1. Pharmacophore perception
The pharmacophore features of protein kinase CHK1 are well described in the literature.
[53] Similarly to CDK2, a hydrogen bond donor and acceptor pair represents the key 
interactions for binding the hinge region of the kinase (features 1, 4 and 5 of Figure 8.5A). 
However, in this case, two locations of the HBD feature are possible for CHK1 ligands and 
the analysis of matching compounds indicates their exclusive behaviors (Figure 8.5B,C). 
Other differences with respect to the CDK2 pharmacophore are that the hydrophobic 
feature (2) (Figure 8.5A) is located in the solvent-exposed region of the binding site and is 
conserved for almost all ligands of the data set (Figure 8.5B), and that an additional HBA 
that is located deep in the binding pocket that represents interactions with the catalytic 
lysine of the CHK1.
178    Chapter 8
Figure 8.5: CHK1 dataset. A: pharmacophore depiction as used in this study on top of PDB entry: 
2YWP. Features used in either pharmacophore 1 or 2 are visualized with dashed lines. B: list of 
pharmacophore features with corresponding matching compounds in the set of actives. C: Two 
dimensional illustration of active compound similarities created using stochastic proximity 
embedding (SPE) with euclidean distances of BCI fingerprints [50-52]. Blue dots represent 
compounds that match pharmacophore 1; green dots represent compounds that match 
pharmacophore 2; and yellow dots represent compounds that match both pharmacophores 
according to the observed ligand alignment in the crystal structures; red dots are the compounds 
not satisfying the pharmacophore.
8.3.4.2. Retrospective compound set analysis. 
For the reasons provided above, two different pharmacophores were defined for this 
CHK1 dataset differing in the position of the donor feature (Figure 8.5A). As seen in 
Figure 8.5C, the pharmacophores correspond to two topologically distinct clusters of 
compounds. Among the whole dataset of 123 actives, only three compounds match all 
five pharmacophore features that are common to pharmacophore 1 and 2 (Fig 8.5C). 
Remarkably those compounds have a relatively high dissimilarity to compounds from 
both clusters. Most compounds, however, do not match either of the pharmacophores 
(Figure 8.5C, red dots).
8.3.4.3. Prospective binding mode reproduction. 
The searches with pharmacophores 1 and 2 retrieve an approximately equal number of 
compounds and match ~20% of compounds with a RMSD of below 3.0Å (~25 compounds) 
with respect to the co-crystallized reference structure (Fig 8.6B,C). This is in agreement 
with the retrospective analysis in which pharmacophore 1 and pharmacophore 2 are 
both derived from ~20% of the compounds. Notably, LigandScout retrieves a low number 
of actives, while the percentage of compounds in the correct conformations is equal to, 
or even better than those generated by other algorithms.
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Figure 8.6: RMSD ranges of matched compounds from the co-crystallized ligand for pharmacophore 
1 and 2; A: pharmacophore 1; B: and pharmacophore 2 ; C:. Both figures refer to the best matching 
pose of multiconformational data sets.
8.3.4.4. Compound library enrichment. 
The stricter matching criteria of LigandScout is reflected in the search of the decoys as 
just over 1% of compounds are retrieved, while the same analysis shows at least 10% 
for all other algorithms, except Unity (Figure 8.7). These tighter criteria may explain 
the improved early enrichment of Unity and LigandScout, for which enrichment factors 
exceeded 20.0 in the top 0.5% of the ranked database (Figure 8.7B). RMSD-based scoring 
methods, like POT, Pharmer, MOE and Phase have also relatively good (≥5.0) enrichments 
at 2.0% percent of the searched database but do not achieve enrichment factors (EF) of 
10.0 or higher. The consecutive screening of compounds with MOE and Unity results in 
the best enrichment (data not shown), mainly due to the strong performance of Unity 
which retrieves 8 out of 30 actives and only 306 out of 15,000 decoys. The consecutive 
application of both algorithms results in an enrichment of 18.7 which is 1.4 times the 
enrichment factor of the Unity search and 10.9 times the enrichment factor of MOE 
search. (Figure 8.7C).
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Figure 8.7: Enrichment analysis of CHK1 MUV-dataset. A: ROC curves showing the enrichment of 
CHK1 actives/decoys (dataset created with MUV, see Table 8.1).  B: AUC values and enrichment 
values at 0.5%, 1.0%, 2.0% and 5.0% false positive rate; green indicates an enrichment factor (EF) 
above 10.0 and orange indicates EF above 5.0. C: Heatmap showing the improvement in enrichment 
factor of the algorithms on the Y-axis if pre-screening with the algorithm on the X-axis is performed. 
8.3.5. PTP1B dataset
8.3.5.1. Pharmacophore perception
PTP1B is a protein tyrosine phosphatase and is characterized by a highly conserved and 
positively charged active-site [54]. The core of the binding features is characterized by a 
dyad of hydrogen bond acceptors (HBAs), often represented by acid moieties, that ensure 
several interactions with arginine and hystidine residues present in the binding pocket. 
Like CHK1, additional features include a further HBA (pharmacophore 2, feature 3, Figure 
8.8A) and hydrophobic sites that occupy the binding site region at different locations. 
Figure 8.8: PTP1B dataset. A: pharmacophore depiction as used in this study on top of PDB entry: 
1NZ7. B: list of pharmacophore features with the number of matching compounds in the set of 
actives. C: Two dimensional depiction of active compound similarities created using stochastic 
proximity embedding (SPE) with euclidean distances of BCI fingerprints [50-52]. Blue dots 
represent compounds that match pharmacophore 1; green dots represent compounds that match 
pharmacophore 2 according to the observed ligand alignment in the crystal structures; red dots are 
the compounds not satisfying the pharmacophore.
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8.3.5.2. Retrospective compound compound set analysis. 
Like CHK1, we defined two distinct pharmacophores for PTP1B (Figure 8.8A). These 
pharmacophores relate to compounds from distinct chemical moieties. For instance, 
pharmacophore 2, which contains 5 features, matches 77 compounds that vary in size 
but all contain the N-substituted oxamic acid moiety, while pharmacophore 1 relates only 
to 21 compounds (Figure 8.8C). 12 compounds match neither pharmacophore 1 nor 2. 
     
Figure 8.9: RMSD ranges of matched compounds from the co-crystallized ligand in two different 
scenarios: A: the best ranked pose from the ligand set in their multi-conformational format; B: the 
best ranked pose from the ligand set in X-ray conformation; C: lowest RMSD from all poses from 
the ligand set in multi-conformational format. D: lowest RMSD from all poses in the ligand set in 
their X-ray conformation.
8.3.5.3. Prospective binding mode reproduction. 
The pharmacophore search based on X-ray conformations (Figure 8.9B) shows that 22 
compounds (~20%) are retrieved by pharmacophore 1 with an RMSD ≤ 2.5Å and ~70% (77 
compounds) by pharmacophore 2. Notably, MOE is able to retrieve ~50% (55 compounds) 
of the compounds with an RMSD < 2.5Å with a search of pharmacophore definition 1. 
This is most likely the result of a less stringent feature definition that also explains the 
relatively high number of retrieved decoys and the moderate performance of MOE in 
compound library enrichment across all targets (Fig 8.10A,B). Conformation generation 
and appropriate scoring seems, however, to be a problem for nearly all algorithms. Only 
20-30% of compounds are matched with an RMSD < 2.5Å (Figure 8.9A), while many more 
are correctly positioned in cases where only the X-ray conformation is used (Figure 8.9B) 
or where the pose with the lowest RMSD is picked amongst all matched poses (Figure 
8.9C). 
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Figure 8.10: Enrichment analysis of PTP1B MUV-dataset. A: ROC curves showing the enrichment of 
PTP1B actives/decoys (dataset created with MUV, see Table 8.1).  B: AUC values and enrichment 
values at 0.5%, 1.0%, 2.0% and 5.0% false positive rate; green indicates an enrichment factor (EF) 
above 10.0 and orange indicates EF above 5.0. C: Heatmap showing the improvement in enrichment 
factor of the algorithms on the Y-axis if pre-screening with the algorithm on the X-axis is performed. 
8.3.5.4. Compound library enrichment. 
Overlay-based scoring functions (Catalyst, LigandScout and Unity) seem to perform 
extremely well with respect to compound library enrichment and exhibit very high early 
enrichment values (Figure 8.10A,B). Nonetheless, one should keep in mind that, for all 
algorithms, scoring is often based on predicted binding modes that do not match the true 
binding modes. For example, in the cases of Catalyst, LigandScout and to a lesser extent 
Unity, ~45% of active compounds are ranked above all decoys (Figure 8.10A), while only 
~20-30% of compounds have RMSD values < 2.5Å (Figure 8.9A). A possible explanation 
for this discrepancy might be the fact that only a fraction of the ligand is represented 
by pharmacophore features, especially in case of pharmacophore 2 (Figure 8.8A). Yet, 
enrichments are extremely good, especially for overlay-based (Catalyst, LigandScout and 
Unity) scoring functions (Figure 8.10B) and the output of nearly every algorithm can be 
improved by pre-screening with another algorithm as indicated by the values above 1.0 in 
Figure 8.10C. Combinations with Catalyst, LigandScout, Unity and MOE show the largest 
enrichment improvement factors (on average > 1.4) in Figure 8.10C. The best enrichment 
factor results from a combination of Catalyst with LigandScout which together retrieve 17 
out of 30 actives and 308 out of 15,000 decoys resulting in an enrichment factor of 27.6.
8.3.6. Urokinase dataset
8.3.6.1. Pharmacophore perception. 
Despite its name, Urokinase is a serine protease that is clinically used for therapy of 
thrombolytic disorders and whose small-molecule inhibitors have already been shown 
to inhibit cancer growth [55]. The pharmacophore created from the list of active 
compounds (Figure 8.11A) shows that two features are always present, specifically 
a hydrogen bond donor (HBD) (feature 1) and a hydrophobic feature (feature 2). The 
rest of the pharmacophore consists of one hydrogen bond acceptor (HBA) and another 
hydrophobic feature that seem to be mutually exclusive since matching compounds are 
almost complementary (Figure 8.11B,C).
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Figure 8.11: Urokinase dataset. A: pharmacophore depiction as used in this study on top of PDB 
entry: 1OWK. Features used in either pharmacophore 2 or 3 are visualized with dashed lines. 
B: list of pharmacophore features with corresponding matching compounds in the set of actives. 
C: Two dimensional illustration of active compound similarities created using stochastic proximity 
embedding (SPE) with euclidean distances of BCI fingerprints.[50-52]  Yellow dots represent 
compounds that match in pharmacophore 1, 2 and 3; blue dots represent compounds that match 
pharmacophore 2; green dots represent compounds that match pharmacophore 3 according to 
the observed ligand alignment in the crystal structures; red dots are the compounds not satisfying 
the pharmacophore.
8.3.6.2. Retrospective compound set analysis. 
Urokinase compounds show relatively diverse features with respect to the other datasets. 
This is exemplified by the fact that the best four-feature pharmacophore (pharmacophore 
1) only satisfied seven compounds (Figure 8.11), as deduced from the ligand overlay 
of co-crystallized ligands. For this reason, we generated two additional three feature 
pharmacophores which both comprise of three of the features from the original four-
feature pharmacophore (Fig 8.11.A,B). Pharmacophore 2 contains a donor, hydrophobic 
and acceptor feature and matched 23 compounds that show little similarity (Figure 
8.11C). Pharmacophore 3 contains a donor and two hydrophobic features and matches 
36 compounds in the co-crystallized overlay. Those compounds are more similar to each 
other than the compounds matching pharmacophore 2 and are clustered together in 
topological structure space (Figure 8.11C). 
8.3.6.3. Prospective binding mode reproduction. 
Retrieval rates for the separate pharmacophores correspond to what is observed in the 
overlay of co-crystallized ligands with ~10% (7 compounds), 40-60% (30-45 compounds) 
and 50-70% (37-52) matching to pharmacophores 1, 2 and 3, respectively. The scoring of 
poses could however be improved for most algorithms, since more accurate poses are 
usually in the ensemble of solutions (Figure 8.12C) but are not scored as being best (Figure 
8.12A). Although RMSD-based scoring methods (MOE, Pharmer, POT) have a comparable 
performance in pose prediction for Urokinase, they perform poorly in compound library 
enrichment (Figure 8.13A,B). 
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Figure 8.12: RMSD ranges of matched compounds from the co-crystallized ligand in two different 
scenarios: A: the best ranked pose from the ligand set in their multi-conformational format; B: the 
best ranked pose from the ligand set in X-ray conformation; C: lowest RMSD from all poses from 
the ligand set in multi-conformational format. D: lowest RMSD from all poses in the ligand set in 
their X-ray conformation.
Figure 8.13: Enrichment analysis of Urokinase MUV-dataset. A: ROC curves showing the enrichment 
of Urokinase actives/decoys (dataset created with MUV, see Table 1).  B: AUC values and enrichment 
values at 0.5%, 1.0%, 2.0% and 5.0% false positive rate; green indicates an enrichment factor (EF) 
above 10.0 and orange indicates EF above 5.0. C: Heatmap that illustrates component importance 
when combining two pharmacophore algorithms.  
8.3.6.4. Compound library enrichment. 
Similarly to the other targets, overlay-based scoring algorithms outperform RMSD methods 
in compound library enrichment (Fig 8.13A,B). It is also notable that the combination 
of two knowledge based scoring algorithms (Catalyst, Unity and LigandScout) improves 
enrichment values (Figure 8.13C), while such trend is not observed for the combination 
of two RMSD based methods (Figure 8.13C). For instance, larger values in Figure 8.13C 
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are obtained if Catalyst, Unity and LigandScout are combined as consecutive screens with 
Pharmer, Phase, POT and MOE. The best enrichment is obtained by a combination of 
Catalyst with LigandScout: together both algorithms retrieve 10 out of 30 actives and 
577 out of 15,000 decoys and have an enrichment factor of 8.7 (paragraph 8.2.3.1. eq.1).
8.4 General Discussion
The compound sets considered in this study have allowed us to explore the different 
characteristics of a range of pharmacophore screening algorithms in terms of compound 
retrieval and pose prediction. Different pharmacophores were derived from the ligand 
alignments observed in 80 CKD2, 120 CHK1, 110 PTP1B and 74 Urokinase crystal 
structures. For CDK2, 1 pharmacophore was defined from 45 actives, while respectively 
36 and 21 actives defined 2 CHK1 pharmacophores, 21 and 77 actives defined 2 PTP1B 
pharmacophores and 7, 23 and 36 actives defined 3 Urokinase pharmacophores. Some 
of these pharmacophores match well-defined clusters of active molecules (CHK1 and 
PTP1B), while others match a more diverse range of chemical structures. Most algorithms 
retrieve a greater number of compounds than one would expect after analysis of the 
ligand poses in the available crystal structures, indicating that several active compounds 
are matched in conformations that do not correspond to the experimental one. The 
ability of the scoring functions to identify the correct bound pose is limited, as this can 
depend on i) the ligand input structures, ii) the pharmacophore’s definition or iii) the 
scoring method applied by the pharmacophore screening tool. For instance, for CDK2, 
PTP1B and to a lesser extent CHK1, running the pharmacophore searches against only the 
X-ray conformations results in better pose reproductions than when searching against the 
conformational ensembles. The pharmacophore definition can also be responsible for 
poor pose reproduction as illustrated by the PTP1B pharmacophore 2, which describes 
only a small part of the interaction patterns of the co-crystallized ligands and generates 
only poses with relatively high RMSD values. Scoring methods are also sub-optimal, as 
they frequently fail to identify the best pose from the full ensemble of matched poses 
(see CDK2 and Urokinase datasets). Compound retrieval based on poses dissimilar to 
the biophysical binding mode suggests that hit identification by serendipity does still 
frequently occur in pharmacophore search strategies.
Compound library enrichment seems not so much related to the pharmacophore search 
algorithm used but more by the compound sets and corresponding pharmacophores 
used in this study. PTP1B, particularly, showed very good early enrichments that might 
be related to the N-substituted oxamic acid moiety present in most active compounds.
Combining the strength of several algorithms seems possible by screening compound 
libraries with different algorithms in a consecutive order. By comparison of the 
enrichment factor of all compounds matching algorithm pairs and enrichment factor of 
all compounds matching a single algorithm, we showed that improvements over a factor 
of 1.5 are possible. 
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8.5 Conclusions
We carried out a comparative study of eight pharmacophore screening tools for their 
ability to retrieve and describe the behavior of active compounds for four biological 
targets of interest. Several analyses allowed us to better elucidate advantages and 
drawbacks of algorithms when they are applied with their default settings for high-
throughput pharmacophore screening purposes. 
Our analysis shows that the correct reproduction of experimental binding poses is 
generally better with algorithms using RMSD-based methods (MOE, Pharmer, Phase 
and POT) than with overlay-based methods (Catalyst, LigandScout, Pharao and 
Unity). However, since many compounds match pharmacophore hypotheses without 
reproducing the experimental pose, it is also important to assess the ratio of correctly 
predicted compounds on the overall number of matched compounds in a given data 
set. In this respect, the performance of overlay-based algorithms is slightly better than 
the RMSD-based methods. Thus, while RMSD-based algorithms generally return ‘more 
shots on goal’ due to the high number of poses, overlay-based methods seem to provide 
the best chance of retrieving the relevant biophysical binding mode. Taken as a whole, 
these findings suggest that one may prefer certain algorithms depending on the research 
application. For example, when optimizing lead compounds, it may be necessary to collect 
a large number of binding modes to explore the conformational space thoroughly. In such 
a case one may prefer an RMSD-based method. Vice versa, if only a single binding mode 
is desired, one may prefer overlay-based methods. In fact, the stricter criteria of overlay-
based methods return better results in compound library enrichment studies, as they are 
better at discriminating between active and inactive compounds. As this is most likely 
due to the stricter fitting criteria (which retrieve subsets of RMSD-based methods) and 
better scoring, it seems feasible to pre-screen large compound databases with RMSD-
based pharmacophore screening methods, which are typically faster, to obtain the same 
results in a less time-consuming manner.
Overall we can conclude that: i) the more advanced overlay-based scoring algorithms have 
better enrichments ii) obtaining good enrichment is dependent on the biological target 
and not strictly on the choice of a given algorithm iii) the use of different pharmacophore 
search algorithms may lead, in their default settings, to non-negligible different results.
We acknowledge that our findings could be extended and corroborated with further 
analyses with other biological targets, but the findings of this paper may be of practical 
use in the planning of more efficient high-throughput pharmacophore screens. 
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Summary
The output of the global drug discovery efforts has been very disappointing the last years. 
Despite ever increasing investments in research and development there has not been 
an increase in the number of approved drugs. To make matters worse, the patents of 
many blockbuster drugs will expire in the coming few years . To prevent a stagnation 
of the drug industry, new drug candidates  with improved properties are required. This 
thesis describes a molecular class-specific information system which contains large 
amounts of heterogeneous data on G protein-coupled receptors (GPCRs) as well as a 
method to predict the ligand interacting residues from these data and to translate them 
into pharmacophore features which describe ligand features complementary to these 
residues. These pharmacophores can either be used to identify new chemical entities 
which show activity on the target or help to understand the relationship between ligand 
structures and their activity on the protein target.  Chapter 2 reviews the methodologies 
and software tools which are available for structure based pharmacophore modeling. 
Methods to derive pharmacophore features typically use the geometric interaction 
properties of residues or observed feature locations of ligands interacting with the protein. 
The selection of the features which are essential for biological activity can be based on 
either interaction energies or experimental data. Chapter 3 describes a GPCR specific 
information system (GPCRdb) containing experimental data on sequences, ligand binding 
constants, mutations, and oligomers, as well as many different types of computationally 
derived data such as multiple sequence alignments and homology models. As such, 
the GPCRdb is a good starting point for drug discovery programs targeted at GPCRs. In 
chapter 4 we report about a method to predict ligand-interacting residues located in 
the transmembrane domains of GPCRs. The intracellular signaling cascade for GPCRs is 
evolutionary very successful as witnessed by the limited number of intracellular signaling 
pathways.  In contrast, the endogenous ligands do vary between different subfamilies and 
show only similarity within small subfamilies. Based on this we hypothesized that ligand 
binding residues are conserved in a multi species multiple sequence alignment (MSA) of 
the members of a small subfamily and not in a MSA of the entire class A GPCR family. We 
proved that we are indeed capable of selecting ligand interacting residues after assessing 
a measure of sequence conservation for both MSA’s. Chapter 5 describes a method 
which uses the identified ligand interacting residues to generate pharmacophores. 
These pharmacophores describe desired ligand features in the receptor ligand binding 
pockets and are used for binding mode hypotheses generation and compound library 
enrichment. We retrospectively show that our method is able to reproduce literature 
supported binding modes for the β2 adrenergic receptor. Since most endogenous GPCR 
ligands are agonists  it is likely that the ligand binding residue predictions and eventually 
resulting pharmacophores are biased to agonism. This hypothesis is in agreement 
with the observation that the retrieval and prediction of agonists is better than for 
antagonists with our β2 adrenergic receptor pharmacophore. Furthermore we showed 
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that our structure based pharmacophores were able to generate enriched target specific 
compound libraries for several different GPCRs. In chapter 6 and 7 we present the results 
of two prospective experiments. Chapter 6 reviews the outcome of the international 
community-wide assessment of GPCRdock structure modeling and ligand docking 
assessment. Binding mode hypotheses of eticlopride in the dopamine D3 receptor based 
on our pharmacophore modeling tool and optimized with the flexible docking tool Fleksy 
scored 2nd , 6th, 7th, 9th and 10th out of over 100 submitted predictions. Chapter 7 describes 
the application of pharmacophores in combination with a frequent substructure mining 
technique of known actives in compound library selection. New active compounds for an 
adenosine A2a, β2 adrenergic and sphingosine 1-phosphate receptor were successfully 
identified from the selected libraries. In chapter 8 we investigated the performance of 
several pharmacophore search algorithms on ligand binding mode reproduction and 
compound library enrichment. From the fact that a fraction of the active molecules was 
predicted to be active based on an incorrect binding mode , we can conclude that the 
discovery of new active molecules by means of pharmacophore techniques still happens 
partly due to serendipity .
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De laatste decennia is er in toenemende mate geïnvesteerd in onderzoek naar en 
ontwikkeling van medicijnen. Maar desondanks zijn er veel minder nieuwe chemische 
entiteiten (stoffen) als medicijn op de markt gebracht als aanvankelijk geanticipeerd. Van 
vele succesvolle medicijnen lopen de octrooien af en dus ook de bescherming van de 
markt. Dit alles leidt er toe dat de farmaceutische industrie in zwaar weer is komen te 
zitten. Er zijn dringend nieuwe medicijnen nodig, in de eerste plaats om de patiënten te 
helpen en in de tweede plaats om de medicijnindustrie in staat te stellen te investeren in 
research naar meer en betere medicijnen. 
Dit proefschrift beschrijft een informatiesysteem dat een grote hoeveelheid gegevens 
bevat, afkomstig van verschillende bronnen. De gegevens zijn specifiek voor een 
familie van eiwitten, genaamd G-eiwit gekoppelde receptoren (GPCR). Verder wordt 
een methode beschreven die het mogelijk maakt te voorspellen welke aminozuren van 
cruciaal belang zijn voor ligand-eiwitinteracties en een methode om de informatie van 
deze aminozuren te vertalen in pharmacophoren die de gewenste ligandeigenschappen 
in de context van het eiwit beschrijven (een pharmacophore is een abstracte beschrijving 
van moleculaire eigenschappen aan welke een ligand herkend kan worden door een 
eiwit.). Deze op eiwitstructuur gebaseerde pharmacophoren kunnen gebruikt worden 
om nieuwe stoffen te vinden die effect zullen hebben op het betreffende eiwit. Ook 
kunnen deze pharmacophoren gebruikt worden om activiteiten van reeds bekende 
stoffen te verklaren.
In Hoofdstuk 2 worden een aantal methodes en softwareapplicaties beschreven 
die beschikbaar zijn voor het genereren van op een eiwitstructuur gebaseerde 
pharmacophoren. Deze methodes gebruiken de typisch geometrische kenmerken van 
eiwit-ligandinteracties of de daadwerkelijk waargenomen ligandkarakteristieken in eiwit-
ligandcomplexen, om de plaatsen te bepalen waar een voorkeur is voor een bepaalde 
feature of eigenschap van een ligand. De uiteindelijke selectie van eigenschappen 
die cruciaal zijn voor de biologische activiteit leidt tot een pharmacophore en is vaak 
gebaseerd op experimentele data of indien niet aanwezig op de berekening van interactie-
energieën.
Hoofdstuk 3 beschrijft een GPCR specifiek informatiesysteem (GPCRdb) met experimentele 
data over aminozuursequenties, bindingsconstanten van liganden, aminozuurmutaties, 
en oligomeren, alsmede verschillende modellen en data afgeleidt van multiple sequence 
alignments  en homologiemodellen. Hiermee is de GPCRdb een goed beginpunt voor 
medicijnonderzoekprogramma’s die gericht zijn op GPCRs. 
Hoofdstuk 4 behandelt een methode die gebruikt kan worden om aminozuren te voorspellen 
in de transmembraandomeinen van GPCRs die betrokken zijn bij ligandinteracties. De 
methode maakt gebruik van de observering dat de intracellulaire signaaltransductie 
slechts plaatsvindt via een beperkt aantal G-eiwitten, terwijl de natuurlijke liganden 
varïeren tussen verschillende subfamilies maar ook grote overeenkomsten vertonen in 
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de verschillende subfamilies. Gebaseerd op deze observering veronderstellen wij dat 
ligandbindende aminozuren geconserveerd zijn in de multiple sequence alignment (MSA) 
van een kleine subfamilie van GPCRs van een groot aantal verschillende organismen en 
dat dit niet het geval is in de MSA van de hele class A GPCR-familie. Doormiddel van 
een berekening van de conservering van aminozuurposities in een MSA van verschillende 
subfamilies en van de MSA van alle class A GPCRs bewijzen we dat we inderdaad met 
deze method in staat zijn om ligandbindende aminozuren te identificeren.
In hoofdstuk 5 wordt vervolgens een methode gepresenteerd die de geïdentificeerde 
ligandbindende aminozuren gebruikt om pharmacophoren te genereren. Deze 
pharmacophoren beschrijven gewenste ligandeigenschappen in de ligandbindingsholte 
van een receptor en worden gebruikt om hypotheses af te leiden voor bekende liganden 
en voor het ontwerpen van bibliotheken met chemische stoffen. In dit hoofdstuk laten we 
met behulp van een retrospectieve studie zien dat de gepresenteerde methode in staat 
is pharmacophoren te genereren waarmee de bindingsmodes van  β2-adrenerge stoffen 
in de β2-adrenerge-receptor kunnen worden gereproduceerd. Aangezien de meeste 
natuurlijke liganden van GPCRs agonisten zijn is het waarschijnlijk dat de ligandbindende 
aminozuurvoorspellingen en de hieruit voortkomende pharmacophoren gericht zijn op 
agonisme. Dit verklaart wellicht ook de observering dat agonisten beter herkend worden 
door de pharmacophore voor de β2-adrenerge-receptor. Verder laten we in dit hoofdstuk 
ook zien dat gegenereerde pharmacophoren in staat zijn om stoffenbibiliotheken te 
maken die een groter percentage actieve stoffen bevat tegen de receptor waarvan de 
pharmacophore is afgeleid dan stoffenbibiliotheken die met een pharmacophore voor 
een andere receptor zijn gemaakt.
In hoofdstuk 6 en 7 presenteren we twee voorspellende experimenten. Hoofdstuk 
6 beschrijft de uitkomsten van GPCR-structuurmodellering en ligandplaatsing, in het 
kader van een evaluatie die plaatsvond in de internationale gemeenschap als een soort 
wedstrijd voordat de kristalstructuren bekend werden gemaakt. Voorspellingen van 
de ligandbindingsmodus van eticlopride in de dopamine-D3-receptor gebaseerd op 
pharmacophoren afgeleidt met de methode beschreven in hoofdstuk 5 en geoptimaliseerd 
met het flexibele dockingprogramma Fleksy eindigden op de 2de, 6de, 7de, 9de en 10de 
plaats uit in totaal meer dan 100 inzendingen.   
In hoofdstuk 7 wordt beschreven hoe pharmacophoren in combinatie met een mining 
(zoekstrategie) techniek gebaseerd op veel voorkomende substructuren in bekende 
liganden wordt gebruikt om een kleine stoffenbibliotheek samen te stellen uit een grote 
collectie van stoffen. Nieuwe stoffen met activiteit op de adenosine-A2a, β2-adrenerge 
en sphingosine 1-fosfaat receptor bleken aanwezig te zijn in de geselecteerde stoffen-
bibliotheek.
Hoofdstuk 8 onderzoekt de kwaliteit van verschillende algorithmen die stoffenbibliotheken 
doorzoeken met behulp van pharmacophoren. Kwaliteitscriteria die in dit hoofdstuk zijn 
beschreven omvatten de reproductie van ligandbindingsmodi en de mate van verrijking 
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gevonden door stoffenbibliotheken te filteren op stoffen die passen in de pharmacophore. 
Gebaseerd op het feit dat een deel van de bekende actieve stoffen voorspeld werd 
met een bindingsmodus die niet overeenkomt met de bio-actieve bindingsmodus kan 
geconcludeerd worden dat de ontdekking van nieuwe actieve stoffen met behulp van 
pharmacophore technieken nog steeds deels plaatsvindt doormiddel van toeval. 
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Dit proefschrift duidt voor mij het einde aan van een leerzame en bijzondere periode. Al 
dit werk heeft echter niet tot stand kunnen komen zonder de hulp van een grote groep 
mensen om mij heen. Zowel begeleiders, collega’s als vrienden hebben mij gedurende 
deze vier jaar geholpen met adviezen met betrekking tot mijn werk en leven en hebben 
gezorgd voor de ontspanning die nodig zijn om een proefschrift te schrijven.
Natuurlijk was dit alles niet mogelijk zonder de ondersteuning van mijn promotor (Jacob 
de Vlieg) en begeleider (Jan Klomp). Als nog bachelor student kwam ik Jacob tegen bij 
de cursus “Bioinformatics for Drug Discovery‘’ in Nijmegen. Dit deed mij besluiten om 
uiteindelijk ook voor mijn afstudeerproject te werken bij de afdeling Moleculer Design 
& Informatics (MDI) bij Organon NV. Hier kwam ik op de kamer te zitten bij Jan Klomp. 
Mijn afstudeerproject was mede hierdoor erg leuk met vele zowel inhoudelijke als 
persoonlijke gesprekken. Toen ik op zoek was naar een promotieplaats en jullie mij deze 
aanboden heb ik daarom ook niet lang getwijfeld. Ik ben jullie dan ook erg dankbaar 
met jullie vertrouwen in mij en dat jullie mij de kans gegeven hebben om mijn promotie 
onder jullie leiding te voltooien. Ik heb gedurende deze tijd erg veel van jullie geleerd op 
verschillende vlakken. 
Jacob, ik heb erg veel bewondering voor de inzet die jij hebt getoond voor de integratie 
van computer modellen in het onderzoek naar nieuwe geneesmiddelen. Dat het in de 
ontwikkeling van software niet slechts draait om het maken van ‘leuke’ tools, maar 
dat het vooral om de toepasbaarheid wordt vaak vergeten. Jouw constante focus op 
deze toepasbaarheid heeft mij erg geholpen en heeft mij doen beseffen dat onderzoek 
teamwork is waarin het cruciaal is dat mensen met verschillende achtergronden met 
elkaar kunnen discussiëren en dat ontwikkelde software hierop aangepast dient te 
worden.
Jan, jouw enthousiasme en wetenschappelijke nieuwsgierigheid heeft mij heel 
gemotiveerd en gestimuleerd wat uiteindelijk geresulteerd heeft in dit proefschrift. Ik 
zal de vele gesprekken op jou kamer voor het whiteboard niet snel vergeten. Ik vond het 
altijd erg fijn om samen te brainstormen over mogelijke oplossingen van problemen en 
om gewoon even bij elkaar binnen te lopen voor een praatje. Jij hebt een grote invloed 
gehad op mijn ontwikkeling van master student tot doctor ingenieur.
Natuurlijk wil ik ook graag alle mensen bij MDI bedanken voor de fijne en leerzame tijd. 
Werken in een prettige en goed gestructureerde omgeving waarin databases op orde zijn, 
software werkt zoals dit hoort en mensen gebruik maken van nieuwe ontwikkelingen en 
feedback geven zorgen uiteindelijk voor een beter eind resultaat. Zodra je een aantal 
namen noemt is het bijna zeker dat je er ook een aantal vergeet, maar zonder de hulp van 
Stefan, Tinka, Ruud, Ross, Scott, Markus, Jos, Ria, Thea en Karin, en natuurlijk Hans was 
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het zeker niet gelukt. Stefan, heel erg bedankt voor al je hulp in mijn project. Het op orde 
houden van onze database en de ontwikkeling van webinterface hebben geresulteert in 
een prachtig eindproduct. Tinka en Ruud, heel erg bedankt voor het installeren van alle 
software en het oplossen van alle computer gerelateerde problemen. Markus en Jos, 
heel erg bedankt dat ik al jullie programma’tjes en scriptjes mocht gebruiken en de vele 
project gerelateerde adviezen. Ross en Scott, bedankt voor alle adviezen en natuurlijk het 
nakijken van al mijn geschreven engels. De secrateresses, Ria, Thea en Karin, ook jullie wil 
ik graag bedanken voor jullie hulp. Jullie waren er altijd als ik iets nodig had of niet wist 
hoe ik bepaalde dingen moest regelen. En als laatste natuurlijk Hans. Jij was gedurende 
vier jaar mijn kamergenoot. Ik heb altijd erg met je gelachen. Ondanks dat we samen 
wat problemen hadden met het op orde houden van onze kamer en het invullen van ons 
labjournaal vond ik het erg fijn om met jou een kamer delen en heb ik ontzettend veel lol 
gehad tijdens deze periode.
Ook moet ik zeker mijn collega’s binnen de computational drug design (CDD) groep niet 
vergeten in dit dankwoord. Samen hebben we denk ik een leuke tijd gehad in Oss ook al 
was het met alle overnamens ook voor ons niet altijd makkelijk. Allereerst Sander, onder 
jouw leiding heb ik mijn afstudeerproject voltooid en jij stond ook tijdens mijn promotie 
altijd klaar om vragen voor me te beantwoorden, brainstormen en om mij te leren hoe ik 
eigenlijk een artikel moest schrijven. Ik heb erg veel van je geleerd en ben ook heel erg 
blij dat je mijn co-promotor wil zijn voor dit proefschrift. Tina en Dave, jullie waren de 
andere ‘modellers’ in het groepje. Naast jullie input voor mijn project en het lezen van 
mijn manuscripten ben ik jullie ook erg dankbaar voor de gezellige tijd en vele koffie’tjes 
om 10 en 3 uur. Dave, het samen lopen van de halve marathon had ik waarschijnlijk ook 
nooit zonder jou gedaan. Jammer alleen dat we elkaar kwijt raakten in de drukte en 
ik ietsje trager was. Hierdoor moeten we dit misschien toch nog maar eens overdoen. 
Verder wil ik ook de andere mensen binnen CDD bedanken. Wilco, Raoul en Eugene, heel 
erg bedankt voor de discussies en de gezelligheid.
Verder zijn er dan natuurlijk nog de studenten die ik heb mogen begeleiden. Sven, jou werk 
heeft mede geleidt tot hoofdstuk 4 van dit boekje. Ik heb heel fijn met je samengewerkt 
en veel geleerd in ons kleine projectteam met ook Jan en Stefan. Cizar en Gwen, ook 
bedankt voor jullie werk en dat ik jullie heb mogen begeleiden tijdens jullie stages.
Door de sluiting van de onderzoeksafdelingen van MSD in Oss, heb ik de laatste 
maanden van mijn promotie gewerkt op de Radboud Universiteit in Nijmegen en de Vrije 
Universiteit van Amsterdam. Ik ben erg welkom geweest op beide werkplekken en wil 
graag de mensen bedanken die dit mogelijk gemaakt hebben. Barbara heel erg bedankt 
met alle hulp omtrend alle administratieve zaken omtrend mijn promotie.
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Ondanks dat ik geen promovendus was aan de VU in Amsterdam was ik hier wel erg 
welkom en ik wil daarom graag de afdeling medicinal chemistry bedanken voor hun 
gastvrijheid. In het bijzonder de mensen die mij geholpen hebben met het schrijven van 
verschillende artikelen en afronden van mijn proefschrift. Luc, ik vond het erg fijn om 
samen met jou een team te vormen wat met name gezorgd heeft voor de hoofdstukken 
2, 6 en 7. Chris ook jij heel erg bedankt voor al jou hulp bij het schrijven. Helaas is dit niet 
mijn sterkste en ik ben dan ook zeer dankbaar met jou hulp. Dit is zonder twijfel heel erg 
belangrijk geweest voor de tot stand koming van dit proefschrift. Als laatste wil ik ook 
graag aan mijn overige roommates op de VU bedanken. Albert en Dana, ik vond het erg 
fijn een bureau bij jullie op de kamer te hebben en heb zeker meer geleerd over het leven 
(en dan vooral over hoe dit buiten Brabant is).
Zoals iedereen wel weet is succesvol zijn in je werk niet mogelijk zonder de steun van 
vrienden en familie. De vele biertjes, schuine moppen en gezellige avonden samen met 
al mijn vrienden hebben mij erg geholpen om het werk even los te laten en gewoon te 
genieten om hierna op maandag erweer tegenaan te gaan. Heel erg bedankt hiervoor 
en ik hoop dat we nog vele biertjes samen kunnen drinken en gezellige avonden mogen 
hebben. 
Als laatste wil ik dan heel graag mijn familie bedanken. Allereerst mijn broer Erik, samen 
hebben we tijdens jouw promotie heel wat tijd samen doorgebracht in de auto naar 
Eindhoven. We hebben vaak gepraat over promoveren. Met jou kon ik altijd goed van 
gedachte wisselen. Je bent voor mij naast mijn broer dan ook een heel erg goede vriend. 
Mijn schoonzus, Rinske, jij bent inmiddels ook begonnen aan je promotie en met jou heb 
ik de laatste paar maanden regelmatig gecarpoold naar Nijmegen. Bedankt voor deze 
gezellige ritjes samen. En natuurlijk mijn ouders. Jullie hebben mij altijd gesteund in mijn 
studie en promotie. Met ‘ons pap’ ben ik de eerste jaren samen naar Oss gereden en 
heb ik veel gesprekken gevoerd over het bedrijfsleven, de pharmaceutische industrie 
en management. Ik heb je gedurende deze jaren heel goed leren kennen en ben je erg 
dankbaar voor deze gesprekken. ‘Ons ma’ die er altijd voor mij was, elke dag vroeg hoe het 
ging en ons stimuleerde om met onze studie een goede basis te leggen voor het verdere 
leven. Als allerlaatste dan ‘mijn meisje’. Joey, ik ben erg blij dat ik je tegen gekomen ben 
en voor jouw steun tijdens de laatste jaren van mijn promotie. Het was voor mij niet altijd 
makkelijk met de vele veranderingen op mijn werk, maar jij hielp mij altijd te relativeren. 
Het allerbelangrijkste is immers dat je werk doet wat je leuk vind en een leuk leven hebt. 
Ik hoop dat wij nog lang samen van het leven mogen genieten.
Nogmaals dank aan iedereen die mij heeft gesteund!
Marijn  
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Spoel onderzoek gedaan naar waterstofbrugpatronen in eiwitten. Hij haalde in 2007 zijn 
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Instituut Pharma. Hij ontwikkelde  een software methode, waarmee op eiwitstructuur 
gebaseerde pharmacophoren kunnen worden gegenereerd. Deze techniek is vervolgens 
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Maastricht en Bologna toegepast in verschillende projecten. Gedurende het grootste 
gedeelte van het onderzoek is hij werkzaam geweest op de afdeling MDI van Organon 
N.V.in Oss onder leiding van dhr. J. Klomp en prof. dr. J. de Vlieg. De resultaten van het 
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